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ABSTRACT 
 
 
HIV-1, the virus that causes AIDS, is spreading at an alarming rate. Subtype C, which 
accounts for approximately 50% of infections worldwide, and 98% of infections in 
Southern Africa, is by far the most prevalent form of the virus. Most molecular and 
biochemical studies have been performed on HIV-1 subtype B isolates and products, 
however, and there is a relative scarcity of corresponding data on subtype C. It is 
therefore of crucial importance to study subtype C HIV-1 strains in order to understand 
their characteristic pathogenic effects and to develop effective treatment strategies. The 
aim of research in our laboratory is the development of novel treatment strategies, with 
particular focus on identifying novel Subtype C Env-binding peptide ligands. This 
necessitates the development of reagents for use in the discovery and testing of these 
compounds. In line with this, the aim of this project was the production and 
characterisation of recombinant Subtype C gp120s generated from a recently compiled 
HIV-1 virus cohort. To this end, the gp160-coding regions of 20 South African Subtype 
C HIV-1 strains isolated from AIDS patients presenting at the Johannesburg General 
hospital in 2005 were amplified by PCR and sequenced. The gp160 amplicons were used 
to amplify and clone the gp120-encoding regions of these isolates. Two clones, pTriEx-
FV3 and pTriEx-FV5, originating from CXCR4- and CCR5-utilising strains respectively, 
were selected for further use. These clones were cotransfected into insect cells together 
with a baculoviral DNA backbone in order to generate gp120-expressing baculoviruses 
by homologous recombination. Recombinant baculoviruses were used to infect Sf9 insect 
cell cultures for expression of recombinant gp120, which was then purified using a 
combination of lectin affinity chromatography and ion exchange chromatography. In 
 vi 
order to determine the functionality and conformational integrity of the recombinant 
gp120, the ability of these purified gp120s to bind CD4 and a panel of well-characterised 
monoclonal antibodies against various epitopes on gp120 (F425 A1g8, 2G12, F425 B4a1, 
F425 B4e8, 48d, 17b, IgG1 b12, 5F7, 4G10, 9301, ID6, Chessie 13-39.1, 654-30D and 
670-30D) was assessed. Gp120 from the CXCR4-using isolate, FV3, appeared to have an 
intact, functional CD4 binding site as measured by its ability to bind to CD4 and the CD4 
binding site antibody 654-30D. It showed low binding to the monoclonal antibody 654-
30D, moderate binding to 2G12, Chessie 13-39.1 and 9301, and high binding to ID6, but 
did not show binding to any of the other antibodies used in the recognition profile. Gp120 
from the CCR5-using isolate, FV5, showed low binding to the monoclonal antibodies 
F425 B4a1 and Chessie 13-39.1, moderate binding to 2G12, and showed good binding to 
9301and ID6. FV5 gp120 could not, however, bind to CD4. This is likely to be related to 
a D368G substitution, a mutation affecting a critical structural determinant of CD4 
binding. The lack of CD4-binding activity of this gp120 highlights the importance of 
Asp368 for CD4 binding and hints at a region vulnerable for therapeutic targeting. Our 
results also highlight the challenges of developing broadly therapeutic drugs for HIV-1, 
as well as the importance of investigating the specific biochemical and pathogenic 
properties associated with subtype C HIV-1.  
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1.Introduction 
 2 
1.1. AIDS and HIV 
 
Acquired Immune Deficiency Syndrome (AIDS) is a disease characterised by a decline in 
CD4-positive (CD4+) T-lymphocytes, which play a central role in humoral and cell-
mediated immunity1, 2. This decline results in patients being unable to mount an immune 
response and therefore vulnerable to opportunistic infections and malignancies3.  
 
AIDS was first recognized as a disease in 1981. In May of that year, the possibility of a 
cellular immune disorder related to a common exposure and predisposing individuals to 
certain infections was first noted in a United States Centers for Disease Control and 
Prevention report of a number of cases of Pneumocystis pneumonia in Los Angeles4. 
Following this the number of reports of unusual infections and tumours in homosexual 
men increased, resulting in speculation about the possibility of a sexually transmitted 
acquired immune disorder1, 2, 5, 6. While the disease was first noted in homosexual men, it 
soon became evident that it was not limited to these individuals. By 1983, AIDS had also 
been identified in intravenous drug abusers, in female partners of drug-abusing males 
with AIDS, in individuals receiving blood products, and among Haitians in the United 
states with no reported history of either drug abuse or homosexuality7-9.  
 
Soon after AIDS was identified as a disease, the search for a causative agent began. The 
fact that AIDS was characterised by a decrease in CD4+ T-cells suggested an agent 
specifically targeting these cells, such as the then recently discovered Human T-cell 
lymphotropic retrovirus (HTLV) family10. Researchers began looking for a retrovirus in 
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AIDS patients, finally isolating a cytopathic, T-lymphotropic retrovirus postulated to be 
the cause of AIDS11-13. The link between this virus and AIDS became stronger as the 
virus was detected frequently in patients with AIDS, AIDS-related complex or in healthy 
people at high risk for AIDS, such as homosexual men, but never in healthy 
heterosexuals not considered at risk for AIDS3, 14. The virus, originally given different 
names by the various research groups involved, was ultimately, although somewhat 
controversially, named Human Immunodeficiency Virus (HIV)15, 16. Later, this virus 
became known as HIV-1 as the existence of another, less virulent variant of the virus 
(HIV-2) was discovered17, 18. 
  
The latest available figures estimate that in 2006, 39.5 million people worldwide were 
living with HIV, 2,9 million lost their lives to AIDS, and 4.3 million people became 
newly infected with HIV-119. In South Africa, it is estimated that 5.5 million people are 
living with HIV and that 1.2 million children (aged 0-17) have been orphaned by AIDS19, 
20. 
 
1.2. HIV-1 structure, genome and life cycle 
 
1.2.1. Viral structure and genomic organisation 
 
HIV-1 is a lentivirus, more specifically, a T-lymphotropic retrovirus11. The mature virion 
is encapsulated by a lipid bilayer derived from the host cell membrane, which includes a 
 4 
number of host cell proteins such as the human lymphocyte antigen alpha and beta 
chains, actin and ubiquitin21. Also embedded in this bilayer are the viral surface envelope 
glycoproteins gp120 and gp41. Beneath the membrane is the viral matrix, with a conical 
capsid core in the centre containing two copies of the unspliced RNA genome of the virus 
in a ribonucleoprotein complex. Also found in the core are the viral protease, integrase 
and reverse transcriptase, as well as the accessory proteins nef, vif and vpr.22 (Figure 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Structure of the HIV-1 Virion. Figure adapted from Sierra et al.23 
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The HIV genome (Figure 1.2) is approximately 9,5 kb in length and consists of 9 open 
reading frames, namely gag, pol, env tat, rev, nef, vpr, vpu and vif 24. Gag encodes the 
viral matrix, capsid and nucleocapsid proteins. Pol codes for the protease, reverse 
transcriptase, RNase H and integrase proteins, while env encodes the surface glycoprotein 
gp120 and the transmembrane glycoprotein gp41.  
 
 
 
 
Figure 1.2: Genomic Organisation of HIV-1. Each open reading frame is shown in a 
different colour. Positions of some major genomic elements are shown (according to 
numbering of the HIV-1 strain, HXB2).  MA: matrix protein, CA: capsid protein, NC: 
nucleocapsid protein, PR: protease, RT: reverse transcriptase, IN: integrase, SU: surface 
glycoprotein gp120, TM: transmembrane glycoprotein gp41, LTR: long terminal repeat. 
Diagram adapted23, 25. 
 
1.2.1.1. Genetic Variability of HIV-1 
 
HIV-1 is a genetically diverse organism. There is a large amount of sequence variability 
across the entire genome between viral isolates obtained from different patients as well as 
between different isolates obtained from the same patient (quasi-species)26-29. This can be 
attributed to the error-prone retroviral reverse transcriptase (which introduces mutations 
LTR
LTRMA  CA  NC
gag PR            RT             IN
pol
vif
vpr
vpu
tat
rev
env
nefSU                     TM
0           790                 2086                            5616         5831  6625                   7758           8797           9719  
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into the reverse-transcribed genome at a rate of 3.4 x 10-5 per base pair per cycle)30-32, the 
high replication rate of HIV-1 (108-1010 virions per patient per day)33-35, and viral 
recombination events36.  
 
Phylogenetic analysis has allowed for HIV-1 to be divided into three distinct groups. 
These are the major group (M), which is responsible for much of the current pandemic, 
and two much rarer groups, an outlier group (O) and a non-M/non-O group (N), both 
found predominantly in Africa and in particular Cameroon37-40. Group M HIV-1 viruses 
have been further divided into distinct subtypes41, of which there are currently nine, 
designated by the letters A-D, F-H, J and K42. The envelopes of viruses within the same 
subtype can differ from each other by up to 20% in their amino acid sequences, while 
those of viruses belonging to different subtypes can differ from each other by up to 
35%43. Recombination between viruses of different subtypes within the same patient has 
also resulted in the emergence of circulating recombinant forms or CRFs. These viruses 
contain clearly defined sections derived from multiple subtypes and to be defined as a 
CRF, such a recombinant virus must form the basis of at least three infections that are not 
epidemiologically linked42, 44. At least 34 CRFs have been described to date45.  
 
The HIV-1 subtypes and CRFs are found with varying prevalence in different regions 
worldwide. Statistics published recently by the WHO/UNAIDS46 showed that Subtype C 
was the most prevalent subtype of HIV-1, accounting for approximately 50% of all HIV-
1 infections worldwide. Subtypes A, B, D and G followed, accounting for 12%, 10%, 3% 
and 6% respectively. Together, subtypes F, H, J and K were responsible for 0.94% of 
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infections. Recombinant forms of HIV-1 accounted for 18% of infections worldwide, 
with CRF01_AE and CRF02_AG being responsible for 5% of cases each and 
CRF03_AB being responsible for 0.1%. Other recombinant forms made up the remaining 
8%. With regards to the global distribution of HIV-1, Sub-Saharan Africa accounted for 
64% of all HIV-1 infections worldwide, with 56% of these infections being subtype C. In 
southern Africa, which accounted for 30% of the world’s HIV-1 positive individuals, 
98% of infections were caused by subtype C. These figures, together with the genetic 
variability of HIV-1, highlight the importance of studying subtype C in order to elucidate 
similarities and differences between subtypes that may be crucial in disease control.  
 
1.2.2. The HIV-1 life cycle 
 
The life cycle of HIV-1 (figure 1.3) begins with the release of the viral core into CD4-
positive host cells. Once the viral core has been released, the capsid disassembles in a 
process known as uncoating, releasing the ribonucleoprotein complex and associated 
proteins into the cell47,48. Reverse transcription of the viral RNA into cDNA is initiated at 
this stage, possibly even before the uncoating process takes place48, 49. Full length, 
double-stranded cDNA is transported via the cell’s dynein and microtubule network as 
part of a preintegration complex (PIC) to the nucleus of the host cell for integration49. 
The PIC is imported into the nucleus and the cDNA is integrated into the host genome by 
the viral integrase. Interestingly, HIV appears to target sites for integration selectively, 
favouring active genes and in particular those activated by HIV-1 infection of the cell50, 
51. Once integration of the viral cDNA has taken place, spliced and unspliced forms of the 
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viral RNA transcripts are synthesized and transported out of the nucleus. Spliced mRNA 
is translated into the viral accessory proteins tat, nef and rev. Rev is responsible for 
transport of mRNA out of the nucleus into the cytoplasm of the cell for translation of the 
gag, the gag-pol precursor protein and env. Full length mRNA binds to the gag protein 
and is packaged into new virions. As new viral particles assemble, they bud from the host 
cell membrane and the viral protease cleaves the viral polyproteins to yield functional 
viral enzymes and structural components, a process known as maturation. Mature virions 
are then able to infect new host cells22.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The life-cycle of HIV-1. Figure adapted from Sierra et al.23 
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1.3. HIV-1 entry into host cells 
 
1.3.1. The HIV-1 Envelope Protein 
 
Entry of HIV-1 into host cells is mediated by the HIV-1 envelope glycoprotein 
(env/gp160), a precursor protein that is transferred into the endoplasmic reticulum during 
translation for folding, disulfide bond formation and glycosylation, before transportation 
into the Golgi complex where it is cleaved to yield gp120 and gp41, the surface and 
transmembrane subunits of the envelope respectively52-57. Cleavage of the gp160 
precursor is catalysed by furin, a protein convertase located in the Golgi complex58-61, 
and results in non-covalently associated gp120/gp41 complexes that are transported to the 
cell membrane, where they assemble as trimers on the surface of budding HIV-1 virions 
55, 62. Investigation of the surface features of HIV-1 using cryo-electron microscopy has 
revealed that although there is much variation in the number of these trimeric spikes on 
each virion (between 4 and 35 per virion), in general there are approximately 14 such 
spikes on the surface of HIV-1, and that these may be clustered63. 
 
Studies of the amino acid sequence of gp160 reveal a hydrophobic leader or signal 
peptide sequence at the N-terminus of the protein (approximately 30-40 amino acids 
long), which is cleaved during maturation64, 65. This region is immediately followed by 
the gp120 and gp41 regions, with an arginine-rich hydrophobic area at the cleavage site 
between the two65. A number of studies comparing sequences of the envelope regions of 
different viruses have been performed65-67. These analyses found that the envelope region 
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of HIV-1 contains relatively conserved regions, as well as regions of extreme variability. 
In a computer-assisted analysis, 6 conserved regions, designated C1-C6 were elucidated 
(although it is now generally accepted that there are 5 conserved regions, C1-C5), 
together with five variable regions designated V1-V566. Strikingly, all of the cysteine 
residues in gp120 were absolutely conserved65. In a study of the disulphide bonds present 
in the protein, gp120 was also found to contain 9 highly conserved disulphide bonds, four 
of which serve to render the hypervariable regions V1-V4 as well-defined loops68 (figure 
1.4).  
 
Examination of gp160 sequences also revealed the presence of a number of potential 
glycosylation sites on gp12064, 65. Approximately half the molecular mass of the HIV-1 
envelope glycoprotein is attributed to N-linked glycans64, 69. The typical envelope 
glycoprotein has approximately 24 N-linked glycosylation sites in gp12068, as well as 
three or four sites in gp4165. Experimental data has revealed the presence of both 
complex-type, as well as high mannose- or hybrid- type carbohydrates on gp120, with all 
of the potential glycosylation sites being used68 (figure 1.4). It has been suggested that N-
linked glycosylation plays an essential role in neutralisation escape by HIV-170. In a 
study of viruses obtained from acutely-infected HIV-1 patients over time, a population of 
virus that was sensitive to neutralising antibodies became slowly resistant to these 
antibodies and developed further resistance over time as the formation of new 
neutralising antibodies occurred70. When the envelope genes of these viruses were 
sequenced, many of the changes present were related to potential N-linked glycosylation 
sites, involving the addition, deletion or repositioning of glycosylation sites in 
 11 
comparison to earlier populations, with some changes becoming fixed and others 
constantly changing over time in response to new antibodies. These findings led to the 
proposal of an “evolving glycan shield”, able to inhibit the binding of neutralising 
antibodies to gp120 sterically, without affecting viral fitness. In a more recent study of 
HIV-1 transmission between heterosexual couples, viruses from newly-infected partners 
were sensitive to neutralization by antibodies from the transmitting partner, suggesting 
that the antibody resistance acquired during chronic infection is accompanied by a 
compromise in viral fitness71.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Schematic representation of gp120. The peptide backbone is coloured 
black, with the variable regions shown in purple and labelled V1-V5. High-mannose 
and/or hybrid-type glycans are shown in green, and complex glycans in blue. Disulfide 
bonds are indicated in red. Figure adapted from Leonard et al.68 
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1.3.2. Gp120 
 
1.3.2.1. Structure of gp120 
 
Determination of the structure of the envelope glycoprotein of HIV has been important 
for understanding of viral pathogenesis, as well as for the design of HIV inhibitors. 
Gp120 exhibits a large amount of conformational flexibility, and is extensively 
glycosylated, making it difficult to produce crystals that diffract well72. In order to 
crystallize gp120, it was therefore necessary to modify the protein, maintaining the 
biologically important properties such as CD4-binding, but in a more ordered structure72. 
For the first crystal structure of gp120, this was achieved by extensive deglycosylation of 
gp120, as well as truncation of gp120 by removal of the disordered and flexible variable 
loops72, 73. The conformational flexibility of gp120 was also restricted by crystallising it 
in complex with CD4 and a monoclonal antibody. Thus, the structure of the HIV-1 gp120 
core (i.e. gp120 without the variable regions and N and C terminal segments) has been 
determined in complex with CD4 and the antigen-binding fragment (Fab) of the anti-
gp120 antibody 17b73, 74.  
 
The structure of an unliganded simian immunodeficiency virus (SIV) gp120 core was 
determined later75. Interestingly, in the case of the SIV core, researchers found that the 
glycosylation of gp120 helped, rather than hindered the crystallization process75. More 
recently, the structure of an HIV-1 V3-loop-containing gp120 core has also been 
determined76.  
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The first available structure of gp12073 revealed the deglycosylated gp120 core to be a 
folded into two major domains (figure 1.5). These are an inner domain (with respect to 
the N- and C- termini, blue in figure 1.5), from which the V1/V2 loop extends, and a 
stacked double-barrel outer domain (green in figure 1.5), which includes the V4 and V5 
loops. These two domains are linked by a four-stranded bridging sheet (orange in figure 
1.5). HIV-1 entry into cells requires that gp120 binds to the host-cell surface receptor  
CD477, 78. HIV-1 entry also requires that gp120 binds to a coreceptor, one of a family of 
G-coupled seven-transmembrane domain chemokine receptors, principally CXCR4 or 
CCR5 79-84. In this structure, a gp120-CD4-17b complex, CD4 was bound at the interface 
of the inner and outer domains and the bridging sheet, with its Phe43 residue “plugging” 
a cavity in gp120 at this interface (figure 1.6). In this structure, it was also noted that the 
binding site for the coreceptor CCR5 is geometrically directed to the cellular membrane 
when gp120 is bound to CD4. 
 
Oligomeric modelling74 (figure 1.7) suggested that all the variable loops of gp120, as 
well as the CD4 and neutralising antibody binding sites, are exposed on the gp120 trimer, 
and revealed the C-terminus of gp120 poised to interact with gp41. In this model, the 
coreceptor binding site is aimed directly at the target cell membrane and is not 
glycosylated. This model further showed that CD4 binds to gp120 at an angle, in a 
position far from the axis of the trimer, allowing for three CD4 molecules to bind to the 
gp120 trimer without sterically hindering one another. This also allows for the binding of 
chemokine receptors together with CD4, as these interact with gp120 close to the trimer 
axis. 
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Figure 1.5: Ribbon diagram of gp120 in the CD4-bound conformation coloured to 
show the main structural domains. Adapted from Kwong et al.73. Crystal structure 
downloaded from the Protein Data Bank85, PDB ID 1gc1, and altered using Swiss-Pdb 
Viewer 3.7 (SP5)86 (http://www.expasy.org/spdbv/). The inner domain is blue, the outer 
domain is green, and the bridging sheet orange. Although the variable loops are missing 
in these structures, their positions are indicated in this diagram. 
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Figure 1.6: A ribbon diagram showing the interaction of CD4 and gp120. Adapted 
from Kwong et al.73. Crystal structure downloaded from the Protein Data Bank85, PDB 
ID 1gc1, and altered using Swiss-Pdb Viewer 3.7 (SP5)86 
(http://www.expasy.org/spdbv/). The inner domain is blue; the outer domain is green, and 
the bridging sheet orange. CD4 is yellow. The residues of gp120 that are in direct contact 
with CD4 are coloured in red, with their amino acid side-chains showing. Phe43 of CD4 
is shown as a space-filled model in order to highlight its position in the Phe43 cavity of 
gp120. 
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Figure 1.7: Model of gp120 oligomer as viewed from the side with the viral 
membrane above and the target membrane below. The gp120 core is purple, while 
CD4 is yellow and carbohydrate structures are blue. In this orientation, the CCR5 binding 
site is on the target membrane side, aimed directly at the target membrane. Picture taken 
from Kwong et al.74 
 
 
When compared to the structure of a non-glycosylated CD4-bound HIV-1 gp120, the 
structure of a fully glycosylated, unliganded SIV gp120 core revealed a number of 
remarkable differences75 (figure 1.8). In this structure, the inner and outer domains of 
gp120 were in different positions relative to each other as compared to the liganded 
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structure, the bridging sheet was no longer an individual domain and the CD4 and 
coreceptor binding sites were not properly formed. This led to the postulation that 
unliganded gp120 has a more relaxed conformation than liganded gp120, and that the 
bridging sheet folds on CD4 binding to form the coreceptor binding site as seen in the 
original CD4-bound structure of Kwong et al.73. This postulation is supported by 
thermodynamic data87, which indicates a great amount of structural flexibility within 
gp120. Large thermodynamic changes are seen on CD4 binding to gp120, which implies 
significant conformational rearrangement of the gp120 core. These changes can be 
accounted for by the folding of the bridging sheet, as well as the pulling together of the 
bridging sheet and inner and outer domains of gp120, leading to a loss of surface area and 
ultimately the  exposure of the coreceptor binding site87. 
 
None of the aforementioned structures, however, included the third variable region (V3 
loop) of gp120, a notable absence as this is a region critical for determination of 
coreceptor usage of HIV-188. It has only recently been possible to elucidate the core 
structure of HIV-1 gp120 with the V3 loop included, providing fascinating insight into 
the role of the V3 loop during coreceptor binding76. The crystal structure of the V3-
containing gp120 core revealed that the V3 loop, 50Å from base to tip, extends from the 
outer domain of gp120 (figure 1.9). It consists of a conserved base with a disulfide 
bridge, a flexible stem and a β-hairpin tip. The structure and position of this loop led to 
the proposal that the N-terminus of the coreceptor reaches up and binds to the gp120 core 
and V3 base, while the V3 tip reaches down, and acts as a “molecular hook”, interacting 
with the second extracellular loop of the coreceptor.  
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Figure 1.8: Crystal Structure of uliganded SIV gp120. Adapted from Chen et al.75 
Crystal structure downloaded from The Protein Data Bank85, PDB ID 2bf1 , and altered 
using Swiss-Pdb Viewer 3.7 (SP5)86 http://www.expasy.org/spdbv/. Ribbon diagram of 
gp120 coloured to show the main structural domains. Inset for comparison purposes is 
figure 1.5, the CD4-bound crystal structure of gp120. For both figures, the inner domain 
is blue, the outer domain is green, and the bridging sheet orange. Glycans are not shown.  
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Figure 1.9: Crystal Structure of gp120 in a CD4-bound conformation, including the 
V3 loop. Adapted from Huang et al.76 Crystal structure downloaded from the Protein 
Data Bank85, PDB ID 2b4c , and altered using Swiss-Pdb Viewer 3.7 (SP5)86 
http://www.expasy.org/spdbv/. Gp120 is coloured in blue, with the V3-loop portion 
coloured in red. Glycans are not shown. 
 
1.3.2.2. The role of gp120, its receptors and coreceptors in HIV-1 entry into 
host cells 
 
Entry of HIV-1 into target cells is initiated by the interaction of gp120 and the host cell 
surface receptor CD477, 78. This causes large conformational changes in gp120, resulting 
in exposure of previously masked gp41 epitopes and, in vitro, dissociation of gp120 from 
gp41 87,89.  Conformational changes also lead to exposure of the V3 loop, as well as 
movement of the V1/V2 loop, which results in exposure of the coreceptor binding site of 
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gp12089, 90. The coreceptors for HIV entry are principally CXCR4 or CCR5 79-84. A 
number of other members of the G-protein-coupled receptor family have also been 
implicated as coreceptors for HIV-1 although to a much lesser extent than CCR5 and 
CXCR4. These include CCR381, CCR2b83, GPR1591, STRL3391, 92, GPR191, CCR893, 
US2894, V2893, APJ95 and ChemR2396. Viral tropism (i.e. Macrophage- or T-cell tropism) 
is linked to coreceptor usage, with CXCR4(X4)-using viruses being T-tropic and 
syncytium-inducing (SI), and CCR5(R5)-using viruses being M-Tropic and non 
syncytium-inducing (NSI)79-84, 97, 98. Coreceptor binding and specificity of the virus 
appears to be principally determined by the V3 loop, which is exposed by CD4-induced 
conformational changes, although the V1/V2 loops, also exposed upon binding of CD4, 
have also been implicated81, 88, 99-104.  
 
Coreceptor usage appears to be an important factor in HIV pathogenesis. Transmitted 
HIV-1 is NSI and these CCR5-using viruses have been shown to predominate in early or 
asymptomatic HIV-infection105-107. In later infection, however, CXCR4-utilising isolates 
often emerge and extensive analysis has shown this shift from a primarily CCR5-using to 
a primarily CXCR4-using virus population  to be closely correlated with increased CD4+ 
T-cell decline and progression to AIDS106-112. When compared to CCR5-using viruses, 
CXCR4-using viruses also show increased cytopathicity113, 114, which may account for 
the link between coreceptor switching and increased pathogenicity of HIV. 
 
Coreceptor usage and switching has been studied across the various HIV-1 subtypes. In a 
study comprising HIV-1 isolates across all nine clades, CXCR4-using viruses were rarely 
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found amongst subtype C isolates115, which account for 50% of HIV infections 
worldwide46. Numerous other studies have found CXCR4-using isolates to be extremely 
rare in subtype C cohorts116-122. Recently, however, a maturing of the HIV-1 subtype C 
epidemic has been suggested as higher percentages of CXCR4-utilising HIV-1 have been 
found amongst clade C isolates123, 124, a disturbing finding when taking into account the 
association between X4 use and disease progression and pathogenesis.  
 
1.3.3. Gp41 
 
1.3.3.1. Structure of gp41 
 
The structure of the transmembrane protein of HIV-1, gp41, has also been extensively 
studied125-128. Early protein dissection studies128 resulted in two peptides designated N-51 
and C-43, from the N- and C-terminal regions of gp41 respectively. When mixed, these 
peptides associated to a trimer with an interior, parallel coiled coil consisting of three N-
51 helices, and with three C-43 helices packed around it in an antiparallel fashion. The 
stability of this structure led to it being proposed as the fusion active conformation of the 
HIV-1 envelope.  
 
Crystal structures of the relevant regions of gp41 later confirmed the presence of a six-
helix bundle within this molecule125-127 (figure 1.10). All of these structures indicated the 
presence of a central, parallel, trimeric coiled coil consisting of three N-terminal helices 
with three C-terminal helices packed in the reverse direction into hydrophobic grooves on 
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its surface, juxtaposing the amino and carboxy termini at one end of the rod-shaped 
structure.  
 
 
 
 
 
 
 
 
 
Figure 1.10: Representation of the coiled coil structure of gp41. N-terminal helices 
are coloured blue and C-terminal helices are purple. (A) Side-on view. (B) View from 
above. Figure taken from Chan et al.125 
 
 
1.3.3.2. Gp41 and the HIV-1 fusion mechanism 
 
The resemblance of gp41 to other viral membrane fusion proteins, including the influenza 
virus haemagglutinin protein, has long been recognised129. This similarity, taken together 
with experimental data, has led to a model for HIV-1 fusion similar to the influenza virus 
haemagglutinin model127, 130-132 (figure 1.11). Based on this model, it has been suggested 
that on CD4 and coreceptor binding, the gp120/gp41 association is considerably 
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weakened, leading to exposure of a gp41 N-terminal fusion peptide, which penetrates the 
host-cell membrane.  
 
It has been suggested that the conformational changes that result in exposure of the fusion 
peptide may be caused by the binding of multiple coreceptors to gp12074. The binding 
site for gp120 coreceptors is close to the axis of the gp120 trimer and thus the binding of 
multiple coreceptors to gp120 may result in steric strain. Movement of the gp120 subunit 
away from the axis of the trimer in order to relieve this strain may result in 
conformational changes in gp41, exposing the fusion peptide and allowing for its 
insertion into the host-cell membrane74. 
 
After exposure of the fusion peptide and penetration of the host cell membrane, gp41 
trimers enter a fusion-active conformation by folding back on themselves to form a six-
helix bundle, bringing the N-terminal fusion peptide, which is inserted into the host-cell 
membrane, into close proximity with the C-terminal transmembrane region fixed in the 
viral membrane. This action brings the viral and host-cell membranes together. Around 
the time of six-helix bundle formation, a fusion pore or channel connecting the aqueous 
compartments of both host cell and virus forms, allowing the passage of the viral core 
into the cell133, 134. It has been suggested that the formation of six helix bundles not only 
brings together the viral and host cell membranes, but also stabilizes the fusion pore for 
efficient transfer of the viral core133. 
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Figure 1.11: Stages of HIV Entry into host cells. Figure adapted from Doms and 
Moore135. 1. CD4 binds to gp120. 2. CD4 binding causes a conformational rearrangement 
in gp120 that results in exposure of the coreceptor binding site and a number of gp41 
epitopes. 3. Upon coreceptor binding, further conformational changes result in the 
weakening of the gp120-gp41 interaction, and exposure of the N-terminal fusion peptide 
(FP), which then inserts into the host cell membrane. 4. Gp41 then folds back on itself to 
form a six-helix bundle, drawing the viral and host cell membranes together, and 
allowing for entry of the virus into the host cell. 
 
1.4. HIV-1 drug targets 
 
The development of drug therapies for HIV-1 has been targeted at many aspects of the 
HIV-1 life cycle, and a number of drug classes exist. These include protease inhibitors 
and reverse transcriptase inhibitors, which form the basis of the currently most effective 
HIV-treatment strategy - highly active antiretroviral therapy (HAART). HAART 
typically combines the use of two nucleoside reverse transcriptase inhibitors (NRTIs) 
with one protease inhibitor (PI) or two NRTIs with one non-nucleoside reverse 
1 2 3 4 
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transcriptase inhibitor in order to inhibit viral replication136. HAART, particularly with 
the inclusion of a protease inhibitor, has been associated with a significant decline in 
morbidity and mortality rates linked with advanced HIV137, but is hampered by the 
toxicity of the drugs, as well as the rapid emergence of drug resistant species of the virus. 
These problems have necessitated the development of novel therapeutic strategies against 
HIV. One class of drugs that has recently attracted a lot of attention is the fusion or entry 
inhibitors, which target various steps and proteins involved in the HIV viral entry 
process.  
 
1.4.1. Therapeutic targeting of gp120 interactions  
 
The pivotal role of gp120 in HIV-1 entry renders it an attractive target for drug design, 
and a number of strategies aimed at inhibition of HIV-1 replication by disrupting the 
interactions of gp120 have been attempted.  
 
1.4.1.1. Large molecule inhibitors 
 
The potential for using soluble CD4 (sCD4) as a competitor to block the gp120-CD4 
interaction was explored early in the HIV epidemic. Initially, these studies yielded 
promising results138, 139, however it later became clear that sCD4 was only effective 
against laboratory-adapted strains of HIV-1, with primary isolates being relatively 
resistant to challenge by this molecule140.  
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Another approach to preventing the gp120-CD4 interaction involves the use of a 
recombinant CD4-based fusion protein, Pro542141, 142. This molecule comprises human 
IgG2, in which the Fv portions of both heavy and light chains have been replaced by the 
V1 and V2 domains of human CD4. Due to its tetravalent structure, Pro542 can bind Env 
with higher avidity than sCD4. Pro542 has been used with promising results in 
patients143, but development of this drug has been halted as the manufacturer has 
refocused its efforts towards development of a more potent drug, Pro140. Pro140 is a  
monoclonal antibody directed against the HIV-1 coreceptor CCR5 that inhibits HIV entry 
at concentrations that do not affect its chemokine receptor activity144. In Phase 1 studies, 
this drug was well tolerated in healthy volunteers145 and is currently under further 
development. Another monoclonal antibody that shows potential as an entry inhibitor is 
TNX-355. TNX-355 (previously called Hu5A8) is a humanized IgG4 monoclonal 
antibody that binds to CD4 domain 2 and does not prevent CD4 binding to gp120, but 
instead appears to prevent further conformational changes necessary for viral entry146, 147. 
Clinical trails using this antibody have shown some success148, 149 and larger trials are 
currently underway. 
 
1.4.1.2. Small molecule inhibitors 
 
The promising results obtained from studies involving entry inhibitors have led to an 
increased interest in molecules that disrupt the interactions between gp120 and its human 
cellular receptors. The focus, however, has shifted onto smaller molecules than those 
described in the preceding section. Reduced size would allow greater access of the 
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molecule to conserved, functionally important domains of gp120 and would possibly 
have the advantage of cost-effectiveness as well as easier administration (i.e. oral) than 
bulkier recombinant proteins and antibodies (which are administered via injection).  
 
One such molecule, identified from a whole cell infection screen against HIV-1JRFL. is 
BMS-378806150-152. This compound inhibits the gp120-CD4 interaction by binding gp120 
in the CD4-binding pocket, thereby blocking the attachment of CD4. It has been shown 
capable of neutralising both laboratory-adapted and primary virus isolates, including 
those resistant to protease and reverse transcriptase inhibitors. Initial studies showed no 
significant cytotoxicity and supported an oral formulation of the compound for man151. 
Further studies, however, revealed that BMS-378806 shows a decreased activity against 
subtype C, as well as other HIV-1 subtypes when compared to its efficacy against 
subtype B strains151, probably due to the inherent variability between HIV-1 envelope 
proteins and the use of a subtype B virus in the screening process. This drug is currently 
under investigation as a microbicide and has shown some promise in this regard153. A 
number of small molecule coreceptor antagonists are also currently under development. 
AMD070 is an orally bioavailable CXCR4 antagonist that has shown promising results in 
early clinical trials154, 155. Maraviroc, an imidazopyridine small molecule CCR5 
antagonist, was discovered through screening of the Pfizer compound file and used with 
positive results in clinical trials, resulting in approval for its use from the FDA156-158. 
 
Other small molecules that have attracted attention as HIV entry inhibitors are peptides. 
In fact, the first FDA-approved entry inhibitor, Enfuvirtide, is a peptide. Enfuvirtide (T-
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20/DP-178), which received FDA approval in 2003 as salvage therapy for AIDS patients 
failing antiretroviral treatment, is a 36 mer synthetic peptide derived from the sequence of 
HR2 in gp41159. It exerts antiviral activity by interacting with the viral sequence within 
HR1 and inhibiting its association with the viral HR2, thereby preventing gp41-mediated 
fusion159, 160. Peptide inhibitors have also been developed against gp120. Peptide-T is an 
octapeptide with the sequence ASTTTNYT that was designed based on an eight amino 
acid sequence in the V2 loop of gp120, and which has been demonstrating antiviral 
activity since 1986161. It was more recently discovered that this peptide works by 
blocking gp120/CCR5 chemokine receptor-mediated chemotaxis162. When administered 
to patients, Peptide-T shows both antiviral activity and immunological benefits and is 
currently under further investigation163.  
 
Peptides interfering with the gp120-CD4 interaction also have great potential as entry 
inhibitors. Aside from rational design, a successful approach for discovery of ligands that 
interact specifically with gp120 and which may inhibit its interaction with CD4 is that of 
selecting such ligands from phage display libraries164, 165. Ferrer and Harrison164 used 
M13 bacteriophage libraries expressing random 12- and 7- mer peptides to select peptides 
that bind to gp120 with high affinity. Competition ELISA assays on peptides selected by 
this method showed that these reduced binding of gp120 to CD4. One specific peptide 
selected during this study, with the sequence RINNIPWSEAMM (designated 12p1), was 
found not only to inhibit the interaction of gp120 and CD4, but also the interaction of 
gp120 with monoclonal antibody (MAb) 17b (an antibody that recognises an epitope 
overlapping the CCR5 binding site). This is significant, as compounds that inhibit CD4 
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binding to gp120 may cause conformational changes similar to those caused by CD4, 
thereby activating gp120 to a state conducive to coreceptor binding and so enhancing, 
rather than inhibiting, virus entry164, 166. Rather than functioning as a competitive 
inhibitor and binding the CD4 binding site in place of CD4, 12p1 appears to function via 
an allosteric inhibitory mechanism, binding gp120 at a site distinct from that of CD4 and 
stabilising gp120 in a non-productive intermediate conformation, which is unable to bind 
either CD4 or a coreceptor166. It is important to note, however, that this study was done 
with recombinant subtype B gp120 clones (HXB2, SF2 and ADA) and the ability of the 
peptide to disrupt interactions between CD4 and gp120 cloned from other clades was not 
established. The efficacy of the compound against primary HIV-1 isolates in cell culture 
was also not established.  
 
The peptides isolated by this method have also served as a starting point for the rational 
design of stronger inhibitors167. 12p1 was modified using click conjugation in order to 
generate the inhibitory molecule HNG-105167, 168. In order to establish whether or not this 
molecule has broad-range specificity, it was tested against a panel of gp120s, as well as 
viral isolates of different subtypes167. These studies revealed that HNG-105 shows 
inhibitory action against a variety of subtypes (A, B, C and D), although the panel used 
only included a maximum of two viruses from each non-B subtype. An additional point 
to note is that the inhibition observed was highly variable between viruses, both between 
different subtypes and within the subtypes themselves. Therefore, while these studies 
indicate that bio-panning is a powerful tool for the selection of gp120 antagonists and 
support the search for small molecule inhibitors of the gp120-CD4 interaction, they also 
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highlight the importance of using a locally relevant clone of gp120 in order to establish a 
compound that will be effective against the subtype C viruses found in Southern Africa. 
 
1.5. Project objectives  
 
One goal of the work in our laboratory is the identification of small 7-mer subtype C-
specific gp120-binding peptides by phage display techniques. The large amount of gp120 
that will be required for this necessitates the development of technologies for the 
expression and purification of recombinant gp120 from locally predominant strains of 
HIV. To this end, the aim of this study was to express, purify and characterise 
recombinant subtype C gp120. In other studies, the HIV-1 envelope protein was 
successfully expressed by recombinant baculoviruses in insect cells169-171, as well as in 
mammalian cells69, 172. A common approach used to purify gp120 is that of capturing 
recombinant gp120 from cell culture supernatants on affinity chromatography columns 
containing immobilised lentil lectin (Lens culinaris), followed by ion-exchange 
chromatography172. This study describes similar work performed in our laboratory to 
produce, purify and characterise two new recombinant Subtype C gp120s. 
 
The purified gp120 produced by procedures established in our laboratory during this 
study will be tested for its sensitivity to existing gp120 antagonists. Ultimately, it will 
also be used to select compounds with high affinity for subtype C gp120 from 
combinatorial phage-display libraries. The ability of these compounds to disrupt binding 
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of gp120 to CD4 and to inhibit the replication of a variety of HIV-1 isolates in cell 
culture will be assessed. This will allow a direct comparison of relative inhibitory effects 
on HIV-1 replication in vitro, of gp120 binding peptides identified in this study and those 
developed by selection with non-C gp120 clones. It is hoped that the ultimate outcome of 
the study will be a lead compound that may be used to augment the local currently 
available therapies. 
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2. Materials 
and Methods 
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2.1. Patient Samples 
 
HIV-infected PBMCs were a kind gift of Ms B Connell, who processed blood samples 
collected in 5ml EDTA tubes from advanced AIDS patients presenting at the 
Johannesburg Hospital AIDS clinic in 2005. HIV-infected PBMCs were cocultured 
according to standard coculture techniques, with PBMCs obtained from healthy donors 
from the South African National Blood Service. Ethics clearance for the acquisition of 
the HIV-infected samples was obtained from the University Ethics Committee (Protocol 
No: M041002). The viral samples collected were designated 05ZAFV1-05ZAFV32, 
hereafter referred to as FV1-FV32 
 
2.2. Viral Nucleic Acid Isolation 
 
After cell culture, proviral DNA from the corresponding PBMC cocultures was isolated 
(from 1 ml PBMCs) using the High Pure PCR Template Preparation Kit (Roche; 
Mannheim, Germany) according to the manufacturer’s protocol.   
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2.3. PCR Amplification of HIV-1 Subtype C gp160 coding 
regions 
 
2.3.1. Primer Design 
 
The basic env primers described by Gao et al173 were adapted for subtype C specificity by 
comparison of 52 complete HIV-1 subtype C genome sequences retrieved from the 
National Library of Medicine Nucleotide Database174. The adapted primers, EnvA-1, 
EnvB-1, EnvM-1, and EnvN-1 are described in table 2.1, with the changes from the 
primers of Gao et al. underlined and in bold. 
 
2.3.2. Nested PCR 
 
Nested PCR was performed directly on proviral DNA, using the outer primers EnvA-1 
and EnvN-1 and the inner primers EnvB-1 and EnvM-1 (Table 2.1). PCR was performed 
using the High Fidelity ExpandPLUS PCR System (Roche ; Mannheim, Germany). 
Proviral DNA isolated from PBMCs was diluted 100 times, and 5 µl (approximately 250 
ng) of the dilution was used in 50 µl PCR reactions, which contained 1 x Expand 
HiFiPLUS Reaction buffer with 1.5 mM MgCl2, 200 µM dNTPs, 0.4 µM of each EnvA-1 
and EnvN-1 primers and 2.5 U Expand HiFiPLUS Enzyme Blend. All PCR reactions were 
done on a Bio-Rad MyCyclerTM (Bio-Rad; Hercules, CA). PCR began with a 3 minute 
hot start, followed by 30 cycles consisting of a 15 second denaturation at 94°C, a 30 
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second annealing step at 61°C, and a 3 minute elongation step at 72°C. This was followed 
by a single 10 minute elongation step at 72°C, where after the reactions were cooled to 
4°C indefinitely. 
 
The second round of amplification of the gp160 coding region was set up as for the first 
round, containing 0.4 µM each of EnvB-1 and EnvM-1 instead of EnvA-1 and EnvN-1. 
PCR began with 3 minute hot start, followed by 30 cycles consisting of a 30 second 
denaturation at 94°C, a 45 second annealing step at 55°C, and a 3 minute elongation step 
at 72°C. This was followed by a single 10 minute elongation step at 72°C, where after the 
reactions were cooled to 4°C indefinitely. 
 
PCR products were run on a 1% agarose (Sigma; St Louis, MO) gel together with 0.5 µg 
of Quick-LoadTM 1 kb DNA Ladder (New England Biolabs; Ipswich, MA). Products 
from successful PCR reactions were purified using a HighPure PCR Product Purification 
Kit (Roche ; Mannheim, Germany) according the manufacturer’s recommended protocol 
and eluted in 50-75 µl of Elution buffer for every 100 µl of PCR product cleaned. 
 
2.4. Population-based sequencing of the gp160 coding regions 
 
Purified second round gp160 amplicons of 20 HIV-1 viral isolates were sequenced with 
15 primers (table 2.1) in order to obtain double stranded sequence in both the forward and 
reverse direction for the entire amplicon. Sequencing reactions were set up in a total 
volume of 21 µl, using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied 
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BioSystems; Foster City, CA). Each reaction contained 20-50 ng of DNA, 4.0 µl of 
Terminator Ready Reaction Mix, 1 x BigDye Sequencing buffer, and 1 µl of primer at 3.2 
pmol/µl (a final concentration of 0.15 µM). Sequencing reactions were placed in a Bio-
Rad MyCyclerTM (Bio-Rad; Hercules, CA); undergoing 25 cycles consisting of 10 
seconds at 94°C , 5 seconds at 50°C and 4 minutes at 60°C. This was followed by an 
incubation of at least 7 minutes at 4°C. 
 
After the cycle sequencing reaction, extension products were purified by isopropanol 
precipitation. Samples were transferred to a sequencing plate and 80 µl an of 80% 
isopropanol solution was added to each well and reverse pipetted in order to mix. The 
plate was then placed in the dark at room temperature for 15 minutes before a 45 minute 
centrifugation (2000 x g) at room temperature. Within one minute of the end of the 
centrifugation step, the plate was removed from the centrifuge and inverted onto paper 
toweling. The plate was then centrifuged in this position (inverted) for 1 minute (700 x 
g). The plate was allowed to air dry for a few minutes, after which, 10 µl Hi-DiTM 
Formamide (Applied BioSystems; Foster City, CA) was added to each well. Sequences 
were run in an ABI 3100 automated sequencer (Applied BioSystems; Foster City, CA). 
Full length gp160 sequences were then assembled and edited using Sequencher v4.6 
(GeneCodes, Ann Arbor, MI).  
 
Phylogenetic analysis was performed by Dr M Papathansopoulos. A phylogenetic tree 
was constructed for the 20 isolates. Briefly, a multiple alignment of the gp160 regions 
with references from HIV-1 subtypes A to K, CRF01_AE and CRF02_AG45 was 
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generated in Clustal X and aligned sequences were converted to MEGA V3.0 format, and 
used in phylogenetic and molecular evolutionary analyses. A phylogeny reconstruction of 
each env gene was performed by Neighbor-Joining using the Kimura two-parameter 
distance matrix. The stability of the nodes was assessed by bootstrap analysis (1000 
replicates) and bootstrap values greater than 70% were considered significant. 
 
2.5. Amplification of gp120 coding regions 
 
Gp120-encoding DNA was amplified from second round gp160 amplicons using a High 
Fidelity ExpandPLUS PCR System (Roche ; Mannheim, Germany) and the primers 
gp120(F) and gp120(R) (Table 2.1). These primers were designed according to consensus 
gp120 5’ and 3’ sequences identified by comparison of 26 complete HIV-1 subtype C env 
sequences published on the NLM nucleotide database174. The primers additionally 
included 5’-terminal restriction endonuclease recognition sequences to facilitate 
subsequent cloning procedures. In gp120(F), a restriction endonuclease recognition 
sequence for Pag I (Bsp HI) (T/CATGA) was included, while in gp120(R), the site 
included was for Xho I (C/TCGAG). 
 
Second round gp160 amplicons were diluted 100 times and 5 µl of this dilution 
(approximately 300 ng) was used in 50 µl reactions containing 1 x Expand HiFiPLUS 
Reaction buffer with 1.5 mM MgCl2, 200 µM dNTPs, 0.4 µM each of gp120(F) and 
gp120(R), and 2.5 U Expand HiFiPLUS Enzyme Blend. PCR began with a 5 minute hot 
start at 94°C, followed by 30 cycles consisting of 30 seconds at 94°C, 30 seconds at 
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55°C, and 2 minutes at 72°C. This was followed by a single 10 minute elongation step at 
72°C, and a 4°C hold. This reaction yielded a product of approximately 1500 bp, which 
was resolved on a 0.8% agarose gel together with 0.5 µg of Quick-LoadTM 1 kb DNA 
Ladder (New England Biolabs; Ipswich, MA) and visualised under UV light.  
 
Products from successful PCR reactions were purified using the HighPure PCR Product 
Purification Kit (Roche ; Mannhein, Germany) according the manufacturer’s 
recommended protocol, and eluted in 50 µl Elution buffer for every 50 µl of PCR product 
added. 
 
2.6. Generation of Recombinant gp120-Expression Vectors 
 
Gp120-encoding DNA was cloned into the protein expression vector pTriEx-3 (Novagen; 
Darmstadt, Germany). This vector incorporates three different promoters allowing the 
expression of protein from sequences inserted into the pTriEx multiple cloning site in 
mammalian, insect and bacterial cells (see Appendix 2 for pTriEx map). A CMV 
immediate early enhancer and promoter allows for protein expression in vertebrate cells 
and a T7 lac promoter regulates expression in E. coli. pTriEx-3 also contains baculovirus 
sequences which permit the generation of recombinant baculoviruses by homologous 
recombination for the infection of insect cells, where the vector’s p10 promoter controls 
protein expression in this host.  
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2.6.1. Digestion and ligation of pTriEx-3 and gp120-encoding DNA 
 
Approximately 2.5 µg  of  each purified gp120 amplicon was digested in a 50 µl reaction 
containing  20 U of Pag I (Fermentas, Ontario, Canada) and 20 U of Xho I (Fermentas; 
Ontario, Canada) in 1 x Fermentas  buffer O (Fermentas; Ontario, Canada). 3.4 µg of 
pTriEx-3 stock was also digested in a 50 µl reaction containing 20 U of Nco I (Promega; 
Madison, WI), 20 U of Xho I (Promega; Madison, WI)  and 1 x Promega buffer D 
(Promega; Madison, WI). All digestion reactions were incubated for 3 hours in a water 
bath set at 37˚C. 
 
Digested gp120 inserts were purified with a GFXTM PCR DNA and Gel Band 
Purification kit (Amersham Biosciences; Freiburg, Germany) according to the 
manufacturer’s protocol and the DNA was eluted in 10-30 µl of dH2O. The pTriEx 
digestions were resolved on a 0.8% preparative agarose gel. The linearised plasmid was 
visualised under ultraviolet light, excised from the gel with a clean razor blade, and the 
DNA recovered using the Amersham GFXTM PCR DNA and Gel Band Purification kit 
(Amersham Biosciences; Freiburg, Germany) according to the manufacturer’s protocol. 
pTriEx DNA was eluted in 50 µl pure H2O. Concentrations of the purified restriction 
products were determined by UV spectrophotometry. 
 
Ligation reactions were set up using a Quick LigationTM Kit (New England Biolabs; 
Ipswich, MA). 50 ng of linearised pTriEx-3 DNA were combined with a 3-fold molar 
excess of gp120-encoding fragments, and the volume adjusted to 10 µl with dH2O. 10 µl 
of 2 x Quick Ligation buffer was added to the mixture, followed by the addition of 1 µl of 
 40 
Quick T4 DNA Ligase. The reaction was centrifuged briefly and left at room temperature 
for 10-15 minutes. 5 µl of the ligation mix was then used to transform competent E.coli 
DH5α according to standard protocols (Appendix 1). 
 
2.6.2. Colony Screening Procedures 
 
2.6.2.1. PCR Screening 
 
Initial screening of colonies present on positive ligation plates was accomplished by PCR 
using Promega PCR Master Mix (Promega; Madison, WI). Colonies were picked and 
cultured overnight in a shaking incubator at 37˚C in 1 ml Luria Broth containing 0.1 
mg/ml ampicillin (Appendix 1). Overnight cultures were diluted 10 times and  2 µl of 
diluted culture was used in a 20 µl PCR reaction containing 1 x Promega PCR Master 
Mix, and 0.5 µM each of gp120(F) and gp120(R) primers. PCR conditions were as 
described in section 2.5 for the amplification of gp120-encoding DNA. PCR products 
were resolved on a 1% agarose gel together with 0.5 µg of Quick-LoadTM 1 kb DNA 
Ladder (New England Biolabs; Ipswich, MA). The presence of an approximately 1.5 kb 
product was indicative of the presence of gp120 in the clone.  
 
2.6.2.2. Restriction Mapping 
 
Cultures of clones positive for gp120 by PCR were grown in a shaking incubator 
overnight at 37˚C in 8 ml of Luria Broth containing 0.1 mg/ml ampicillin. 5 µl of these 
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cultures were used to make replica plates, and the rest of the culture was used for 
isolation of recombinant plasmids. Plasmids were isolated using a Sigma GenEluteTM 
Plasmid Miniprep Kit (Sigma; St. Louis, MO) according to the manufacturer’s protocol. 
The presence of plasmid DNA in the elution was confirmed by resolving the samples on 
a 1% agarose gel and visualizing the DNA under UV light. 
 
The integrity of the clones was investigated using restriction digestion analysis.  Each 
plasmid was linearised using Xho I (Fermentas; Ontario, Canada) in order to get an 
accurate estimation of the size of the plasmid containing the insert (approximately 6.5 kb 
for successful clones). This was done in 20 µl reactions containing 5 U Xho I in 1 x 
Fermentas Buffer R. As a further control, the gp120 fragment was excised from the 
plasmid using Xba I (New England Biolabs; Ipswich, MA) and Xho I (Promega; Madison 
WI). These reactions were set up as double digests in a volume of 20 µl containing 10 U 
Xba I and 5 U Xho I with 100 µg/ml Bovine Serum Albumin (New Englad Biolabs 
(NEB); Ipswich, MA) in 1 x  NEB Buffer 2. All digestion reactions for screening 
purposes were incubated in a water bath for one hour at 37˚C. The products of these 
reactions were resolved on a 0.8% agarose gel together with 0.5 µg of Quick-LoadTM 1 kb 
DNA Ladder (New England Biolabs; Ipswich, MA) and visualised under UV light.  
 
2.6.2.3. Sequencing and clone selection 
 
From a panel of 17 recombinant pTriEx-gp120 clones, two representative plasmids were 
selected for further analysis. These were selected according to in vitro viral culture 
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studies done in our laboratory. Clones originating from one CXCR4-utilising and one 
CCR5-utilising isolate as determined by phenotypic studies were chosen. The clones 
selected for further propagation were those originating from 05ZAFV3 (CXCR4-
utilising) and 05ZAFV5 (CCR5-utilizing). These clones are hereafter referred to as 
pTriEx-FV3 and pTriEx-FV5 respectively. Clones of these isolates that had tested 
positive for the presence of the gp120 insert by PCR, and that showed correct orientation 
on restriction digestion analysis were selected for sequencing in order to further confirm 
the integrity and frame of the insert. Sequencing was done by Inqaba Biotech (Pretoria, 
South Africa) using primers PTF, PTR, PF(2), PR(2), PF(3) and PR(3)  as described in 
table 2.1. The inner primers (PF(2), PR(2), PF(3) and PR(3)) were designed as 
sequencing progressed, according to sequences generated by the preceding sequencing 
reactions. Full length gp120 sequences were then assembled and edited using Sequencher 
v4.6 (GeneCodes, Ann Arbor, MI). Sequences were then inspected for in-frame start and 
stop codons. 
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Table 2.1: PCR and cycle sequencing primers 
Primer Sequence 
EnvA-1§ 5’-GGCTTAGGCATTTCCTATGGCAGGAAGAA-3’ 
EnvB-1§ 5’- GGAAAGAGCAGAAGACAGTGGCAATGA -3’ 
EnvM-1§ 5’- TAACCCATCCAGTCCCCCCTTTTCTTTTA –3’ 
EnvN-1§ 5’- TTGCCAATCAGGGAAGAAGCCTTGTGT -3’ 
gp120-5’‡ ψ 5’- AGA GCA GAA GAC AGT GGC AAT GA-3’ 
TU-A‡ ψ 5’- TAT TAT GGG GTT CCT GTG TGG-3’ 
ES21‡ ψ 5’- ACA CAT GCC TGT GTA CCC ACA G-3’ 
ED5‡ ψ 5’-ATG GGA TCA AAG CCT AAA GCC ATG TG-3’ 
A590‡ ψ 5’-AAT CGC GAA ACC AGC CGG CGC ACA AT-3’ 
Env1f‡ ψ 5’-CCA TAA CAC AAG CCT GTC CAA AGG-3’ 
JL74‡ ψ 5’-ACA TGT GGA AAA ATA ACA TGG TAG AAC AG-3’ 
Envf*‡ ψ 5’CTG TAG AAA TTG TGT GTA CAAGAC CC-3’ 
AES6‡ ψ 5’-GGA CAA GCA TTC TAT GCA ACA GGT G-3’ 
AA1570*‡ ψ 5’-GGA GCA GCA GGA AGC ACT ATG GGC-3’ 
Env3F‡ ψ 5’GGA AGC ACT ATG GGC GCG GC-3’ 
JL103‡ ψ 5-TAA CAA ATT GGC TGT GGT ATA TAA-3’ 
ZM184D‡ ψ 5’CCA CTC AGC TAC TGC TAT TGC TAT GGT-3’ 
Env4f‡ ψ 5-GAG TTA GGC AGG GAT ACT CAC C-3’ 
TU-J‡ ψ 5’-GTT AGG CAG GGA TAC TCA CC-3’ 
gp120(F)¥ 5’-TCG ATC TCA TGA GAG TGA TGG GGA TAC AGA  GG–3’ 
gp120(R)¥ 5’-CCT CGA GTT ATC TTT TTT CTC TCT CCA CCA CTC TCC  T-3’ 
PTF¶ 5’- GTT ATT GTG CTG TCT CAT C-3’ 
PTR¶ 5’- TCG ATC TCA GTG GTA TTT GTG-3’ 
PF(2) ¥ 5'-AAA TTG CTC TTT CAA TGT AAC CA-3’ 
PR(2) ¥ 5'-TCT ACA ATT AAA GCT ATG TGT TG-3’ 
PF(3) ¥    5'- ACA CAT AGC TTT AAT TGT AGA G-3’ 
PR(3) ¥  5'- AAG TGA CAC AGA GTG GG-3’ 
RTF¥ 5’-ATG GGG CAT CTT AGG CTT TTG G-3’ 
RTR¥ 5’-GTG GGT ACA CAG GCA TGT GT-3’ 
 
§Adapted from Gao et al173; changes from the original primers are bold and underlined 
‡ F. McCutchan, personal communication with Dr. M Papathanasopolous 
¥ Designed during this study 
¶Source: Novagen, Darmstadt Germany 
*These primers were only used on isolates 05ZAFV8, 05ZAFV9, 05ZAFV27, 05ZAFV28  
ψThese primers were used for sequencing of gp160-coding regions 
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2.7. Gp120 expression in bacteria 
 
2.7.1. Transformation of E. coli BL21  
 
As a pilot experiment designed to further confirm the presence a functional open reading 
frame in the clones, expression of gp120 in a bacterial system was assessed. Competent 
E.coli BL21 (Stratagene; La Jolla, CA) (Appendix 1) were transformed with 
approximately 0.075 µg pTriEx-FV3 according to standard protocols (Appendix 1). 
Single colonies were selected for inoculation of Luria Broth containing both 0.1 mg/ml 
chloramphenicol (Sigma; St Louis, MO) (Appendix 1) and 0.1 mg/ml ampicillin. This 
culture was grown overnight in a shaking incubator at 37˚C, and 5 µl was used to 
construct BL21-pTriEx-FV3 replica plates containing 0.1 mg/ml each of ampicillin and 
chloramphenicol. 
 
2.7.2. Induction of FV3 gp120 expression in E. coli BL21. 
 
For protein expression experiments, 8 ml of Luria Broth with 0.1 mg/ml each of 
ampicillin and chloramphenicol was inoculated with a single colony from the BL21-
pTriEx-FV3 replica plate and grown overnight in a shaking incubator at 37˚C. As a 
negative control, untransformed E. coli BL21 were grown up overnight in 8 ml Luria 
Broth containing 0.1 mg/ml chloramphenicol. The following morning, the cultures were 
split between two tubes, diluted 10 times in Luria Broth containing antibiotics, and grown 
for a further hour in a shaking incubator at 37˚C. A 1 ml sample was then taken from 
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each tube (time = 0). Isopropyl-β-D-thiogalactopyranoside (IPTG) (Roche; Mannheim, 
Germany) was then added to one tube at a final concentration of 1 mM in order to induce 
protein expression by the T7 promoter. IPTG was omitted in negative control cultures. 1 
ml samples were taken from each tube on an hourly basis for 4 hours. Bacterial culture 
samples were centrifuged for 1 minute at 13 000 rpm in a Biofuge Pico (Heraeus; Hanau, 
Germany), and the pellets resuspended in 75 µl of PBS. Pellets were analysed for the 
presence of gp120 by SDS-PAGE and Western Blotting analysis as described in section 
2.8. 
 
2.8. Gp120 Assays 
 
2.8.1. Antibodies 
 
The following reagents were obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 IIIB gp160 Monoclonal 
Antibody (Chessie 13-39.1) from Dr. George Lewis175;  HIV-1 gp120 Monoclonal 
Antibody (ID6) from Dr. Kenneth Ugen and Dr. David Weiner;176, 177. NEA 9201 and 
NEA 9301 were obtained from Perkin Elmer (Wellesley, MA). ECLTM Anti-Human IgG, 
HRP linked whole antibody (from sheep) (Anti-human) and ECLTM Anti-Mouse IgG, 
HRP linked whole antibody (from sheep) (Anti-mouse) were obtained from Amersham 
Biosciences (Freiburg, Germany)  
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2.8.2. Sample preparation and SDS-PAGE 
 
Clarified cell culture supernatants (or resuspended pellets in the case of bacterial 
expression) were added to equal volumes of 2 x treatment buffer (Appendix 1), and 
boiled for five minutes. Samples were resolved on 8% SDS-polyacrylamide gels 
according to a standard protocol (Appendix 1).  Gels were then either stained with 
Coomassie® Brilliant Blue R-250 (Sigma; St Louis, MO), silver stained, or used for 
Western Blotting. 
 
2.8.3. Staining of SDS-PAGE gels 
 
Gels were fixed for an hour in a 40% Methanol, 10% Acetic Acid solution. Following 
this, gels were either silver stained using the Bio-Rad Silver Stain Kit (Bio-Rad; 
Hercules, CA) according to the manufactirer’s recommended protocol, or  stained with 
Coomassie® Brilliant Blue R-250 (Appendix 1).  
 
2.8.4. Western Blot analysis of gp120 expression 
 
Western blotting of gels was performed according to a standard protocol (described in 
Appendix 1).  
 
A number of alternatives were used throughout this study as the primary antibody 
solution in order to detect expressed FV3 and FV5 gp120. The first alternative was using 
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human plasma as a primary antibody solution. Human plasma from HIV-1 positive 
individuals was obtained from the South African National Blood Service and heat-
inactivated at 60°C for one hour before use. Membranes were shaken gently for 1 hour at 
room temperature in 20 ml of a 1:1000 dilution of plasma. A second alternative was the 
use of the monoclonal antibody 9201 diluted in 2 ml T-TBS to a concentration of 1:1000 
and placed on top of the nitrocellulose membrane for 1 hour at room temperature. 9201 is 
a mouse monoclonal antibody directed against an epitope near the C-Terminus of gp120. 
It was raised against the peptide MRDNWRSELYKY178, although the epitope has also 
been noted as the slightly overlapping sequence GGGDMRDNWRSE179 . The third 
alternative for detection of gp120 was the use of a cocktail of three mouse monoclonal 
antibodies, ID6, Chessie13-39.1, and 9301 each at a concentration of 1:500, made up in 2 
ml T-TBS and incubated on the membrane for 1 hour at room temperature. 9301, which 
replaced 9201 when it was discontinued, is directed against the epitope 
MRDNWRSELYKY180. Chessie 13-39.1 is directed against LAI gp120 amino acids 252-
273: RVVSTQLLLNGSLAEEEVVIR175, while ID6 is directed against the first 204 
amino acids of LAV-1 gp160176, 177. 
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2.9. gp120 Expression in Sf9 insect cells  
 
2.9.1. Insect cell culture 
 
Once the presence of a functional open reading frame in the pTriEx-gp120 clones was 
confirmed, preparations were made for the expression of fully glycosylated recombinant 
gp120 in Sf9 insect cells. 
 
2.9.1.1. Insect cell culture in monolayers 
 
Recommended cell lines for Insect cell expression of recombinant protein using pTriEx 
are the Ready-Plaque™ Sf9 and TriEx Sf9 cells (Novagen; Darmstadt, Germany). Ready-
Plaque™ Sf9 cells were maintained in serum-free BacVector Insect Cell medium 
(Novagen, Darmstadt, Germany) with no additives. TriEx Sf9 cells were maintained in 
serum-free TriEx Insect Cell Medium (Novagen, Darmstadt, Germany) with no additives. 
Both TriEx and BacVector Insect cell media are specifically optimized for cell growth 
and protein expression in these cell lines. Cells were maintained in monolayers at 28°C 
and split approximately once every seven days when confluent. The splitting procedure 
involved pouring off the old medium, washing the cells once in PBS (Sigma; St Louis, 
MO) and flushing them off the side of the flask using a pipette and fresh medium. One 
tenth of these cells were then added to a new flask in a suitable volume of fresh medium.  
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2.9.1.2. Insect cell suspension culture 
 
TriEx Sf9 cells were grown until confluent as a monolayer in a 175 cm2 tissue culture 
flask (Nunc; Roskilde, Denmark). Cells were then washed with PBS and resuspended in 
100 ml of TriEx medium in a conical flask at a concentration of 5 x 105 cells/ml. Cells 
were incubated at 28°C, shaking at 150 rpm.  
 
2.9.2. Liquid Overlay Transfection Procedure 
 
Liquid overlay transfections were done based on the manufacturer’s recommended 
protocol. The basis for the production of recombinant baculoviruses is homologous 
recombination between sequences in the backbone baculoviral DNA supplied in trans by 
cotransfection and recombinant pTriEx-3 plasmids. For each transfection, a 25 cm2 flask 
was seeded with total of 2.5 x 106 Ready PlaqueTM Sf9 cells in 5 ml of BacVector 
Medium. Cells were left to attach to the flasks for at least 20 minutes. For each 
transfection, the following components were assembled in a sterile 6 ml polystyrene tube 
(in order): BacVector medium (25 µl less the amount of DNA added to the reaction), 100 
ng of of BacVector®-3000 Triple Cut Virus DNA (Novagen, Darmstadt, Germany) and 
500 ng of recombinant pTriEx-FV3/FV5. The negative control was set up in an identical 
manner, substituting BacVector medium for the recombinant plasmid. For each 
transfection, 5 µl of Eufectin™ Transfection Reagent (Novagen, Darmstadt, Germany) 
was added to 20 µl of Nuclease-free Water in a separate sterile polystyrene tube. The 
entire 25 µl DNA mixture was immediately added to this tube, swirled to mix and 
incubated at room temperature for 15 minutes. During the incubation, cells in the 25 cm2 
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flasks were washed twice with BacVector medium. After the final wash, 1 ml of medium 
was added to each flask. 
 
After the DNA/Eufectin incubation was complete, 450 µl BacVector medium was added 
to the mixture and gently mixed. 100 µl of this mixture was then added to 400 µl medium 
in a separate tube to constitute a 1/5 dilution. The DNA mixtures were then added to the 1 
ml of medium covering the cells in the flasks and the flasks were then incubated for 1 hr 
at room temperature. During this hour, even and consistent distribution of the transfection 
mixture was achieved by gently swirling the flask every 15-20 minutes. After one hour, 6 
ml of BacVector medium containing 5% Foetal Bovine Serum (FBS) (Invitrogen, 
Carlsbad, CA) was added to the flasks, which were then incubated at 28°C for 5 days. 
After 5 days, the medium was harvested from the cells, centrifuged at 300 x g for 5 
minutes in an Eppendorf 5810R centrifuge (Eppendorf; Hamburg, Germany) and 
recombinant baculovirus (Bac-FV3/Bac-FV5)-containing supernatants were used to 
reinfect Ready PlaqueTM Sf9 cells. 
 
2.9.3. Re-infection using the transfection supernatant 
 
Successive rounds of reinfection with Bac-FV3 and Bac-FV5 were performed in order to 
increase baculoviral titers. 6-well culture dishes (Nunc, Roskilde, Denmark) were seeded 
with 1 x 106 Ready PlaqueTM Sf9 cells in 4 ml of BacVector medium. 1 ml of each 
transfection supernatant was added to each well and plates were incubated at 28°C. After 
5 days, the medium was harvested from the cells and centrifuged at 300 x g for 5 minutes 
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in an Eppendorf 5810R centrifuge (Eppendorf; Hamburg, Germany). The supernatants 
were then assayed for protein expression as described in section 2.8. Successive rounds 
of reinfection were performed until supernatants were positive for gp120 by Western Blot 
analysis (2-3 rounds of reinfection were usually required to obtain a sufficient viral titer 
to result in detectable protein expression). 
 
2.9.4. Plaque purification and amplification of baculoviral clones 
 
2.9.4.1. Plaque purification 
 
Plaque assays were performed according to a protocol adapted from the manufacturer 
(Novagen, Darmstadt, Germany). 6-well culture plates were seeded with 1 x 106 Ready 
PlaqueTM Sf9 cells per well (in 2 ml BacVector medium) and incubated at room 
temperature for at least 20 minutes in order to allow the cells to adhere. During this 
incubation period, serial dilutions of the virus-containing supernatant were made. Plaque 
assays for purification purposes required baculoviral dilutions of 5, 50, 500, 5 000 and 50 
000 times in BacVector medium. Once the dilutions were set up, the medium was 
aspirated from the cells and 900 µl of each dilution was added to its allocated well. 900 
µl of fresh medium was added to the sixth well of the plate to serve as a negative control. 
Plates were then incubated at room temperature for 1 hour. During the incubation period, 
the agarose overlay was prepared from an autoclaved 3% BacPlaque Agarose (Novagen, 
Darmstadt, Germany) stock. BacVector medium containing 5% FBS was added to the 
melted BacPlaque Agarose stock to a final agarose concentration of 1%. The agarose was 
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kept at 37°C in a water bath until further use. After the 1 hour incubation, the baculoviral 
dilutions were aspirated from the cell monolayer and 1 ml of the agarose overlay was 
added gently to the side of each well and allowed to set. 1 ml of BacVector medium 
containing 5% FBS was then added to each well. Plates were incubated at 28°C on damp 
tissue paper in a closed container for 2-5 days, until plaques were visible. 
 
2.9.4.2. Plaque Staining 
 
For plaque staining, a 0.33% (w/v) stock solution of Neutral Red (kind gift of Dr Clem 
Penny) was diluted 1:13 with sterile PBS just before use. The liquid overlay was 
aspirated from the plates, and 1 ml of diluted neutral red was added to the centre of each 
well and incubated at 28°C for 2 hours. After 2 hours, the neutral red was aspirated and 
plates were left at room temperature to allow the cells to take up the stain overnight. Only 
live cells are stained and thus plaques can be visualised under a microscope as grey 
clearings in a pinkish red background. 
 
2.9.4.3. Plaque picking and amplification 
 
Several Bac-FV3 and Bac-FV5 plaques visualised by neutral red staining were removed 
using a sterile glass Pasteur pipette. Plaque-containing agarose plugs were placed in 1 ml 
of BacVector medium and incubated at 4°C overnight in order to allow baculoviruses to 
diffuse out of the agarose plug and into the medium. 400 µl of this medium was then used 
in successive rounds of reinfection in order to amplify each virus as described in section 
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2.9.3. The plaque assay was then repeated in order to refine the selection of single 
baculoviral clones. 
 
2.9.4.4. Generation of high-titer baculoviral stocks 
 
After the second round of purification, high-titer stocks of Bac-FV3 and Bac-FV5 were 
generated. Single, well-defined plaques were selected after the second plaque purification 
step by withdrawal in a sterile glass Pasteur Pipette. These agarose plugs were then each 
placed in 1 ml medium and incubated at 4°C overnight in order to allow the 
baculoviruses to diffuse out (Bac-FV3’ and Bac-FV5’). The following morning, 25 cm2 
flasks were seeded with 5 ml Ready-Plaque™ Sf9 cells at a density of 5 x 105 cells/ml 
and left for 20 minutes in order to allow the cells to attach. Following attachment, the 
medium was aspirated from the cells and 300 µl of Bac-FV3’ or Bac-FV5’was added to 
the cells, which were allowed to incubate at room temperature for 1 hour. The medium 
was swirled over the cells twice during this time. After 1 hour, 5 ml fresh BacVector 
medium was added to the cells, which were then left for 5 days at 28ºC.  
 
After 5 days, supernatants (Bac-FV3’’ and Bac-FV5’’) were harvested from these cells 
and clarified by centrifugation. To expand the baculoviral stock, 75 cm2 flasks were 
seeded with 10 ml of Ready-Plaque™ Sf9 cells at a density of 2 x 106 cells/ml. After 
allowing the cells to attach for 20 minutes, the medium was aspirated and 500 µl Bac-
FV3’’ or Bac-FV5’’ were added to the flasks. The flasks were incubated for 1 hour, with 
the liquid being swirled over the monolayers twice during this time. 10 ml of fresh 
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BacVector medium was then added to the cells, which were left for 5 days at 28ºC. This 
generated high titer Bac-FV3 and Bac-FV5 stocks to be used for protein expression 
studies. 
 
2.9.5. Baculoviral titering 
 
2.9.5.1. Plaque assay 
 
Plaque assays were set up in order to determine Bac-FV3 and Bac-FV5 titers. These were 
performed as described in section 2.9.4.1. Dilutions of baculovirus stocks were optimized 
for each individual experiment, and ranged from 1 in 1000 to 1 in 10 000 000.  
 
2.9.5.2. Real time PCR 
 
A quantitative real-time PCR assay was established as an alternative method for 
quantification of baculoviral titers. Baculoviral DNA was extracted from 200 µl of 
clarified supernatant by automated extraction procedures using a MagNA Pure LC 
(Roche; Mannheim, Germany) and a MagNA Pure LC Total Nucleic Acid Isolation Kit 
(Roche, Mannheim, Germany) according to the manufacturer’s instructions. 
 
Baculoviral DNA was amplified using the gp120-specific primers PTR and PTF (table 
2.1), which amplify an approximately 180 bp segment in the C1 region of gp120. These 
primers were designed based on the sequences of the clones FV3 and FV5. A standard 
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curve was set up for each clone, using pTriEx-FV3/FV5 at known concentrations ranging 
from 102 to 107  copies/µl.  
 
PCR reactions were set up in a final volume of 20 µl containing 10 µl of SYBR® Green 
JumpStart Taq ReadymixTM (Sigma; St. Louis, MO), 2 µl of extracted DNA or diluted 
plasmid and 0.5 µM of each primer (PTR and PTF). PCR was performed on a 
LightCycler® platform (version 1.2) (Roche Applied Sciences ; Mannheim, Germany).  
 
PCR began with a 30 second hotstart at 95°C, followed by 40 cycles consisting of 10 
seconds at 95°C, 10 seconds at 57°C and 15 seconds at 72°C, with a single acquisition of 
fluorescence signals after each 72°C extension. The rate of temperature change was 
20°C/second. After the PCR program, a melting curve was established by raising the 
temperature of the reaction to 95°C for 5 seconds, dropping it to 40°C for 30 seconds and 
then raising the temperature gradually back to 95°C at a rate of 0.15°C/second. 
Fluorescence data was acquired continuously throughout this program. Fluorescence was 
detected using channel F1 on the LightCycler® instrument. Quantitative analysis (by the 
Second Derivative Maximum Method), including the construction of standard curves was 
done using the LightCycler® Software version 3.5.3.  
 
2.9.6. Expression of recombinant gp120 
 
Bac-FV3 and Bac-FV5-containing supernatant was added to suspension cultures of TriEx 
Sf9 cells (2 x 106 cells/ml) at an MOI of 3 gp120 copies/cell. Suspension cultures were 
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incubated for three days before the protein-enriched supernatants were harvested. 
Cultures were centrifuged at 300 x g for 8 minutes. Complete Protease Inhibitor Cocktail 
tablets (Roche; Mannheim, Germany) were added to the clarified supernatant (1 tablet/50 
ml supernatant), which was then assessed for the presence of gp120 by SDS-PAGE and 
Western Blotting analysis as described in section 2.8. 
 
2.10. Protein Purification and concentration 
 
Gp120-containing supernatants were purified using the Bio-Rad BioLogic LP 
chromatography system. Absorbance data was captured by the LP Data ViewTM v1.03 
software (Bio-Rad; Hercules, CA) 
 
2.10.1. Purification of recombinant gp120 
 
In this section, “PBS” refers to Dulbecco’s Phosphate Buffered Saline without calcium 
chloride and magnesium chloride (Sigma; St Louis, MO). 
 
2.10.1.1. Lectin-Affinity Purification 
 
Columns containing lectin from Galanthus Nivalis immobilized on cross-linked 4% 
beaded agarose (Sigma; St Louis, MO) were equilibrated with PBS containing 0.5 M 
NaCl. Clarified supernatants containing recombinant FV3 or FV5 gp120 were loaded 
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onto columns at a flow rate of 0.2 ml/minute. Columns were then washed with 15 column 
volumes each of PBS containing 0.65 M NaCl, PBS, PBS containing 1 M NaCl and PBS 
again. 15 column volumes of elution buffer (20 mM sodium acetate, 0.1 mM EDTA, 0.5 
M methyl α-D-mannopyranoside (MMP) (Sigma; St Louis, MO), pH 5.0) were then 
passed through the columns at 2.0 ml/minute in order to elute the protein. The eluates 
were collected in 1 ml fractions and fractions corresponding to A280 peaks as recorded by 
the LP Data ViewTM v1.03 were assayed for the presence of gp120 as described in section 
2.8. Fractions that tested positive for the presence of gp120 by Western Blot analysis 
were pooled and dialysed three times against 50 volumes of 50 mM sodium acetate 
buffer, pH 5.0 for 5 hours at 4ºC. 
 
2.10.1.2. Ion Exchange Chromatography 
 
Following dialysis of affinity-purified gp120s, ion exchange chromatography was 
performed. Briefly, ion exchange columns were poured using SP SepharoseTM Fast Flow 
(Amersham Biosciences; Freiburg, Germany) and equilibrated with 50 mM sodium 
acetate, pH 5.0. Dialysed gp120-containing fractions eluted from the lectin column were 
loaded onto columns at a flow rate of 0.1 ml/minute. Columns were then washed 
sequentially with 15 column volumes each of 50 mM Sodium Acetate buffer, first at pH 
6.0 and then at pH 7.0. Bound gp120 was then eluted using a NaCl gradient increasing 
from 0 to 400 mM in a 50 mM Sodium Acetate buffer, pH 7.0 over a volume of 40 ml. 
Fractions corresponding to A280 peaks as recorded by the LP Data View
TM v1.03 were 
assayed for gp120 as described in section 2.8. Fractions positive for gp120 by Western 
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Blot analysis were pooled and dialysed three times for 5 hours each against 50 volumes 
of PBS (pH 7.4) at 4°C. 
 
2.10.2. Sample Concentration 
 
Dialysed gp120-containing fractions were concentrated using Amicon® Ultra-15 
Centrifugal Filter devices (Molecular Weight cut off 50 kDA) (Millipore; Billerica, MA). 
Briefly, the columns were prewashed by adding 15 ml of PBS (pH 7.4) and centrifuging 
at 3200 x g for 5 minutes. The dialysed eluate was then added and, if necessary, the 
volume was brought to 15 ml with PBS. Columns were then centrifuged at 3200 x g for 5 
minutes. Where the original volume of dialysed eluate was greater than 15 ml, this step 
was repeated in the same column until all of the eluate had been passed through. The 
concentrated retentate was then recovered from the filter unit. Protein was quantitated 
using the BCATM Protein Assay Kit (Pierce; Rockford, IL), using a slightly adapted 
version of the manufacturer’s recommended protocol (described in appendix 1) and 
stored at -70°C. 
 
2.11. Protein Characterisation 
 
 
2.11.1. Silver Staining and Coomassie® Staining 
 
In order to determine the level of purity of the concentrated protein, 1 µg and 1.5 µg of 
concentrated gp120 were loaded onto two 1 mm thick 8% SDS-PAGE gels, which were 
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resolved as described in appendix 1. Following this, the gel loaded with 1 µg gp120 was 
silver stained and the gel loaded with 1.5 µg gp120 was stained with Coomassie® 
Brilliant Blue R-25, both as described in section 2.8. The Coomassie®-stained gel was 
then analysed using a Bio-Rad Chemidoc XRS and Bio-Rad Quantity One 1-D Analysis 
Software for densitometric analysis in order to determine the percentage purity of the 
protein. 
 
2.11.2. Monoclonal antibody binding to recombinant gp120 
 
2.11.2.1. Materials 
 
The following reagents were obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 IIIB gp160 Monoclonal 
Antibody (Chessie 13-39.1) from Dr. George Lewis175;  HIV-1 gp120 Monoclonal 
Antibody (ID6) from Dr. Kenneth Ugen and Dr. David Weiner;176, 177 HIV-1 gp120 
Monoclonal Antibody (654-30D) from Dr. Susan Zolla-Pazner181-184; HIV-1LAI (BRU) 
V3 Monoclonal Antibody (4G10) from Dr. Albrecht von Brunn, Courtesy of the MRC 
AIDS Directed Programme185, 186; HIV-1 gp120 Monoclonal Antibody (F425 A1g8) from 
Dr. Marshall Posner and Dr. Lisa Cavacini; HIV-1 gp120 Monoclonal Antibody (670-
30D) from Dr. Susan Zolla-Pazner184, 187; HIV-1 gp120 Monoclonal Antibody (F425 
B4e8) from Dr. Marshall Posner and Dr. Lisa Cavacini; HIV-1 gp120 Monoclonal 
Antibody (48d) from Dr. James Robinson188, 189; HIV-1LAI (BRU) V3 Monoclonal 
Antibody (5F7) from Dr. Albrecht von Brunn, Courtesy of the MRC AIDS Directed 
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Programme185, 186; HIV-1 gp120 Monoclonal Antibody (2G12) from Dr. Hermann 
Katinger190-194; HIV-1 gp120 Monoclonal Antibody (F015) from Dr. Marshall Posner and 
Dr. Lisa Cavacini195-198; HIV-1 gp120 Monoclonal Antibody (F425 B4a1) from Dr. 
Marshall Posner and Dr. Lisa Cavacini; HIV-1 gp120 Monoclonal Antibody (17b) from 
Dr. James E. Robinson73, 103, 189, 199-201; HIV-1 gp120 Monoclonal Antibody (IgG1 b12) 
from Dr. Dennis Burton and Carlos Barbas202-205;  HIV-1BaL gp120 from DAIDS, NIAID; 
HIV-1 gp120 CM; HIV-196ZM651 gp120 from DAIDS, NIAID. NEA 9301 was obtained 
from Perkin Elmer (Wellesley, MA). sCD4 was obtained from Progenics (Tarrytown, 
NY).  
 
2.11.2.2. Characterisation of antibody-binding properties 
 
All ELISA’s were done in F96 Maxisorp Nunc-Immunoplates (Nunc; Roskilde, 
Denmark). All washes were done five times with 300 µl of PBS-T (0.05% Tween-20 in 
PBS) per well per wash on a ELX50 Auto Strip Washer (Bio-Tek; Winooski, VT).  Wells 
were coated with 100 ng of gp120 (Bal, CM, 96ZM651, FV3 or FV5) diluted in PBS (pH 
7.4), and incubated for three hours at room temperature in the dark. Gp120 was then 
aspirated from the wells and 300 µl of PBS-TB (PBS with 0.05% Tween-20 and 10 
mg/ml Bovine Serum Albumin Fraktion V (BSA)) was added to each well. Plates were 
incubated at 4°C overnight. Wells were then washed and 100 µl of primary antibody 
diluted in PBS-T was added to each well. The epitope for each antibody, as well as the 
concentration each was used at is described in table 2.2. After addition of the primary 
antibody, plates were incubated for 2 hours at 4°C and then washed. 100 µl of secondary 
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antibody diluted in PBS-T was then added to each well at a concentration of 1:2000. 
ECLTM Anti-Human IgG, HRP linked whole antibody (Amersham Biosciences; Freiburg, 
Germany) was used for the human antibodies F105, 2G12, 654-30D, F425 A1g8, F425 
B4a1, F425 B4e8, 670-30D, 17b, IgG1 b12 and 48d. ECLTM Anti-Mouse IgG, HRP 
linked whole antibody (Amersham Biosciences; Freiburg, Germany) was used for the 
mouse antibodies 4E10, 5F7, Chessie 13-39.1 and ID6. Plates were incubated at 4°C with 
the secondary antibody for one hour, and then washed. 100 µl of 1-StepTM Ultra-TMB-
ELISA Substrate (Pierce; Rockford, IL) was then added to each well, and the plate was 
incubated for 30 minutes at room temperature to allow a colour reaction to develop in the 
wells. After 30 minutes, the reaction was stopped by the addition of 2 M Sulphuric Acid 
and the absorbance of the wells at 450 nm was read on a Bio-Rad Model 680 Microplate 
Reader (Bio-Rad; Hercules, CA). 
 
2.11.3 Characterisation of CD4-binding properties 
 
Wells of a 96-well micro-titer plate were coated for 3 hours at room temperature with 100 
ng of sCD4 diluted in PBS. sCD4 was then removed by automated aspiration and 300 µl 
of PBS-TB was added to each well before plates were incubated at 4°C overnight. Wells 
were then washed and 150 ng of gp120 (Bal, CM, 96ZM651, FV3 or FV5) diluted in 
PBS-T was added to each well in a volume of 100 µl. The plate was incubated for two 
hours at room temperature and then washed. 100 µl of primary antibody diluted in PBS-T 
was then added to each well as follows: 2G12-1:2 000 (38 nM), 48d-1:100, F425 A1g8-
1:1000 (13.4 nM), 17b-1:100 (21 nM). After two hours at 4°C, plates were washed and a 
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anti-human secondary antibody, diluted 1:2000 in PBS-T was then added. Plates were 
incubated at 4°C with the secondary antibody for one hour, washed and developed with 
1-StepTM Ultra-TMB-ELISA Substrate  as described in section 2.11.2.2. 
 
Table 2.2: Table of antibodies used for protein characterisation, the concentration 
and molarity antibodies were used at (where available), and their epitopes 
Antibody Concentration  Molarity Epitope 
F425 A1g8 1:2000 6.7 nM CD4i, binding enhanced by sCD4 
F425 B4e8 1:250 000 0.04 nM V3, I309, R313, F315 of gp120JRCSF 
F425 B4a1 1:250 000 0.12 nM V3 loop 
2G12 1:200 000 0.38 nM Glycan-dependent 
17b 1:10 000 0.21 nM Overlaps binding site for CCR5 
IgG1 b12 1:40 000 0.23 nM Overlaps CD4 binding site 
48d 1:100 TCS Complex, binding enhanced by CD4  
654-30D 1:2 000 0.16 nM Intact tertiary structure, blocks cd4 binding 
670-30D 1:200 0.18 nM C5 region, PTKAKRR 
F105 1:50 000 0.21 nM Conformational, overlaps CD4 binding site 
ID6 1:1000 TCS gp120MN Aa86-100, VNVTENFNMWKNNMV 
Chessie 13-39.1 1:1000 TCS C2 region, RVVSTQLLLNGSLAEEEVVIR 
NEA9301 1:1000 TCS C5 region, MRDNWRSELYKY 
4G10 1:100 TCS V3, TRKSIRIQRGPGRAFVTIGKIGNMR 
5F7 1:100 TCS V3, TRKSIRIQRGPGRAFVTIGKIGNMR 
 
TCS: Antibody provided at undetermined concentration in a tissue culture supernatant.
 63 
 
 
 
 
 
 
3. Results 
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3.1. PCR amplification of Env-encoding regions 
 
The Env regions of 20 viral isolates were amplified, sequenced and analysed in order to 
obtain background information about this cohort and enable the selection of two 
representative isolates for cloning and production of recombinant gp120. Env-encoding 
DNA was amplified from proviral DNA isolated from PBMCs infected with primary 
isolates of HIV-1 (figure 3.1a). After several rounds of optimization, gp160 was 
successfully amplified by nested PCR from 20 isolates, namely FV2, FV3, FV5-FV15, 
FV20, FV22, FV23 and FV25-FV28. These PCR products were used for sequencing, as 
well as in PCR reactions to amplify the gp120-encoding regions of Env for cloning 
purposes (figure 3.1b). 19 gp120-coding regions were amplified from these products. We 
were unable to amplify FV28, and this is likely related to significant differences observed 
between the reverse primer and the 3’ gp120 primer region of this isolate. 
 
3.2. Population-based sequencing of the gp160 coding regions 
 
Sequence data was generated for all 20 full length gp160s. The 20 env sequences were 
submitted to GenBank using Sequin V5.35206 and are available under the accession 
numbers DQ382361 to DQ382380. Nucleotide sequence analysis showed that the full-
length env genes for the 20 isolates ranged from 2526 to 2634 bp and revealed that all 20 
isolates had intact open reading frames, confirming the presence of functional env genes.  
 
 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Agarose gel electrophoresis of Env PCR products. PCR products were 
resolved on 0.8% agarose gels with the Molecular Weight (MW) Marker (Quick-Load 1 
kb DNA Ladder (New England Biolabs, Ipswich, MA) and visualised under UV light. 
(A) Representative gp160 PCR.: Lane 1: MW marker, Lane 2: gp160 (FV6) PCR 
product before purification, Lane 3: gp160 (FV6) PCR product after purification with a 
GFXTM PCR DNA and Gel Band Purification kit. (B) Representative gp120 PCR. Lane 
1: MW marker, Lane 2: gp120 amplicon (FV6), Lane 3: gp120 amplicon (FV9), Lane 4: 
gp120 amplicon, (FV13), Lane 5: Negative Control. Similar results were obtained for all 
other Env PCR reactions. 
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Phylogenetic analysis of the 20 full-length env nucleotide sequences, together with 
reference viruses from the major subtypes revealed that 19 isolates clustered within HIV-
1 subtype C with a bootstrap value of 100%, while one isolate (05ZAFV10) showed 
evidence of recombination (Figure 3.2). The FV10 sequence was further analyzed using 
the RIP 2.0 Program45, which showed that it is a unique CD recombinant. There are two 
recombination breakpoints at approximate nucleotide positions of 160 and 1850. 
Segments within positions 1-160 and 1850 to 2559 were identified as subtype C, while 
the segment between positions 160 and 1850 was subtype D.  Phylogenetic analysis also 
indicated that there were no differences in clustering between the CCR5-using isolates 
and those able to utilize CXCR4. Coreceptor usage of the 20 isolates was determined 
phenotypically in our laboratory by Ms. B Connell. This was performed by measuring 
viral replication on U87.CD4, MT-2 cells and Cf2Th-CD4 cells expressing either the 
CCR5 or CXCR4 coreceptors independently124. FV3, FV10, FV14 and FV26 were 
CXCR4-using, FV15 and FV27 were dual-tropic and the rest of the isolates used CCR5 
as a means of gaining entry into host cells. 
 
The amino acid sequences were derived and aligned using GeneDoc207 and compared to 
the consensus C and ancestral C sequences from Los Alamos45. The full length amino 
acid alignment can be seen in figure 3.3. The predicted proteins ranged from 842 to 878 
amino acids in length, with the variation being primarily due to insertions/deletions in the 
variable regions (V1 toV5) of gp120, and deletions in the gp41 cytoplasmic tail region. 
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Figure 3.2: Phylogenetic relationships of the full-length gp160s from 20 South 
African subtype C isolates with HIV-1 subtype reference sequences from the Los 
Alamos database
45
. The 20 isolates are named 05ZAFVn, and sequences from isolates 
able to use the CXCR4 coreceptor are boxed. The phylogenetic tree was constructed from 
nucleotide sequences, using the neighbour-joining method with maximum parsimony 
bootstrap values to estimate the stability of the nodes. Only bootstrap values of 70% or 
higher are shown. Figure courtesy of Dr M Papathanasopoulos. 
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                      *        20         *        40         *        60         *        80         *       100          
CONSENSUS_ : MRVRGILRNCQQWWIWGILGFWMLMICNVVGNLWVTVYYGVPVWKEAKTTLFCASDAKAYEKEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKNDMVDQM : 103 
C.anc      : ...M.........................................................R....................M.................... : 103 
FV2        : ...M..Q..YPR............IN.I................R.............G.......................QAMV................. : 103 
FV5        : ........S..H.....L..........GTE.............R.............S..R....................M.................... : 103 
FV6        : .K.K.....WK................SGGE.............................V..A..I................N................... : 103 
FV7        : .....TQ..W.................F-ATS...............NP..............K..................MK.I..............E.. : 102 
FV8        : ..AM.......R.....L......L...GM.................N.............Q....................MFM............T..... : 103 
FV9        : ...M..Q....P................................R..............HDT..............N.D....A.A................. : 103 
FV11       : ...M.TQ..WP............IIM.S.M..............TD...............R.......................G...........N..... : 103 
FV12       : ......Q..WP............I.V.R......................................................VL................... : 103 
FV13       : ...M..P.....LL.............SIK.D.............D...............R.M..................L..G.........E....... : 103 
FV20       : ...M..Q...P...........V.L...G--S..................................I...............MF................... : 101 
FV22       : ...M......PR...........VI.S.G.EK.............................R.....................YMK................. : 103 
FV23       : .........W.P.............S..GL-EK.........................S.......................WE.K................. : 102 
FV25       : .........WK............F.....W.................R............VQ....I.......................H............ : 103 
FV28       : ...M.PEE-LE...T..........V..-MQD........G...R..E.....G.Y.A..DA.....G..........S...VE.V..A.........V..H. : 101 
FV3        : ...M.TQ.....................-G....................................................MK.R................. : 102 
FV10       : ...K..Q..W.............IIM.R.ES.............R..T..........G....A..I.................M............S..E.. : 103 
FV14       : .....TQ..Y..............IM..GKEKM...........R...A.................................L..I..............E.. : 103 
FV15       : .........W......VS.........SGGKD............R...A.....T.....AT....I...............M..G................. : 103 
FV26       : ......Q..WP...........IILS.RG..D............R..............HVR....I...............M.................... : 103 
FV27       : ...K..S..WP...........II.M.RGM.........................E....D.....................MI................... : 103 
 
 
 
                                                                                                                           
                                                                                                                           
                   *       120         *       140         *       160         *       180         *       200             
CONSENSUS_ : HEDIISLWDQSLKPCVKLTPLCVTLNCTN-----ATNATNT-------------------------MGEIKNCSFNITTELRDKKQKVYALFYRLDIVPLNEN : 176 
C.anc      : .............................-----.......-------------------------...M...............................D. : 176 
FV2        : .............................-----INKTCSNNTST--------TNTPNIGTYNNKTCE.....T..V...I...TK.MH.......L...D.G : 193 
FV5        : ............................D-----FDPLD.G----------------------TDA.........KA....K...R.EQ....T....SIDKV : 179 
FV6        : Q............................-----VNATGTG-----------------TATYNSTMKE.MR.....A...I...EKHMH....E......D.. : 184 
FV7        : .R.......E.................SIVNATGIRIVNG.NV---------------TIPYNESIARDMR.....T...I...NR.ES........T..A.. : 190 
FV8        : .........................K.S.-----VAYNG.---------------------ITNNGSIDM......V...I...TK.MS....K....QIEDK : 180 
FV9        : .........................D.R.-----...SSSLNET----------------------IR.M......V........KNTF....K........H : 179 
FV11       : ...V..I.....................D-----.SFNVTSVSN---------------VTYIGNLT..V......T...I.....TA......P........ : 186 
FV12       : .........................Q..K-----.NCNNI.TTCN----------NTNGNLTNIIKD..V......T...I..R...A......S.....DNS : 191 
FV13       : .........................H...NISRK..GS.TPPPTN-----------TTMTTVSDTMI..V......V.......EKNE.....K......EK. : 195 
FV20       : ................R...........D-----.NITH.VNTNN-----------ASNVTYEENMK.........R...V....K.ET........A...K. : 188 
FV22       : ...V.........................-----..ITS.G-----------------TIAHNDTMK...Q....DT...II..TK.E..............K : 184 
FV23       : .........................H.S.-----.NYTGTN------------------VTYN-GTQI.M......T...I...ES.A.....IP.....DG. : 181 
FV25       : ...V.....................H...-----V.SN--------------------SISVNSTN-S.MR.....A....I.....MN.............. : 180 
FV28       : LD.V.....HY.L..GEM.....AFY.SIP----------------------------TINNTTNNNTDVI.....AAA..L..E..K.....N..V...H.E : 176 
FV3        : N........E.................SD-----V.YNATNATNNTTTTTHN-TTETTPYAKISNITDDM......V..G....RKQES........I...G. : 199 
FV10       : ....................F.......EWK---GNQTISN------------------TTAKNIENIGMR.....MA..V....KQA.....K..V.QM.DS : 185 
FV14       : .........E..........I......S.-----V.LSKSNDTYT------------TAKMNPLNITN.M......V.A.I.N..RTE..........S..GE : 189 
FV15       : ...........................SK-----VVAI--------------------NSTNNDTS-K.M...T..T......R.R.E.....K....S...D : 180 
FV26       : .....N....G......I.......R...-----..FTA.---------------DSNDNNVTMSEWT.MTT...SN..QIG.AL.TA...L.LT.SK..F.- : 185 
FV27       : .................I.......R.AD-----.KLNYTNAEVNCTNVNDTRKDNGTSNNIENLECVKV......T...I.....EAH....KH....V..- : 200 
                                                                                    
 
 
                                        
                                                                                                                           
                *       220         *       240         *       260         *       280         *       300                
CONSENSUS_ : NS-------------YRLINCNTSAI-TQACPKVSFDPIPIHYCAPAGYAILKCNNKTFNGTGPCNNVSTVQCTHGIKPVVSTQLLLNGSLA-EEEIIIRSEN : 264 
C.anc      : ..-------------...........-.................................................................-.......... : 264 
FV2        : K-NSSKKNNNNSSRE.I.......T.-.....Q.P.............F...........................................-.......... : 293 
FV5        : YDSCY-----RHFSM....D......-...........V................D....................................-.G........ : 275 
FV6        : SNSSK----------.........T.-.............................Q...................................-.K........ : 275 
FV7        : SNNSSN-----NFSE.......S.RL-V........................E..D...G.....H..........................-.D........ : 286 
FV8        : S-------NSSNSSE.I.......T.-.......T....................DE..S.....T..........................-.K........ : 274 
FV9        : .NNS--------SGY.........TV-.....T.A...F.................E.................................ANLAK.V...... : 273 
FV11       : .---------KSSGE.I.......T.-.............................E........R..........................-.G..M..... : 278 
FV12       : S----SDNSSSDHRD.I.......T.-............................DS........S.....H....................-..D....... : 288 
FV13       : GNSSN-----SNSNE..........V-.........E......................................................S-.DG.....K. : 291 
FV20       : DN------------T.V.........-......GN...F.................E...................................-G...V..... : 277 
FV22       : KNNSSSNSSSSNYSK.I.....S.T.-............................D.K.......R..........................-..D.....K. : 285 
FV23       : D-NSS----------.........TL-.......T.............F......D...S.M..............................-.......... : 271 
FV25       : .KTSQE---------.........T.-.......T.............F............................R..............-.......... : 272 
FV28       : -NSDDN-----DAGEDG..I.S....-.......A...L...F.........R...N........K...........R..............-K...M...Q. : 271 
FV3        : K---------ENSSE.........T.-R....................F......D.........HD.........................-....V..... : 291 
FV10       : .------------SS....H..A.T.-.......T.E...........F......D.KY.................................-...V...... : 274 
FV14       : SNETSN--------E.......S.TV-.......N.............................................G...........-.KD....... : 282 
FV15       : ..T------------.........S.-.......N.............F................Q..........................-.K....K... : 269 
FV26       : -------------RC.TS.HLPYLTHG.LGD..A.CYRA............R...DR.........R.........................-....M..... : 274 
FV27       : -------------DK.I..H....T.-.........E...................N...................................-.K........ : 288 
       Signal Peptide                         
C1 
                                              C1 
                                                                           V1                                                         V2 
                                                                 C2 
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             *       320         *       340         *       360         *       380         *       400         *         
CONSENSUS_ : LTNNAKTIIVHLNESVEIVCTRPNNNTRKSIRIGPG--QTFYATGDIIGDIRQAHCNISEDKWNKTLQKVSKKLKEHFPNKT-IKFEPS-SGGDLEITTHSFN : 363 
C.anc      : ..D.................................--......................E.......R.GE..........-...A..-............. : 363 
FV2        : ..........Q.K.A.G...........E.......--...F............Y....KND......E.G...S.R.NKEN-.T.R.PPP............ : 393 
FV5        : .A..V.....QF..................V.....--.......E...N..........S.......N.A.R........N-.T.A.A-.R...Q...P..Y : 374 
FV6        : ......I.............A..G......V....--G...F..........K.......AN..R...R..E..........-...N..-............. : 374 
FV7        : I.C.S.N...........N....G......V.F...--.A.......................V....R.TE..G.......-.E..SL-....P.V...... : 385 
FV8        : ..D.......Q..K....N...H.......V.....--......................E...D...Q.KD..QK...D..-.I.NS.-............. : 373 
FV9        : ..D.V.....Q..Q.........S......V.....--...F...E..............K...E...E.G...A.Q.....-.P.A..-............. : 372 
FV11       : ..D.................I..G......V.....--.A..................TRRN.TE..G..TE..........-.N.K..-............. : 377 
FV12       : ..D.V.....Q.KDP.A.............V.....--......................R...D..NQ.R...R.LYN...-.I...H-....P.V.M.... : 387 
FV13       : .SD.T...............A..G....R.V.....--.A.....E......K.......GR..R..TL.RE.........S-.S.NS.-............. : 390 
FV20       : I.........QFT.P.K.............M.....--.A...M................RD.....HG..E..R.......-.....H-............. : 376 
FV22       : V.DS.R.T..........I.........R.......--....TN-.........Y..V.RGN.T....R..D....Y.SSG.-KILFAPS....P........ : 384 
FV23       : ..........Q..K.I.......G......V.....--.V...................RKD..N...W.GE..RK..S.TI-.F.HS--.....L.I.PR.Y : 369 
FV25       : ..........S...P...............V....--G.......E..............EN.TE......E..EA......-.E.NS.-............. : 371 
FV28       : I.D.T.....Q..K..D...........T.V.....--.A....NG.............TRD..I...N.....E.......-.E.K.H-....P...M.T.. : 370 
FV3        : ......I...........K.S..G......V...I.RG.......KV..........V.REA.....E..KR..G.....S.-.T.NH.-............. : 392 
FV10       : F.....I...Q.....T.N....YKSS.RRTH..T.--.AW.T.-N.E....K.......KQ......H.AN..GGLLNKT.-.V.NK.-............. : 372 
FV14       : ......I.........Q.N....A.TRI.RLG....--.A.RTVKQ.......S.....AWQ..R...R..E...K......F...Q.P-............. : 382 
FV15       : ..D...I.............A........HV...I.RG.......A.............KSN.TR...R..N..R...N...-...NS.-......V...T.. : 370 
FV26       : ..D.T.....Q.K.P...N....GKGK.TRV.....--R......AVT....K...TVNGSR..S..EQ.RE...KYYD.R.-....QP-....P.V...... : 373 
FV27       : I.E.T..........IV.N....S.....R..V...--..V...DA...........L.RGD.ER.IEQ.R...Q.YYH.S.-...K..-............. : 387 
                                                                                                                           
                                 
 
 
                                                                                           
                  420         *       440         *       460         *       480         *       500         *            
CONSENSUS_ : CRGEFFYCNTSKLFNSTYNS-----------------TNSTITLPCRIKQIINMWQEVGRAMYAPPIAGNITCKSNITGLLLTRDGG---------------- : 433 
C.anc      : ...........R........-----------------K..................G..............................---------------- : 433 
FV2        : .Q.........R.....W--------LNSTEPTDQANDT.V................................R........V....KGNS------------ : 476 
FV5        : ........Y..S.....S..HDA---ERDYNGAGNSSSD.F..IL.....F.I...R..........V.SV..C.F...........---------------- : 458 
FV6        : .G.............G--------TYNGTDMSNNTESN-.....Q............................R........L...--GFCQ----------N : 456 
FV7        : .G.........S...G....----------TRNSTG---R....Q............................N......I......YDNNNATKENKTTNNT : 475 
FV8        : ........D......R.F..TN----TKGNSTDARGNS.A..........F.H...P............K............A....NTN------------- : 459 
FV9        : .Q.........Q........NE-----------TTSDS........T..........................V.....I.......QNGG-----------N : 453 
FV11       : ..........TE..KN----------------DSSTKNDTY................................R........V....NEN------------- : 451 
FV12       : ..........T...K-------------ENSTNENDT----..........V....T..Q.............N.S...........NGNS------------ : 461 
FV13       : .G.............NSEDKDSP----------FNSTR.A..IIQ...R.F....................................ENDT-----------N : 472 
FV20       : ...........R.....HLP----------NGTQVNG.DAN.........F.....K.RL.........D...E.D...........D-ST-----------N : 457 
FV22       : ..........AG...TSL--------INSTKSTSTKN.QDP...T.....F.....Q.........................MY...---------------- : 463 
FV23       : .G......C..P..F..S--------YPPSCPPSTADNS.I.-...-.I.L..L.R....PVL.A.LV.S.I.C.S...I..ST...---------------- : 446 
FV25       : .G.K...........G--------TYNGTYNATERNIGPG.LC.Q...........Q................T........V...--GNSS----------N : 454 
FV28       : .G............HG...G----------TYNSSGED......Q.....F.............................I......NDNG--------TNDT : 455 
FV3        : ...........D..KDN-------------ITITNSTN.TV...Q...........RA.Q.I.....R.....N.............KDNKT----------N : 472 
FV10       : .G...............WTVN---------NTVNETGV.N....Q...R..V....G..K.......E.Q.N.S.............AGNNS----------- : 455 
FV14       : .G.........N...R....-------TDKSDRFNSTD.....IQ...R.F.....R..........E.......K...........EGNKN----------- : 467 
FV15       : ...........N...GNWY.NGSFLFNGSWDNNNTDTE......Q......................E..............V....TGNDT----------E : 463 
FV26       : ........D.TN...-------------ISNINSTSN----...Q.K.........K..........E.T...I.............SSNET----------S : 449 
FV27       : ........Y.T...CDNT--------TKLCYTNETSNP.N........R.......K..............N.......I.......NETEG----------D : 472 
                                                                  
 
 
                                                          
                                                                 
 
 
                                                           
               520         *       540         *       560         *       580         *       600         *       6       
CONSENSUS_ : -KNNTETFRPGGGDMRDNWRSELYKYKVVEIKPLGIAPTKAKRRVVERE--KRAVGIGAVFLGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIEA : 533 
C.anc      : -......................................E.........--.................................................... : 533 
FV2        : TD.KS.I.......................V........Q.........--......................V..MA......N.................. : 577 
FV5        : -S.T......V...................VR.......R.Q......V--...............................................K.... : 558 
FV6        : --.T............N..................V.............--.................................................... : 555 
FV7        : NS.K..K...V..E...................................--.....L.............................................. : 576 
FV8        : ---.S........N.K..............V........G.........--...........................................G........ : 557 
FV9        : NT.VP.I...A.....L......F...............E.........--.........................V.......................... : 554 
FV11       : --.I..I......N.K.......................T......Q..--.....M...L...............M.......................... : 550 
FV12       : ---TN.....T....K...................V...ES........--...A.....L.......................................... : 559 
FV13       : ----P.I................................G.........--.........L.....T.........LA......................... : 569 
FV20       : SN........E..N.K.......................T.........--.....L.............................................. : 558 
FV22       : RNETNA...........................................--.........LF......................................... : 564 
FV23       : PDDDA........N.K..............V..................--...............T..............L..................... : 547 
FV25       : --LKI.I...NR.E.......K..E....K.....V...E........Q--...A...........V.........M.......................... : 553 
FV28       : TT.K..I.......................V....V.......K.....RV.....L....I..................A...................... : 558 
FV3        : NE.K..I................................T.........--.........L...................A....V................. : 573 
FV10       : ---QN..................N--ISSKLG.I.L.............--...I.L..L................MS....T...M.......N.......V : 551 
FV14       : DT.D..I............................L.............--........L...V..V...........................N........ : 568 
FV15       : --.D..I......N......N..........R.......E.........--..................................V................. : 562 
FV26       : SI.K..I......N.K.......................G.........--.................................................... : 550 
FV27       : GT-KV.I......N.....................V.......N..Q..--.......V.L.......................................... : 572 
              V3                                         C3 
          V4                                                                                   C4                                              V5 
                       C5                                                  Fusion Peptide                                    N34 
end gp120, start gp41    
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             20         *       640         *       660         *       680         *       700         *       720      
CONSENSUS_ : QQHMLQLTVWGIKQLQTRVLAIERYLKDQQLLGIWGCSGKLICTTAVPWNSSWSNKSQEDIWDNMTWMQWDREISNYTDTIYRLLEDSQNQQEKNEKDLLALD : 636 
C.anc      : ...........................................................E....................................Q...... : 636 
FV2        : ..........................R................P......I....R.ETE..G.....E.....N...NI..N...E.............S.N : 680 
FV5        : ...L............A.........Q..................S.....T...R..DE..Q...............SI..G..GEA.IK..Q......... : 661 
FV6        : ...L.................M.......................N.......N..T.DE........E.........N...N...V...............S : 658 
FV7        : ...L............A.........R.R....L.....................RT..E........E........SE.....................E.. : 679 
FV8        : ................A.........Q............................R..QE...........K......N.......................S : 660 
FV9        : ................A........................................KDA..............N...........V..T...Q........N : 657 
FV11       : ...L.............................L......V..P...........R..T...E........K......N...W...E................ : 653 
FV12       : ................A.........Q......L...........N..........TKNE..........EK..........W...V......E........N : 662 
FV13       : .........................................................EDE..Q...........N...N.......E................ : 672 
FV20       : ................A....L....Q......M.................T....TK....N.L...E.E...E.......S..G...I...A...E..... : 661 
FV22       : .............................................T............A.....L............SN.......E..T...Q......... : 667 
FV23       : ...L.....................................................LN...N...........N.......Q...K......Q......... : 650 
FV25       : .................................L......I..P.............YSE..............N...N...T...E................ : 656 
FV28       : ...........V....A....V.............................T.....VTE..........E...D...........I......E...E..... : 661 
FV3        : ................A....L....Q............................RNYS............G......NI..Q...E..I............. : 676 
FV10       : H..L............A.I..V.S................H....T...........VNE...K....E.E...D...EQ..N.IQE..T......QE..Q.. : 654 
FV14       : ................A.........Q..R...............N.........RTYD...N.T.........N..SNI.HW......I......QE..... : 671 
FV15       : .................................F........................T...................E........................ : 665 
FV26       : ................A....L....T......L...........N...........RA...............N...........E..T............. : 653 
FV27       : ................A................L...........N...........YG........I......N...........E..T............. : 675 
                                                                                                                           
                                       
 
 
                                                                                     
                     *       740         *       760         *       780         *       800         *       820           
CONSENSUS_ : SWKNLWNWFDITNWLWYIKIFIMIVGGLIGLRIIFAVLSIVNRVRQGYSPLSFQTLTP-NPRGPDRLGRIEEEGGEQDRDRSIRLVSGFLALAWDDLRSLCLF : 738 
C.anc      : ..E.......................................................-............................................ : 738 
FV2        : ..DS.....G........R..............T.....V.K...............Q-..GE...P.....G......S......N.S...V.......... : 782 
FV5        : K.H...S.....Q...........................................I.-S......P...................N.....V.E...N.... : 763 
FV6        : R.Q...T.................................................I.-....................NN.........SI........... : 760 
FV7        : K.NS...................................L..................-HS...................G.........P.V.........Y : 781 
FV8        : H.Q......S..............................................I.-.......PEG...G.............N................ : 762 
FV9        : ..Q...S....SK..G..Q..T...............I..A.................-...EL.........S...N......................... : 759 
FV11       : N.NS........S......................G.....K................-...EL........G......SK.V.................... : 755 
FV12       : ..DS.....N..K.......................................L..PI.-.Q.E...P.G........G.G..........P.V.....N.... : 764 
FV13       : ......S.....K.....R.....................I...........L...I.-.....................K.V...N....II.....N.... : 774 
FV20       : K.NS.....N.............V...........T.I.L..................RST.E...........................S.V.....N.... : 764 
FV22       : ..Q...S..S.S......R..............V........................-S..E....RG.....................S............ : 769 
FV23       : .........N...............................KK...............-...E.....G.................N....I........... : 752 
FV25       : ..NS.....S..K..........................V.....H............-...EL....G.................N...PIV.......... : 758 
FV28       : ......S....S......R......................K................-.........G.....................S.F.......... : 763 
FV3        : ..NS.....S..K...........I...VC.......I.L..................-S..DL...RG.....................PIV.......... : 778 
FV10       : Q.AS.....G..K......L..............C..F.L................I.-.......P.GT.........N.....AN................ : 756 
FV14       : K.N...S...........R...............V.....................N.-S..E................NK...................... : 773 
FV15       : R.NS.....N.S......R.................................L...I.-....L....G.........K.......N....I........... : 767 
FV26       : .........N.S...........V..........LG.....K..............I.-...D.....G.....................S............ : 755 
FV27       : .........S.S.......................S.....R................-...EL...............K......N................ : 777 
                                                                                                                           
                                                                                
 
 
                                            
                  *       840         *       860         *       880         *       900         *       920              
CONSENSUS_ : SYHRLRDFILIAARAVELLGRSSLRGLQRGWEALKYLGSLVQYWGLELKKSAISLLDTIAIAVAEGTDRIIELIQRICRAIRNIPRRIRQGFEAALQ------ : 835 
C.anc      : ................................................................................................L------ : 835 
FV2        : ...L.......VL.T......R-------................S......V........V..........A.RN....................L------ : 872 
FV5        : ..........V...T.......................N......................V..G.......VV...........T...........------ : 860 
FV6        : .......L....R.T.........K.......I............V.........F....V...............FG...L..............L------ : 857 
FV7        : ...L........V...................T.......................................F..G.........T..........L------ : 878 
FV8        : ...Q.......V..........................G.G....................................I...L...T.......T..L------ : 859 
FV9        : I.........VTT.........IFK.......V....................N.........G.........V..A....C...I.....L.T...------ : 856 
FV11       : ...Q....V..VV.........................N..L..............................FF.G.........T........S.L------ : 852 
FV12       : ......................................................................L.V..............V........L------ : 861 
FV13       : C..Q...........A...............Q......N..L.G.Q............L..T..........VA...W...C...........V..L------ : 871 
FV20       : ........T..VV.......H...K.......I.......A......I........................F...L...VLH..............------ : 861 
FV22       : ..........VT........QR-------...............I........N.......T.............G....................L------ : 859 
FV23       : ..........LI..V.....QR-------................................S...K..S...F..........L............L------ : 842 
FV25       : C.............................................K......N...IT...........L....GF..GLL.........L.....------ : 855 
FV28       : ...........VV................V..T.....G...................T..............A.G.Y...LH.............L------ : 860 
FV3        : ...........VV......................F..N..............N..................F...F....L...T..........L------ : 875 
FV10       : ...L.......V..V.................T...................T..I.......G.......V...G.....L...........V..L------ : 853 
FV14       : C...........V......................E..N................F.SF..T...........VRG.....YH..........T..L------ : 870 
FV15       : ..RQ...........A......L.K.......I.....GII....................R..........IV..F....Y...............------ : 864 
FV26       : ...Q..S...VT....Q...........G.........N..........R...........T.............G.....C...........R..L------ : 852 
FV27       : ...L..........T.G....R-------...V......I..............................L.A...F........T..........L------ : 867 
 
 
 
Figure 3.3: Legend overleaf.
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Figure 3.3: Alignment of the predicted envelope glycoprotein amino acid sequences 
of 20 South African HIV-1 subtype C isolates. Dots indicate identity to the consensus 
subtype C sequence and dashes indicate insertions or deletions. Potential N-linked 
glycosylation sites are shaded in yellow. Residues that have direct contact with CD4 are 
shaded grey, and red indicates an overlap between a potential N-linked glycosylation site 
and a residue in direct contact with CD4. The gp120/gp41 cleavage site is shaded blue. 
Approximate locations of the various envelope regions are indicated in the bars above the 
sequence alignment. C1-C5: gp120 constant regions, V1-V5: gp120 variable regions, 
N34 and C28 are peptides derived from N51 and C43 (see section 1.3.3.1) that form the 
six-helix bundle of gp41 and which were used to resolve it’s crystal structure. TM: 
Transmembrane domain.  
 
 
Potential N-linked glycosylation sites in the Env sequences of the 20 newly characterized 
isolates, as well as the consensus C and ancestral C sequences were predicted using 
Prosite208.These are highlighted in yellow in figure 3.3. Overall positive charge in the V3 
loop of each isolate was also calculated (table 3.1), by starting at zero and adding 1 for 
the positively charged amino acids lysine and arginine, adding 0.5 for histidine, and 
subtracting 1 for the negatively charged amino acids aspartic acid and glutamic acid. The 
V3 loops of the isolates able to use CXCR4 had a consistently higher charge than those 
exclusively utilizing CCR5, and the V3 loops of the CXCR4-using isolates tended to be 
longer than those of the CCR5-using isolates. 
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Table 3.1: Table of charges and lengths of the V3 regions of the 20 isolates 
Isolate Charge of V3 loop Length of V3 loop 
Isolates exclusively using CCR5 
FV2 +1 35 
FV5 +4.5 35 
FV6 +4.5 35 
FV7 +3.5 35 
FV8 +4 35 
FV9 +3.5 35 
FV11 +3.5 35 
FV12 +3.5 35 
FV13 +4.5 35 
FV20 +3.5 35 
FV22 +3 34 
FV23 +3.5 35 
FV25 +3.5 35 
FV28 +3.5 35 
Isolates able to use CXCR4 
FV3 +6.5 37 
FV10 +6 34 
FV14 +6.5 35 
FV15 +6 37 
FV26 +8.5 35 
FV27 +4.5 35 
     
C: Charge, L: Length 
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3.3. Generation of Recombinant gp120-Expression Vectors 
 
Gp120-encoding DNA amplified from 19 of the 20 full-length gp160 products was 
inserted into the multiple cloning site of pTriEx. 17 of the 20 isolates that were sequenced 
were successfully cloned. We were unable to generate clones for FV11, FV27 and FV28. 
In order to confirm the presence of the insert within the vector, PCR was performed on 
colonies from the ligation plates that were cultured overnight (figure 3.4a). Where PCR 
confirmed the presence of the gp120 insert within the vector, plasmids were isolated from 
the overnight culture and their integrity confirmed by restriction digestion analysis (figure 
3.4b). The restriction endonuclease recognition site for Xba I is upstream of the point of 
insertion of the 5’ end of the gp120-encoding DNA and the Xho I site is reconstituted at 
the 3’ end of the insert upon ligation. Thus a single, intact and correctly positioned insert 
in pTriEx would yield two DNA products of approximately 4.8kb (plasmid DNA) and 
1.7kb (insert) (For map of pTriEx-gp120, see appendix 2, figure S1).  
 
Plasmids containing the correct size inserts of FV3 and FV5 gp120 coding regions were 
sequenced, which confirmed the presence of start and stop codons in the correct reading 
frame of the plasmid. Selection of clones for further propagation was based on 
phenotypic determination of coreceptor use (i.e. one CXCR4-using and one CCR5-using 
clone were required). As FV3 (CXCR4-using) and FV5 (CCR5-using) were performing 
well in culture, these two clones were selected for expression of gp120 as this presented 
an opportunity for interfacing biochemical data obtained from recombinant proteins with 
data obtained from cell culture studies. 
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Figure 3.4: Screening for gp120 clones.  Representative agarose gels showing (A) PCR 
screening. Colonies selected from positive ligation plates were cultured overnight and 
subjected to PCR with gp120-specific primers. Generation of a 1.5 kb fragment implied 
positive ligation between pTriEx and gp120-encoding inserts. Lane 1: MW marker 
(Quick-Load 1 kb DNA Ladder). Lane 2: Negative control. Lanes 3,5: gp120-negative 
colonies. Lanes 4,6: gp120-positive colonies (FV5). (B) Restriction digestion analysis 
of FV3: After PCR, clones with a gp120 insert were digested with XhoI and XbaI. 1:MW 
Marker (Quick-Load 1 kb DNA Ladder). Lanes 3,4,6,7: Clones containing the correct 
size insert. Lanes 2,5: Clones containing an aberrant insert. Similar results were obtained 
for all clones. 
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At the time of clone generation, the population based sequences of the gp160 amplicons 
were not available for comparison with the cloned sequences. Later, once population-
based sequencing data became available, sequences of the cloned gp120’s were compared 
to the gp120 portion of the population-based sequences of their gp160 counterparts 
(figure 3.5). FV3 (523 amino acids in length) was cloned with only one amino acid 
difference between the population-based gp160 and the gp120 insert (99.8% sequence 
similarity). This difference occurred at amino acid 6 (I6T), in the signal peptide region of 
gp120, which is cleaved before the protein reaches maturity, and thus the actual protein 
sequence is exactly the same as that of the predominant viral population in the patient. 
FV5 (508 amino acids in length) was cloned with 36 differences between the population-
based amino acid sequence and the clone (93% sequence similarity). These differences 
are spread throughout the entire gp120 sequence, with the FV5 clone having two more 
potential glycosylation sites than its gp160 counterpart in the V4 region, one at position 
383 and another at position 395 (highlighted yellow in figure 3.5). 
 
The sequences of FV3 and FV5 were also aligned and compared (figure 3.6). FV3 was 
523 amino acids long and contained 29 potential N-linked glycosylation sites, while FV5 
was 508 amino acids long and contained 23 potential glycosylation sites (highlighted in 
yellow in figure 3.6). Comparison of the variable loops of each sequence reveals much 
shorter V1 and V5 loops in FV5, while FV3 has a shorter V4 region (figure 3.6).  
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                    *        20         *        40         *        60         *        80         *       1       
FV3gp120 : MRVMGIQRNCQQWWIWGILGFWMLMICNGGNLWVTVYYGVPVWKEAKTTLFCASDAKAYEKEVHNVWATHACVPTDPNPQEMKLRNVTENFNMWKNDM :  98 
FV3gp160 : .....T............................................................................................ :  98 
                                                                                                                    
                                                                                                                    
           00         *       120         *       140         *       160         *       180         *             
FV3gp120 : VDQMNEDIISLWDESLKPCVKLTPLCVTLNCSDVTYNATNATNNTTTTTHNTTETTPYAKISNITDDMKNCSFNVTTGLRDKRKQESALFYRLDIIPL : 196 
FV3gp160 : .................................................................................................. : 196 
                                                                                                                    
                                                                                                                    
            200         *       220         *       240         *       260         *       280         *           
FV3gp120 : NGNKENSSEYRLINCNTSTIRQACPKVSFDPIPIHYCAPAGFAILKCNDKTFNGTGPCHDVSTVQCTHGIKPVVSTQLLLNGSLAEEEIVIRSENLTN : 294 
FV3gp160 : .................................................................................................. : 294 
                                                                                                                    
                                                                                                                    
              300         *       320         *       340         *       360         *       380         *         
FV3gp120 : NAKIIIVHLNESVEIKCSRPGNNTRKSVRIGIGRGQTFYATGKVIGDIRQAHCNVSREAWNKTLEKVKRKLGEHFPNSTITFNHSSGGDLEITTHSFN : 392 
FV3gp160 : .................................................................................................. : 392 
                                                                                                                    
                                                                                                                    
                400         *       420         *       440         *       460         *       480         *       
FV3gp120 : CRGEFFYCNTSDLFKDNITITNSTNNTVITLQCRIKQIINMWQRAGQAIYAPPIRGNITCNSNITGLLLTRDGGKDNKTNNENKTEIFRPGGGDMRDN : 490 
FV3gp160 : .................................................................................................. : 490 
                                                                                                                    
                                                   
                  500         *       520          
FV3gp120 : WRSELYKYKVVEIKPLGIAPTTAKRRVVEREKR : 523 
FV3gp160 : ................................. : 523 
                                                   
 
                                               
 
    
                                                                   
                    *        20         *        40         *        60         *        80         *       1       
FV5gp120 : MRVMGIQRSCQRWWIWGLLGFWMLLICNGTENLWVTVYYGVPVWREAKTTLFCASDAKSYEREVHNVWATHACVPTDPNPQEMVLENVTENFNMWKNDMV : 100 
FV5gp160 : ...R..L....H............M........................................................................... : 100 
                                                                                                                      
                                                                                                                      
                    *       120         *       140         *       160         *       180         *       200       
FV5gp120 : DQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDFDPLDNGTDAMGEIKNCSFKATTELKDKKRKEQALFYRLDIVSIDKVSNSSNRNFSMYRLINCNTSAI : 200 
FV5gp160 : .....................................................................T.........YD.CY.H.......D...... : 200 
                                                                                                                      
                                                                                                                      
                    *       220         *       240         *       260         *       280         *       300       
FV5gp120 : TQACPKVSFDPIPIHYCAPAGYAILKCNDKTFNGTGPCNNVSTVQCTHGIKPVVSAQLLLNGSLAEGEIIIRPENLANNVKTIIVQFNESVEIVCTRPNN : 300 
FV5gp160 : ...........V...........................................T................S........................... : 300 
                                                                                                                      
                                                                                                                      
                    *       320         *       340         *       360         *       380         *       400       
FV5gp120 : NTRKSVRIGPGQTFYATGEIIGNIRQAHCNISESKWNKTLQNVAKRLKEHFPNKNITFAPASGGGLEITTHSFNCRGEFFYCNTSKLFNSTYNSNDTERD : 400 
FV5gp160 : ..............................................................R.D.Q...P..Y........Y..S.....S..H.A... : 400 
                                                                                                                      
                                                                                                                      
                    *       420         *       440         *       460         *       480         *       500       
FV5gp120 : YNGTGNNSTDSIITIQCRIKQFINMWQRVGQAMYAPPIEGNVTCKSIITGLLLTRDGGSNTTETFRPVGGDMRDNWRSELYKYKVVEVRPLGIAPTRAQR : 500 
FV5gp160 : ...A..S.S..F...L.......I......R.......V.S...C.F..................................................... : 500 
                                                                                                                      
                           
                           
FV5gp120 : RVVEREKR* : 508 
FV5gp160 : .....V..  : 508 
                                    
 
 
Figure 3.5: Alignments of cloned gp120 sequences with their population-based 
gp160 counterparts. Dots indicate identity to the top sequence and dashes indicate 
insertion/deletions. Where potential N-linked glycosylation differs between the gp120 
clone sequence and the gp160 sequence, sites are highlighted in yellow. (A) FV3 (B) 
FV5. 
 
B 
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              *        20         *        40         *        60         *        80         *       1       
FV3 : MRVMGIQRNCQQWWIWGILGFWMLMICNG-GNLWVTVYYGVPVWKEAKTTLFCASDAKAYEKEVHNVWATHACVPTDPNPQEMKLRNVTENFNMWKND :  97 
FV5 : ........S..R.....L......L....TE.............R.............S..R.....................V.E............ :  98 
                                                                                                               
                                                                                                               
      00         *       120         *       140         *       160         *       180         *             
FV3 : MVDQMNEDIISLWDESLKPCVKLTPLCVTLNCSDVTYNATNATNNTTTTTHNTTETTPYAKISNITDDMKNCSFNVTTGLRDKRKQESALFYRLDIIP : 195 
FV5 : .....H........Q.................T.---F---DP------LD.G.----D.M----G-EI.....KA..E.K..KRK.Q........VS : 175 
                                                                                                               
                                                                                                               
       200         *       220         *       240         *       260         *       280         *           
FV3 : LNG----NKENSSEYRLINCNTSTIRQACPKVSFDPIPIHYCAPAGFAILKCNDKTFNGTGPCHDVSTVQCTHGIKPVVSTQLLLNGSLAEEEIVIRS : 289 
FV5 : IDKVSNSSNR.F.M.........A.T....................Y................NN...............A..........G..I..P : 273 
                                                                                                               
                                                                                                               
         300         *       320         *       340         *       360         *       380         *         
FV3 : ENLTNNAKIIIVHLNESVEIKCSRPGNNTRKSVRIGIGRGQTFYATGKVIGDIRQAHCNVSREAWNKTLEKVKRKLGEHFPNSTITFNHSSGGDLEIT : 387 
FV5 : ...A..V.T...QF......V.T..N.........--.P........EI..N.......I.ESK.....QN.AKR.K.....KN...APA...G.... : 369 
                                                                                                               
                                                                                                               
           400         *       420         *       440         *       460         *       480         *       
FV3 : THSFNCRGEFFYCNTSDLFKDNITI----------TNSTNNTVITLQCRIKQIINMWQRAGQAIYAPPIRGNITCNSNITGLLLTRDGGKDNKTNNEN : 475 
FV5 : ................K..NSTYNSNDTERDYNGTG.NSTDSI..I......F......V...M.....E..V..K.I...........--SN.---- : 461 
                                                                                                               
                                                              
             500         *       520         *                
FV3 : KTEIFRPGGGDMRDNWRSELYKYKVVEIKPLGIAPTTAKRRVVEREKR- : 523 
FV5 : -..T...V...................VR.......R.Q.........- : 508 
 
 
 
Figure 3.6: Alignment of cloned FV3 and FV5 sequences. Dots indicate identity to the 
top sequence and dashes indicate insertion/deletions. Potential N-linked glycosylation 
sites are shaded in yellow. 
 
 
3.4. Bacterial expression of gp120 
 
In order to evaluate whether gp120 fragments had ligated with pTriEx to produce 
functional open reading frames, E. coli BL21 were transformed with the pTriEx-FV3 
clones in a pilot expression induction experiment. Since E. coli  BL21 do not glycosylate 
post-translationally, an activity essential for the generation of fully functional gp120, the 
objective of these experiments was simply to determine whether or not clones were 
capable of producing protein. Western Blots using gp120-specific antibodies confirmed 
the presence of two different sized gp120 bands (approximately 60 kDa and 50 kDa) 
(figure 3.7b), possibly formed by differential processing of gp120 in E. coli. These bands 
were absent in samples from untransformed cultures.  
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Lane  M BaL Sf 1 2 3 4 5 6 7 8 9 10 
Time (hours)    0 0 2 2 2 2 4 4 4 4 
IPTG    - - - + - + - + - + 
pTriEx-FV3    - + - - + + - - + + 
` 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Expression of gp120 in E. coli BL21. BL21-pTriEx-FV3 cells, together 
with untransformed controls, were induced with 1 mM IPTG. Samples taken hourly were 
resolved by SDS-PAGE. Lane labeling is shared for both A and B: M: Prestained Protein 
Marker, Broad Range (New England Biolabs), Sf: Sf162. A: Coomassie®-stained gel. 
(B) Western blot (approximate positions of molecular weight markers are shown). 
 
 
175 kDa 
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It was also noted that pTriEx-FV3-transformed E. coli BL21 showed continuous low-
level protein expression, regardless of whether treated with IPTG (lane 2, figure 3.7). No 
gp120 was seen in the induced BL21-pTriEx-FV3 culture at four hours (lane 10, figure 
3.7b), and it thus appears that high levels of expression of gp120 in E. coli BL21 may be 
toxic to the cells, resulting in cell death and degradation of protein. 
 
3.5. Expression of gp120 in Insect cells 
 
3.5.1. Transfections and Plaque Purification 
 
3.5.1.1. Generation of recombinant baculoviruses 
 
Transfection was achieved using a liquid overlay method, which involves adding a 
transfection mixture directly to the culture medium on a cell monolayer. The transfection 
mixture consisted of triple-cut baculoviral DNA and pTriEx-FV3/FV5, together with the 
transfection reagent. The promoter and cloning regions of pTriEx are flanked on either 
side by regions of baculovirus genomic DNA. This facilitates the generation of 
baculovirus recombinants by homologous recombination at the viral polh locus. 
 
Supernatants obtained from transfection experiments were negative for gp120 when 
tested by Western Blotting analysis (figure 3.8a), but were nonetheless used to reinfect a 
cell monolayer in a five day infection. The resulting supernatant was used in a further 
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120 kDa 
round of infection, after which supernatants were testing positive for the presence of 
gp120 by Western Blot (figure 3.8b). 
 
 
 
 
 
 
Figure 3.8: Western Blots representative of baculoviral transfection and 
amplification results. Transfection and amplification supernatants were resolved on 8% 
SDS-PAGE gels and gp120 was detected by Western Blotting analysis. (A) Transfection 
supernatants: Lane 1: CM gp120 (positive control), Lane 2: negative transfection. Lane 
3: FV3 Undiluted transfection, Lane 4: FV3 transfection (1/5 dilution of transfection 
mixture). (B) Amplified transfection supernatants (obtained by amplification of 
transfection supernatants, after 2 rounds of amplification): Lane 1: CM gp120 (positive 
control), Lane 2: FV3 from undiluted transfection, Lane 3: FV3 from1/5 dilution of 
transfection mixture. 
 
3.5.1.2. Plaque selection and generation of high-titer baculoviral stocks 
 
Baculovirus-containing supernatants required purification in order to select single 
baculoviral clones to be used for protein expression. This was accomplished by two 
rounds of plaque assays, each time picking a single plaque for further use. Plaque-derived 
  
1 2 3 4 1 2 3 
A B 
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viruses were amplified by two successive rounds of reinfection between plaque assays. 
After two rounds of plaque purification, selected clones were used to generate high-titer 
stocks of recombinant baculoviruses (Bac-FV3 and Bac-FV5).  
 
3.5.1.3. Viral Titering 
 
Once high-titer baculoviral stocks of Bac-FV3 and Bac-FV5 had been obtained, it was 
necessary to calculate corresponding viral titers in order to determine the optimal 
multiplicity of infection (MOI) required for consistent and efficient protein expression. 
Plaque assays are the recommended method for calculating viral titers, however we found 
these to be challenging and subjective and the failure of a number of such assays due to 
difficulties in visualizing and counting plaques necessitated the development of a 
different assay for the titering of baculoviral DNA. To this end, we designed a 
quantitative real-time PCR assay for quantifying the number of baculoviral DNA copies 
in Bac-FV3 and Bac-FV5 stock solutions. An approximately 180 bp target sequence 
within both FV3 and FV5 gp120-encoding genes was amplified using pTriEx-FV3 and 
pTriEx-FV5 as templates in order to generate external standard curves describing DNA 
concentration as a function of the amplification curve crossing point. DNA was extracted 
from baculoviral supernatants using automated extraction techniques and, using the 
generated standard curves externally, the number of copies of gp120-encoding DNA (and 
therefore the number of baculoviruses containing a gp120 insert) within each sample was 
quantified. Viral nucleic acid titers obtained ranged from 0.8 x 109 to 1.0 x 109 gp120 
 82 
copies/ml of gp120. See appendix 2, figures S2 and S3 for standard curves and 
amplification curves. 
 
3.5.2. Protein expression studies 
 
Expression of protein in insect cells presented a number of challenges. Consistently low 
protein expression was obtained using monolayer cell cultures, and before methods for 
viral titering by real time PCR had been established. Using the baculoviral titers 
calculated by real time PCR, conditions for protein expression were optimized. Proteins 
were expressed in both suspension and monolayer cultures and monitored each day for 
three to five days for cell viability in the culture and protein expression (figure 3.9). In 
suspension cultures, while protein expression increased over time, lower molecular 
weight products, probably a combination of degraded and incompletely glycosylated 
proteins, also began to be produced at around day 2 or 3 (figure 3.9b, days 2 and 3).  
 
After several rounds of optimization, it was determined that maximal expression of intact 
recombinant FV3 and FV5 gp120 was obtained in suspension cultures and required cells 
that had undergone fewer than 20 passages be infected at a density of 2.0 x 106 cells/ml. 
For both FV3 and FV5, the optimal MOI (as determined by real-time PCR) was 3 gp120-
encoding copies/cell. Suspension cultures were grown for three days until cell viability 
(as determined by trypan blue staining) was less than 50%. These conditions resulted in a 
significant amount of protein with minimal degradation due to proteases and other 
enzymes released from dying cells.  
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Figure 3.9: Gp120 expression in monolayers and suspension culture. Monolayers as 
well as suspension cultures were infected with supernatants containing Bac-FV3 and Bac 
FV5 and monitored for 3-5 days. (A) Representative monolayer culture (FV3) at 
unknown MOI, days 1-5 (D: Day) (B) Representative suspension culture infection, 
days 1-3 The MOI is written above each lane in the top image and corresponds to the 
same lane in all three days.  
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BaL 0.1 1 2 3 4 5 10   (MOI) 
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3.6. Protein Purification 
 
A number of strategies for purification of gp120 were attempted, including lectin-affinity 
chromatography, size-exclusion chromatography and ion-exchange chromatography. 
While attempts at size-exclusion chromatography were never met with any appreciable 
amount of success, the final protocol for protein purification involved both lectin 
purification and ion-exchange chromatography. Purification of protein-containing 
supernatants using lectin from Galanthus Nivalis involved binding of protein to lectin 
columns, followed by extensive washing with NaCl and elution with MMP. This resulted 
in purification to a level of approximately 60-65% (by visual analysis of silver stains). 
The purity of these eluates was increased by subjecting them to ion-exchange 
chromatography using a pH and NaCl gradient. After dialysis of the ion-exchange eluate 
against PBS and concentration of protein samples, the yield of FV3 and FV5 gp120 
obtained per 200 ml starting volume of culture supernatant was approximately 50 µg.   
 
Analysis of protein purity by silver staining showed FV3 and FV5 purified to near 
homogeneity (figure 3.10). Silver staining of FV5 revealed a number of lower molecular 
weight bands, suggesting incomplete glycosylation or degradation of gp120. It was also 
noted that FV3 is smaller than FV5. This is clearly seen in Western Blot analysis (figure 
3.10). The sizes of each protein were estimated using the molecular weight marker and 
Bio-Rad Quantity One 1-D Analysis Software. According to this analysis, FV3 was 
estimated to be 112 kDa and FV5 83 kDa (figure 3.10).  
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Figure 3.10: Analysis of purified gp120. Purified recombinant gp120 was analysed by 
Western Blot and Silver Stain (with BaL gp120 as a positive control). WB: Western Blot, 
SS: Silver Stain, MW: Molecular Weight Marker (Prestained Protein Marker, Broad 
Range (New England Biolabs)). 
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3.7 Protein Characterisation 
3.7.1. Characterisation of binding of recombinant gp120 to a panel of 
monoclonal antibodies. 
 
In order to determine epitope exposure and conformational integrity of the purified 
gp120s, proteins were concentrated, quantified and their antibody-binding profiles 
compared to each other, and to those of three reference gp120 proteins obtained from the 
NIH, by direct ELISA. The control proteins were the Subtype B gp120BaL (BaL), Subtype 
C gp12096ZM651(96ZM651) (both produced in mammalian cells), and the insect-cell 
produced Subtype E (CRF01_AE) gp120CM (CM). The reactivity of these five proteins 
against a panel of antibodies was determined by ELISA in two experiments, performed 
each time in triplicate, with the same results each time. Due to the variability of the 
reactivity of the gp120s with the various antibodies, the A450 value was set to 3.5 when it 
was above the readable amount. The results of the antibody binding studies can be seen in 
figure 3.11. Graphs including experimental standard deviations can be seen in 
supplementary figure S4 in appendix 2.  
 
In these experiments, and in comparison to the control panel of proteins, as well as a BSA 
blank, FV3 had low binding to the monoclonal antibody 654-30d, moderate binding to 
2G12, Chessie 13-39.1 and 9301, and high binding to ID6. FV5 had low binding with the 
monoclonal antibodies F425 B4a1 and Chessie 13-39.1, moderate binding with 2G12, 
and good binding to 9301 and ID6 (figure 3.11). 
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Figure 3.11:  Comparison of antibody recognition characteristics of the panel of five 
gp120’s studied. A450 values equal or lower to the highest blank value (0.07) were 
classified as having no binding. A450 values between 0.07 and 0.5 were classified as 
having low binding. A450 values between 0.5 and 1.5 were classified as showing moderate 
binding. A450 values between 1.5 and 2.5 were classified as showing good binding. A450 
values between 2.5 and 3.5 were classified as showing high binding. Data was obtained 
from a triplicate experiment. Blank values were obtained by testing antibody binding to 
wells coated with BSA. 
 
 
 
 
 
 
 
 
 
 BaL CM 96ZM651 FV3 FV5 Blank 
F105 3.04 0.04 0.08 0.05 0.04 0.04 
F425 A1g8 1.92 0.04 0.08 0.04 0.04 0.04 
F425 B4a1 3.19 0.24 0.04 0.04 0.18 0.04 
F425 B4e8 3.50 0.05 1.37 0.04 0.06 0.04 
670-30D 2.31 0.18 0.07 0.05 0.03 0.03 
654-30D 1.72 0.04 1.01 0.36 0.04 0.04 
17b 0.04 0.04 0.03 0.04 0.04 0.04 
2G12 3.50 0.76 0.06 1.08 0.71 0.04 
ID6 2.19 0.19 2.57 2.74 2.00 0.04 
Chessie 13-39.1 0.94 1.87 0.26 0.58 0.27 0.04 
5F7 0.04 0.04 0.04 0.04 0.04 0.04 
4G10 0.04 0.04 0.04 0.04 0.04 0.04 
9301 2.73 2.89 3.49 1.70 1.64 0.07 
IgG1 b12 1.41 0.07 0.05 0.04 0.04 0.04 
48d 0.04 0.04 0.04 0.04 0.04 0.04 
 
KEY 
Binding Colour 
No  
Low  
Moderate  
Good  
High  
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3.7.2. CD4-binding capability of recombinant gp120 
 
The presence of intact and functional CD4 binding sites in the expressed recombinant 
gp120 was also assessed by ELISA. ELISA plates were coated with CD4 and after a 
blocking step, gp120 was added to the coated plates and allowed to bind. CD4-bound 
gp120 was then detected using a selection of anti-gp120 monoclonal antibodies (figure 
3.12). These analyses showed that FV3 reacted with CD4, as measured by its binding to 
2G12. FV5 however, did not show any evidence of being able to react with CD4.  
 
In order to quantify how well FV3 binds to CD4 relative to BaL, the value obtained for 
BaL binding to 2G12 in the antibody recognition experiments was normalized to 100%, 
and the percentage of FV3 binding to 2G12 relative to this value was calculated. These 
calculations indicated that FV3 binds to 2G12 with an efficiency that is 31% of the BaL 
binding efficiency to 2G12. This value was then used to normalize the values obtained for 
BaL and FV3 binding to 2G12 from the CD4-binding data. By these calculations, it is 
reasonable to infer that FV3 binds to CD4 with approximately 22.5% efficiency relative 
to BaL. 
 
The CD4-binding data were also aligned next to the CD4-unbound data (figure 3.13). In 
this figure, a remarkable increase in binding to some gp120s by the antibodies targeted to 
 the CD4-induced epitope (17b, 48d, and F425 A1g8) is seen in the presence of CD4. 
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Figure 3.12: CD4 binding activity of a panel of gp120s. ELISA plates were coated with 
sCD4, after which gp120 was bound and detected by a number of monoclonal antibodies. 
A450 values were classified as follows: those equal to or lower than the highest blank 
value (0.07) showed no binding, low binding values were between 0.07 and 0.5, moderate 
binding values were between 0.5 and 1.5, good binding values were between 1.5 and 2.5 
and high binding values were between 2.5 and 3.5. Data obtained from a triplicate 
experiment. ZM: 96ZM651. Blank values were obtained by testing antibody binding to 
wells coated with BSA. 
 
 
 
 
 
  
 
 
 
Figure 3.13: Comparison of monoclonal antibody binding to gp120 in the presence 
and absence of CD4. Error bars represent standard deviations. 
  BaL CM ZM FV3 FV5 Blank 
2G12 3.50 0.21 0.05 0.26 0.04 0.04 
17b 3.50 1.30 3.19 0.07 0.04 0.04 
48d 1.26 0.09 0.04 0.04 0.04 0.04 
F425 A1g8 3.50 0.77 1.14 0.04 0.05 0.07 
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4. Discussion 
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The aim of this project was the expression, purification and characterization of 
recombinant gp120 from recently obtained South African HIV-1 subtype C isolates. To 
this end, gp120-coding sequences were cloned from locally relevant isolates, expressed in 
insect cells and purified using a combination of lectin-affinity and ion-exchange 
chromatography. Purified recombinant FV3 and FV5 gp120s (CXCR4-utilising and 
CCR5-utilising respectively) were characterised according to their ability to bind CD4, as 
well as their ability to bind to a number of monoclonal antibodies. Following is a 
discussion of the issues surrounding this work. 
 
4.1. PCR amplification of Env-encoding regions  
 
PCR amplification of gp160 coding regions was successful when using proviral DNA as 
a template. Amplification of gp120 coding regions from gp160 products was also 
successful, except in the case of FV28. Inspection of the nucleotide sequence of this 
isolate revealed an 18 nucleotide insertion in this sequence where the binding site for the 
reverse primer for gp120 amplification is located. This insertion results in a complete 
mismatch between primer and proviral DNA at the 3’ end, thereby preventing primer 
binding and successful PCR. Should it become of specific interest to clone this gp120, the 
problem can be easily rectified by the design of a reverse primer specific to this isolate. 
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4.2. Population-based sequencing of the gp160 coding regions 
 
4.2.1. Amino acid sequences 
 
Population based sequencing provided interesting insights into this cohort of AIDS 
patients. Due to the high mutation rate of HIV-1, patients infected with the virus usually 
contain a number of related viral quasispecies in the circulating viral population. 
Population based sequencing is based on PCR of all proviral DNA present in the patient’s 
blood sample, and thus does not represent a single virus in the patient, but rather a 
sequence that is reflective of the entire viral population, usually the most predominant 
sequence. 
 
All of the isolates sequenced in this study were shown to be subtype C, except for one 
isolate, FV10. This virus is a CD recombinant. Subtype D is typically found in 
West/West Central Africa, while subtype C is more common in Southern Africa. Thus, 
this strain could have originated in West Central Africa, or it could represent a 
recombination event between a West Central African and South African strain. 
 
The amino acid sequences of the env regions of the 20 isolates were extensively analysed 
and compared. The variable loops of gp120, particularly the V1/V2 and V3 loops have 
been directly implicated in coreceptor usage81, 99-104.  Coreceptor usage amongst these 
isolates was determined phenotypically in our laboratory, using a MT-2 fusion assay. The 
sequencing results confirmed the phenotypic findings as the typical features of the V3 
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loop that differentiate X4 from R5 isolates were present. The V3 loop of the R5 isolates 
was more conserved compared to that of the X4 isolates. The tetrapeptide crown 
sequence in the V3 loop of the R5 subtype C isolates was GPGQ (with the exception of 
FV6 and FV25, which was GPGG) and these V3 loops carried a net charge of +1 to +4.5 
(table 3.1). A neutral serine residue was present at position 11 (corresponding to position 
339), and amino acids with a negatively charged side chain (either D or E) were present 
at position 25 (corresponding to position 355) of the V3 loop, except for FV28. This 
pattern of amino acids at these positions has been shown to correspond to R5 usage 
among HIV-1 isolates209. In contrast, 4 of the 6 CXCR4-using isolates exhibited changes 
in the V3 tip tetramer motif and two of these isolates each had two amino acid insertions 
within this motif. The overall positive charges of the V3 loops for the X4 isolates range 
from +4.5 to +8.5 (table 3.1). The X4 phenotype has been associated with the presence of 
at least one basic or positive amino acid substitution at position 11 or 25209. Interestingly, 
all of the CXCR4-using isolates, except for FV3 had a positively charged residue at 
position 11 of the V3 loop and all, except FV10, had either a neutral or positively charged 
residue at position 25. Until recently, X4 usage amongst subtype C viruses was reported 
as extremely rare115-122. Recently, however, reports of higher percentages of CXCR4-
using isolates in subtype C populations have emerged123, 124, and the determinants of 
CXCR4-usage within subtype C populations have been extensively studied210, 211. The 
predominance of subtype C infection makes it of paramount importance as a focus of 
research efforts. The rarity of subtype C CXCR4-using isolates makes this cohort a 
valuable tool to study subtype C pathogenesis and CXCR4-usage within this clade, as 
well for the design of drugs specific to this clade. 
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Analysis of the residues involved in formation of the CD4 binding site73 (shaded in 
grey/red in figure 3.3) revealed that most were conserved, although some differences 
were noted and these sequences were thus compared with those of other isolates found in 
the Los Alamos database45. Comparison of sequences revealed that amino acids can occur 
in various combinations around the CD4 binding site. It is interesting to note, however, 
that residues of gp120 crucial for CD4 binding, D368, E370 and W427 of the HIV-1 
reference sequence HXBc2 (residues 403, 405 and 467 in figure 3.3 respectively)73, are 
highly conserved among the 20 isolates. Only FV5 and FV23 have a different amino acid 
at position E370, a residue interacting with Phe43 of CD473. Both of these isolates have 
been grown in culture, however, with FV5 replicating efficiently in both PBMC cultures 
and in lymphocytic cell lines following adaptation, suggesting that substitutions at this 
position do not altogether abrogate CD4 binding. It has indeed been found that 
substitutions at this site compromise, but do not altogether abrogate binding of CD4212. It 
should also be noted that the gp120 clone of FV5 did not contain this mutation (Figure 
3.5b). 
 
All 20 isolates, except FV28, had the consensus motif -R/K-X-R/K-R at the gp120/gp41 
cleavage site (shaded blue in figure 3.3). Proteolytic activation of the HIV-1 gp160 
precursors occurs at the carboxyl side of the consensus motif in this region213. This region 
of the precursor is the main determinant for cleavage, which is catalyzed by a cellular 
subtilisin-like protein convertase located in the Golgi complex58. It is thus expected that 
the gp160 precursor of these isolates would be efficiently cleaved into the gp120 and 
gp41 subunits with no differences between the R5 and X4 variants. In the case of FV28, 
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cleavage may be affected due to the two amino acid insertion at position 565, which 
abolishes the consensus cleavage site. HIV does, however, contain a secondary cleavage 
site, corresponding to position 555, with the sequence KAKRR214. This sequence is 
conserved in FV28, and thus cleavage of the envelope may occur here, although it is 
likely that the corresponding gp41 will be a monomer and therefore not biologically 
active214. 
 
The gp41 sequences of the 20 isolates are highly conserved relative to those of gp120, 
with fewer potential glycosylation sites, and no notable differences between the SI and 
NSI isolates. It was also noted that four of the 20 new isolates (3 CCR5-using and 1 
CXCR4-using) contained 5-7 amino acid deletions in the gp41 cytoplasmic tail (figure 
3.3). 
 
4.2.2. Glycosylation 
 
Potential glycosylation of the 20 amino acid sequences was also analysed. Overall, there 
was no drastic alteration in the number of potential glycosylation sites, and the number 
and positioning of sites appeared to be mostly conserved between the R5 and X4 isolates 
(figure 3.3). Interestingly, all the CCR5-utilizing sequences contained an N-linked 
glycosylation motif within the V3 loop (positions 334 to 337), consistent with recent 
findings highlighting the close association of this site with CCR5 usage215. Furthermore, 
the X4 isolates were likely to have an extra glycosylation site within the V4 loop and 
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further investigations could reveal whether glycosylation at this site could mask any 
immunologically relevant epitopes.  
 
Glycosylation also plays a key role in the efficacy of antibody neutralisation70. 2G12 is a 
neutralizing antibody which relies on the presence of certain glycans for its activity. One 
postulation of the epitope for 2G12 suggests that two N-linked glycans (positions 295 and 
332 of gp120HxBc2, corresponding to positions 328 and 366 in figure 3.3) form the core 
epitope for 2G12, which is maintained conformationally by other N-linked glycans (at 
positions 339, 386 and 392 of gp120 HxBc2, corresponding to positions 373, 421 and 427 
in figure 3.3)216. The high mannose glycan of residue 295 was absent in 14 of the 20 
isolates, suggesting that they may be resistant to neutralization by the monoclonal 
antibody 2G12. It is interesting to note, however, that N295 was present in 3 of the 5 
subtype C CXCR4-utilizing envelope glycoproteins, perhaps suggesting different 
evolution of glycosylation patterns in these isolates. 
 
4.3. Generation of gp120-encoding vectors 
 
Integrity of the gp120-encoding vectors was confirmed by sequencing. FV3 had 99.8% 
similarity when compared to the corresponding population-based gp160 sequence, while 
FV5 only had 93% sequence similarity. The reasons for these differences are unclear. 
One possibility is that the errors were obtained during PCR. This seems unlikely 
however, as a high fidelity polymerase was used to perform the PCR reactions, and the 
percentage of differences from the population based sequence are very different for each 
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clone. A more probable reason stems from the presence of a number of viral quasispecies 
in each patient. All of the viral quasispecies present in the patient would have been 
amplified by PCR and although the population-based sequence would represent the 
predominant species, it is possible that a less predominant quasispecies of the virus could 
have been the one incorporated into the vector during cloning. 
 
4.4. Protein Expression 
4.4.1. Bacterial Protein Expression 
 
Expression of gp120 from pTriEx-FV3 was induced in transformed E. coli (BL21) in 
order to confirm the competence of the cloned open reading frames for protein 
expression. Culture lysates from transformed E. coli BL21 tested positive for the 
presence of gp120 in time course induction experiments by Western Blot analysis (figure 
3.7). It is interesting to note that two different sized bands were detected by probing with 
the anti-gp120 antibody 9201. Gp120 has previously been expressed in E.coli, also 
producing two bands upon Western blot analysis217. These bands were approximately 45 
kDa and 55 kDa, with the smaller band corresponding to mature, secreted gp120 without 
the signal peptide sequence, and the bigger band corresponding to gp120 including the 
signal peptide sequence217. In our gp120 clones, the HIV-1 signal peptide sequence was 
left intact, while Morikawa et al.217 replaced the HIV-1 signal sequence with a bacterial 
signal sequence. While there is no evidence of the HIV-1 envelope leader sequence being 
processed in E. coli, it may be possible that the bigger and smaller bands seen in our cell 
extracts correspond to immature unprocessed gp120 with the signal sequence and mature, 
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processed gp120 without the signal sequence respectively. It is estimated that the bands 
are a similar size to those obtained by Morikawa et al. The estimated sizes of the bands 
(approximately 50 kDa and 60 kDa) is consistent with unglycosylated gp120, as would be 
produced in E.coli, which do not have glycosylation machinery64, 69.  
 
4.4.2. Insect Cell Protein Expresssion 
 
While production of recombinant baculoviruses was relatively simple, protein expression 
and viral titering presented a number of challenges. Before viral titering procedures were 
in place, protein expression in insect cells was consistently low, regardless of whether 
studies were done using monolayer or suspension cell cultures. Viral titering itself was 
also problematic. In our hands, plaque assays, the recommended method for calculating 
viral titers, were poorly reproducible and defining titers in this manner was problematic. 
Plaque assays involve infecting a cell monolayer with varying dilutions of baculoviruses 
and counting the number of plaques (or defined areas of dead cells) that form as the 
baculovirus multiplies and begins to destroy the cells surrounding the originator infected 
cell. It was often difficult, however, to distinguish between plaques, cells destroyed 
during the process of setting up the assay, and gaps in the monolayer. Cells also tended to 
detach or overgrow very quickly, making plaques even harder to discern. Thus, while it 
was relatively straightforward to isolate a single plaque for plaque purification purposes, 
we experienced difficulties in obtaining accurate plaque counts for viral titering purposes.  
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Because of these problems we developed a real-time PCR assay in order to quantitate 
baculoviral DNA in the supernatants of infected cultures. This seemed a promising 
approach as, during infection, recombinant baculoviruses are released into the tissue 
culture supernatant. Once the supernatant has been clarified, any gp120 DNA present 
should originate from recombinant baculoviruses in the supernatant. Thus, if this DNA 
could be quantitated, it would give an idea of how many recombinant baculoviruses are 
present in the supernatant. 
 
DNA was isolated from insect-cell culture supernatants using automated extraction 
procedures in order to obtain a uniform yield. The real-time assay proved to be extremely 
robust and allowed for quantification of the number of copies of the gp120 insert (and 
therefore the number of gp120-containing baculoviruses) per ml of supernatant. While 
this number does not distinguish between infectious and non-infectious baculoviruses, it 
provides a platform for addition of uniform amounts of virus to insect cell cultures. Real-
time PCR has been used previously in order to quantitate baculoviral DNA218. In that 
study, which used a similar protocol, the baculoviral titers obtained from real-time PCR 
correlated closely with titers detected from 50% tissue culture infectious doses (TCID50s) 
of baculovirus. It is therefore likely that the number of gp120 copies per ml calculated by 
real-time PCR approximates the number of infectious baculoviruses present. This 
supposition is supported by the fact the baculoviral titers calculated by real-time PCR 
were within the range that should be present as specified in the manufacturer’s suggested 
protocols. In any event, the assay provided a basis for infecting cultures with uniform 
amounts of baculoviruses, and enabled optimization of required innocula. 
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Once a platform for viral titering was in place, it was possible to optimize the conditions 
for protein expression in insect cultures. During this process, a number of factors were 
found to influence the expression of protein in insect cells. Cells generally supported 
superior recombinant protein expression the fewer passages they had undergone. 
Suspension cultures exceeded monolayers in amount of protein produced (figure 3.9). 
The use of suspension cultures was also important in order to obtain high volumes of 
gp120-containing supernatants. Most gp120 expression systems employed involve 
secretion of recombinant protein into the supernatant media of mammalian or insect cell 
cultures, enabling purification of secreted protein by simple chromatographic methods219-
221. In this study, experiments using Bac-FV3 and Bac-FV5 showed comparable levels of 
cell-associated and secreted gp120s. In order to simplify the purification protocol, and 
consistent with other successfully employed purification methods, we decided to focus 
exclusively on purifying soluble, secreted gp120. 
 
Incubation times after infection also proved important for maximal production of intact 
protein. It has been reported that the best expression of completely glycosylated gp120 in 
insect cells occurs approximately 24 hours post-infection170. In that study, after 
approximately 30 hours, while gp120 production continued, it was  produced in what is 
proposed to be a non-glycosylated form, as it is postulated that Sf9 cells are unable to 
process large amounts of glycosylated proteins.170. These experiments were performed on 
cell extracts, however, rather than on the cell-culture supernatant. In another study, while 
peak expression of gp120 occurred at approximately 48 hours in the cells themselves, 
peak levels of gp120 were only present in the supernatant 72 hours post-infection169. In 
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our study, peak expression of gp120 in the cell-culture supernatant occurred at 
approximately 72 hours post-infection (figure 3.9). Between 72 and 96 hours post-
infection, additional low molecular weight bands were detected by Western Blot analysis. 
These bands were not distinct, however and possibly correspond to incompletely-
glycosylated proteins, rather than completely non-glycosylated ones.  
 
Possibly the most important factor for optimal protein production, however, was the 
amount of baculovirus used to infect insect cells. Before a platform for baculoviral 
quantification was in place, the amount of baculovirus being added to cultures (an 
estimated MOI of 5 gp120-encoding copies/cell) was estimated based on the amount of 
baculovirus the manufacturer suggested should be present after plaque purification and 
amplification of recombinant baculoviruses. Under these circumstances, protein 
expression in both monolayer culture and suspension was extremely poor. Once the 
supernatants being used were analysed by the real-time assay, however, it became clear 
that the amount of recombinant baculovirus being used to infect the infect cells was far 
below the required amount. Once the viral titer was accounted for, and the MOI increased 
to 3 gp120-encoding copies/cell, protein production dramatically improved (figure 3.9).  
 
Thus, in our hands, consistently efficient protein expression could be obtained by 
infecting fresh suspension cultures at a cell density of 2 x 106 cells/ml and an MOI of 
approximately 3 gp120-encoding copies/cell. The formation of degraded and 
incompletely glycosylated proteins was minimized by restricting the time of incubation of 
infected insect cell cultures to a maximum of three days. 
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4.5 Protein Purification 
 
Lectin-affinity chromatography is a common method used for the purification of HIV-1 
envelope glycoproteins172, 222-225 because of the affinity of lectins for carbohydrate 
residues. We attempted to use both  Galanthus Nivalis lectin, which is specific for α-D-
glucose and α-D-mannose and Lens Culinaris lectin, which is specific for branched 
mannoses with fucose-linked α(1,6) to N-acetyl glucosamine. Recombinant gp120 bound 
to both lectins with similar affinity and produced an end product of similar purity. Going 
forward, however, Galanthus Nivalis lectin was used to purify gp120 due to availability. 
Lectin-affinity chromatography is generally used in conjunction with other purification 
procedures, however, in order to obtain protein of higher purity172, 225. When oligomeric 
gp140 was produced by Jeffs et al.224 in Chinese Hamster Ovary cells and purified by 
Galanthus Nivalis lectin alone, the purity of the protein obtained was only between 50 
and 70%. This is consistent with our experience during the purification of FV3 and FV5 
gp120.  
 
Interestingly, in other experiments being performed in our laboratory, a single 
purification step with Galanthus Nivalis lectin was required in order to obtain 
recombinant gp120 (96ZM651) of greater than 90% purity. This protein, however, was 
expressed in mammalian cells (293T). Supernatants obtained from these transfected 
mammalian cells appeared to require far less intensive purification steps than 
supernatants obtained from infected insect cell cultures. This may be due to insect cell 
proteins forming complexes with the recombinant gp120, which co-purify on the lectin 
column. Insect cells may also produce and secrete a number of glycoproteins absent from 
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the mammalian cells used, or else it is possible that many more cells die in insect cell 
culture than in mammalian cell culture due to the baculoviral infection, and therefore 
release a large amount of extra proteins into the supernatant. Nevertheless, with the 
addition of an ion-exchange chromatography step to the purification protocol, the purity 
of the protein was dramatically increased. 
 
4.6 Protein Characterisation 
 
4.6.1. Protein Size and Purity 
 
FV3 was estimated to be 112 kDa and FV5 83 kDa (figure 3.10). Examination of the 
clones’ sequences (figure 3.6) provides the reason for the smaller size of FV5 when 
compared to FV3, as FV5 is not only 15 amino acids smaller than FV3, but it also 
contains six less potential glycosylation sites than FV3. 
 
It was also interesting to note that FV3 expression appeared to be associated with the 
presence of fewer lower molecular weight products than FV5 (figure 3.10). This is 
suggestive of higher levels of protein degradation, as well as incomplete glycosylation of 
FV5. The presence of proteases released from dying cells in the cell culture supernatant 
may be the reason for the degradation observed.  Decreasing the incubation time of 
infected insect cell cultures, however, did not solve the problem, which is also not seen 
with FV3. It seems possible, therefore, that there may be something intrinsically toxic 
about FV5, which destroyed the cells almost as soon as the protein was produced. 
Analysis of cell viability during insect cell infections, however, does not support this 
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theory (see supplementary figure S5 in appendix 2) as, in general, cells infected with FV5 
appeared to remain viable for longer than those infected with FV3. It may be possible that 
FV5, having fewer glycosylation sites, is simply more accessible to cellular proteases 
than FV3, which may explain why it was more prone to proteolytic activity. 
 
Another interesting observation regarding gp120 size is the difference between insect-cell 
and mammalian-cell produced proteins. While a number of attempts were made to 
produce gp120 in mammalian cells, these did not meet with a large amount of success. A 
small amount of His-tagged FV3 was produced in 293T cells in other experiments in our 
laboratory however, and when this gp120 was compared to its insect-cell produced 
counterpart, a notable difference in size was seen between the two (supplementary figure 
S6 in appendix 2). This size difference is common when comparing proteins produced in 
mammalian cells to those produced in insect cells.  It has been widely reported that while 
insect cells have the ability to add N-glycans to proteins, the glycosylation pathways are 
less complex than those in mammalian cells226-228. There was no evidence of addition of 
complex carbohydrates to proteins or sialylation in insect cells in these studies. Rather, it 
is likely that the carbohydrates added were of the high-mannose variety, which are 
smaller and less complex than the sugars added to proteins in mammalian cells. In studies 
of gp120 produced in insect cells, these findings were confirmed, as the carbohydrates 
present were all of the high-mannose variety229. These differences account for the slightly 
lower molecular weight of insect-cell produced gp120 (approximately 110 kDa), when 
compared to mammalian-cell produced gp120169. 
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Despite the differences in carbohydrate structure, gp120 has been widely produced in 
baculoviral systems, reportedly with full biological activity169, 170. Recombinant 
baculoviral gp160 has been used as an immunogen in order to produce monoclonal 
antibodies against gp120176, 230 . Monoclonal antibodies, such as ID6, produced in such a 
manner are able to bind to both mammalian and insect cell gp120176. Baculoviral gp120 
has also been used to study the mechanisms of the pathogenesis and neutralization of 
HIV-1231.  
 
4.6.2. Recognition of monoclonal antibodies by recombinant gp120  
 
4.6.2.1. Antibodies to the CD4-binding site of gp120 
 
4.6.2.1.1. F105 
 
F105 is a human monoclonal antibody, which binds to a conformational epitope on gp120 
overlapping with component residues of the CD4 binding site198, 232 (shaded grey in 
figure 4.1). In early studies, F105 inhibited the binding of HIV-1 virions to CD4 positive 
cells, and its binding to gp120 was competitively inhibited by soluble CD4198. Resolution 
of the crystal structure of F105 revealed the presence of an extended loop with a Phe 
residue at its tip232. Computer modeling supports the hypothesis that this residue binds to 
gp120 in the same cavity as Phe43 of CD4232. F105 did not bind well to the subtype C 
proteins, only showing low binding to 96ZM651 and none to FV3 or FV5. The reasons 
for this are unclear. It may be possible however, as this antibody was isolated from an 
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HIV patient in the USA198 where subtype B HIV predominates, that some structural 
difference between the gp120s from different clades is responsible for the lack of binding 
of F105 to clade C isolates. 
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Figure 4.1: Amino Acid Alignment of the gp120s characterised by ELISA, including 
HXBC2 as a reference sequence, with the CD4 binding site highlighted. Amino acids 
in direct contact with CD4 are shaded grey.  
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4.6.2.1.2. 654-30D 
 
654-30D is a monoclonal antibody that recognizes a discontinuous epitope in the CD4 
binding domain of gp120183 (shaded grey in figure 4.1). Its reactivity with gp120 is 
strictly conformation dependent and thus reactivity with gp120 is a good indicator of a 
conformationally intact protein. BaL showed good binding with this antibody, while 
96ZM651 showed moderate binding and FV3 showed low binding. This suggests that 
FV3 has a conformationally intact CD4-binding site, and this was subsequently further 
confirmed in the CD4 binding studies. CM and FV5 showed no binding, however. It is 
known that CM has an intact CD4 binding site, as is it distributed as an intact, functional 
gp120 from the NIH, and therefore the lack of reactivity of this protein with 654-30D is 
probably due to protein-specific conformational or sequence differences. In the case of 
FV5, the reason for the lack of activity of this antibody is less clear. These analyses were 
performed to assess the conformation of the recombinant gp120, and thus the lack of 
binding of FV5 to 654-30D cannot simply be attributed to conformational differences as 
for the control gp120, CM. Although it is possible that the lack of binding reactivity may 
be due to protein-specific differences, it may also be possible that the CD4-binding site of 
FV5 is not conformationally intact. This, in fact, appears to be case, as a mutation was 
found in a critical CD4-binding residue of FV5 (discussed in section 4.6.3). 
 
4.6.2.1.3. IgG1 b12 
 
The monoclonal antibody IgG1 b12 was developed using combinatorial phage display 
technology, and binds to gp120 in or near the CD4 binding site202, 203. Resolution of the 
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crystal structure of IgG1 b12 resulted in the suggestion that IgG1 b12 and gp120 interact 
by the insertion of a tryptophan residue (W100) of IgG1 b12 into the same binding pocket 
on gp120 that is used by Phe43 of CD4233. The residues of gp120 important for this 
interaction are S365, D368, I371, Y384 and V430 of HXBc2 (corresponding to consensus 
residues 388, 391, 394, 407 and 455 in figure 4.1 respectively)233. While these residues 
are relatively highly conserved amongst the panel, with only a single substitution each in 
CM, FV3 and FV5, the only gp120 that showed any reactivity with IgG1 b12 was BaL, 
which had moderate reactivity. The differences may not be attributable to subtype 
differences as IgG1 b12 has previously been shown to bind well to subtype C envelopes 
171 and generally shown good cross-clade reactivity with gp120, as well as cross-clade 
neutralising activity187, 204, 234, 235. Binding of IgG1 b12 to gp120, however, is particularly 
sensitive to changes within the V1/V2 region205. Although this was determined by 
experiments involving inhibition of IgG1 b12 binding by deletion of the V1/V2 region, it 
is possible that differences in these regions between the five proteins examined may 
contribute to the poor recognition of four of them by IgG1 b12.  
 
4.6.2.2. Antibodies to the CD4-induced conformation of gp120 
 
4.6.2.2.1. F425 A1g8 
 
F425 A1g8 is a human MAb that appears to bind preferentially to the CD4-induced 
conformation of gp120236, although it does show some binding to gp120 in the absence of 
CD4236, 237. In these experiments, A1g8 showed good binding to BaL and low binding to 
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96ZM651. It did not show binding activity with any other isolates. In the presence of 
sCD4, F425 A1g8 showed high binding to BaL and moderate binding to 96ZM651 and 
CM protein. No binding was seen for FV3 and FV5 in the presence of sCD4, however. 
Inspection of the sequences does not reveal an obvious reason for these differences as the 
amino acids implicated in the CD4i epitope (shaded green in figure 4.2) are well 
conserved between the entire panel, with the only exception being two substitutions in 
FV5.  The difference in binding to A1g8 between the subtype C proteins is therefore 
possibly due to conformational variation between these isolates. 
 
4.6.2.2.2. 48d 
 
This monoclonal antibody recognises a complex discontinuous epitope in gp120, which 
includes amino acids in all of the constant regions of gp120, and which shows enhanced 
binding to gp120 in the presence of CD4189.  In our experiments, none of the gp120 panel 
analysed showed binding to 48d in the absence of CD4. In the presence of CD4, however, 
moderate binding was seen in the case of BaL, and low binding was seen for CM. 
Analysis of the amino acids shown to important for binding of 48d to gp120189 (shaded 
green in figure 4.2) revealed that only BaL contained all of these with no substitutions. 
All of the other isolates had at least one substitution. In a cross-clade study, 48d did not 
show good cross-clade reactivity, and demonstrated particularly poor reactivity with 
subtype C isolates238. Taken together, these results indicate that the poor performance of 
48d in these assays is to be expected. 
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BaL  : MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVELENVTENFNMWKN :  98 
CM  : .....T-.MN.PNL-K...LI..LVI....SNN............RD.D....-..N...HE-....................IH............. :  94 
96ZM651  : ...R.I-LRN.QRW.T..ILGFW.....NVWGN...............K..........S.EK....................IV.G........... :  97 
FV3  : ...MGI-.RNCQQW.I..ILGFW.....N-GGN...............K............EK....................MK.R........... :  96 
FV5        : ...MGI-.RSCQRW.I..LLGFW..L..NG..N............R..K..........S.ER....................MV............. :  97 
HXBc2  : ....................................................................................V.V........... :  98 
                                                                                                                      
                                                                                                                      
             00         *       120         *       140         *       160         *       180         *             
BaL  : NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNC-T-----DLR-NATNGNDTNTTSSS-REM-MGG-GEMKNCSFKITTNIRGKVQKEYALFYELDIV : 186 
CM  : ......Q..V.....................H.TN-----AKL-TTA.NHNNI.SV.N--TIGNIT-D.VR....NM..EL.D.K..VH....K.... : 183 
96ZM651  : D..D.............................TE-----VNVTRNV.N-SV--VNNTTNVNNSMNG-D......N...ELKD.KKNV.....K.... : 186 
HXBC2  : D..D..N........E.................SDVTYNATNAT.N.TTTTH...ETTPYAKISNITDD......NV..GL.D.RKQ.S....R...I : 194 
FV5        : D..D.............................TD--------------------FDPL-DNGTDAM..I......A..ELKD.KR..Q....R.... : 174 
HXBc2  : D............................S...-.-----..K-.D..-----.N...-GR.I.EK-..I.....N.S.S..........F..K...I : 182 
                                                                                                                      
                                                                                                                      
              200         *       220         *       240         *       260         *       280         *           
BaL  : PIDNNS-----NNR--YRLISCNTSVITQACPKISFEPIPIHYCAPAGFAILKCKDKKFNGKGPCSNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVI : 277 
CM  : ..ED.K-----TSSE-....N......K........D.......T...Y.....N.-N...T...K...S.......K.................II. : 274 
96ZM651  : SLNETDDSETG.SSKY....N....AL......V..D...........Y.....NN.T...T...H...........K................GII. : 284 
FV3  : .LNG.KE----.SSE-....N....T.R.....V..D.................N..T...T...HD..........K.................I.. : 287 
FV5        : S..KV.NSSNR.FSM-....N....A.......V..D...........Y.....N..T...T...N...........K....A..........G.II. : 271 
HXBC2  : ....-D-----TTS--.T.T.......S.....V....................NN.T...T...T................................ : 272 
                                                                                                                      
                                                                                                                      
                300         *       320         *       340         *       360         *       380         *         
BaL  : RSENFADNAKTIIVQLNESVEINCTRPNNNTRKSIH--IGPGRALYTTGEIIGDIRQAHCNLSRAKWNDTLNKIVIKLREQFGN-KTIVFKHSSGGDP : 372 
CM  : ....LTN.......H..K.........S....T..P--....Q.F.R..D......K.Y.EINGT...EV.TQVTE..K.H.-.N...I.QPP....L : 369 
96ZM651  : ....LTN.V.....H..R.I..V.V.......Q.--IR....QTF.A..D...........I..TN.TK..REVRN....H.-PN.N.T..P.....L : 379 
FV3  : ....LTN...I...H.......K.S..G......VRIG..R.QTF.A..KV..........V..EA..K..E.VKR..G.H.-PNS..T.N......L : 384 
FV5        : .P..L.N.V......F......V...........--VR....QTF.A......N.......I.ES...K..QNVAKR.K.H.-PN.N.T.APA...GL : 366 
HXBC2  : ..V..M...........T.........S...I.R.RIQR.....FV.M.K-...M......I......N..KQ.AS........N...I..Q...... : 369 
                                                                                                                      
                                                                                                                      
                  400         *       420         *       440         *       460         *       480         *       
BaL  : EIVTHSFNCGGEFFYCNSTQLFNSTW-N-----VTEESNNTVENNTITLPCRIKQIINMWQKVGRAMYAPPIRGQIRCSSNITGLLLTRDGG--P-ED : 461 
CM  : ..TM.H...-.......T.R...N.--CIE----N-GTMGGC-.G..I...K........-GA.Q.......S.R.N.V.....I....-..--AINT : 454 
96ZM651  : ..T......R.......TSG..-----------SINYTE.NTDGTP.......R.......E..........E.N.A.K.D......V....STNDST : 466 
FV3  : ..T......R.......TSD..----------KDNITIT.STN.TV...Q...........RA.Q.I.......N.T.N.............-KDNKT : 471 
FV5        : ..T......R.......TSK.....YNSNDTERDYNGTG.NSTDSI..IQ.....F.....R..Q.......E.NVT.K.I...........---SNT : 461 
HXBC2  : ..........................F.ST--WS..G....EGSD...................K.......S...................--K-GN : 462 
                                                                                                                      
                                                                                       
                    500         *       520         *       540         *              
BaL  : NK---TEVFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR--------------- : 510 
CM  : T-----.T......NIK..-..-.......Q.....I...R......E....--------------- : 499 
96ZM651  : .N--N..I...A..................E.K...I...E......E....--------------- : 516 
FV3  : .NENK..I......................E.K...I...T......E....--------------- : 523 
FV5        : -----..T...V..................EVR...I...R.Q....E....--------------- : 508 
HXBC2  : .E---S.I............................................--------------- : 511 
 
Figure 4.2: Amino Acid Alignment of the gp120s characterised by ELISA, including 
HXBC2 as a reference sequence, with amino acids implicated in the CD4-induced 
(CD4i) epitope
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 shaded green. 
 
4.6.2.2.3. 17b 
 
17b binds to an epitope on gp120 that is very similar to that of 48d189. The epitope, 
overlapping the CCR5 binding site of gp120, is well defined as the crystal structure of 
gp120 was first defined in complex with CD4 and17b73. Residues that have been defined 
as important for binding of 17b to gp120 (HXBc2 numbering, consensus numbering from 
figure 4.2 in brackets) are K121 (121), R419 (444), I420 (445), K421 (446), Q422 (447), 
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I423 (448) and Y435 (260)73, 239, 240. These residues are well conserved among the panel 
of gp120s under investigation, except for a single residue each in FV5 and CM. None of 
the isolates were reactive with 17b in the absence of CD4. In the presence of CD4, 
however, BaL and 96ZM651 showed high binding to 17b and CM showed moderate 
binding. Neither FV3, nor FV5 showed binding to 17b in the presence of CD4. In the 
case of FV5, the presence of Phe instead of Ile at position 445 may help to explain the 
lack of reactivity with 17b, as the aromatic side chain of phenylalanine may alter or 
prevent important gp120/17b interactions. FV3 has no mutations in the amino acids 
essential for binding of 17b, but it may be worth noting that FV3 has at least three extra 
potential glycosylation sites in the V1 loop in comparison to the other gp120s. It has been 
suggested that the V1/V2 loop shields the epitope for 17b and that binding of CD4 
induces conformational changes that unmask the epitope in order to allow the antibody to 
bind201. The presence of extra glycans in the V1 loop of FV3 may supply extra bulk that 
cannot be moved completely out of the way by CD4-induced conformational changes, 
thus hindering the binding of 17b. It is also interesting to note that FV3 is a CXCR4-
using isolate and, inaccessibility of the 17b (CCR5) epitope would not affect viral fitness. 
 
4.6.2.3. Anti-V3 loop antibodies 
 
4.6.2.3.1. F425 B4a1 
 
MAb F425 B4a1 (B4a1) reacts with the V3 loop of clade B laboratory isolates, as well as 
primary isolates with diverse V3 loop sequences, and its binding to gp120 is enhanced 
after incubation with CD4236. B4a1 reacts more efficiently with dual-tropic isolates, than 
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solely CCR5-using isolates236. In our experiments, high binding to B4a1 by BaL was 
seen, as well as moderate binding by CM and low binding by FV5. Interestingly, FV3 
and 96ZM651, which do not bind B4a1, have a mutation in the second residue of their V3 
loops (amino acids 318-354, shaded red in figure 4.3), when compared to BaL, while CM 
and FV5 do not. This is the only residue in this epitope which is substituted in FV3 and 
96ZM651. It is therefore tempting to speculate that this residue may be important for the 
binding of B4a1 to gp120.  
 
4.6.2.3.2. F425 B4e8 
 
Human MAb F425 B4e8 (B4e8) reacts with the crown/tip of the V3 loop of gp120 in X4, 
R5 and dual-tropic viruses237. In early experiments, B4e8 reacted well  against a number 
of clade B HIV-1 isolates, but showed no reactivity with HXB2237. More recent studies 
indicate that B4e8 effectively neutralises clade B viruses as well as some clade C and D 
primary isolates241. These studies also clarified the B4e8 epitope241, which incorporates, 
minimally, the amino acids I331, R337, F339 in figure 4.3 (highlighted blue) . 
Interestingly, BaL, which showed high binding to B4e8, has a Leu residue at position 
339, rather than a Phe. This substitution is clearly well tolerated by the antibody. This 
finding is consistent with recently published structural data showing this antibody in 
complex with a V3 peptide, which revealed that the interaction of B4e8 with gp120 does 
not center on this residue, but rather the Ile and Arg residues implicated in the previously 
mentioned study242. In support of these findings, an Arg to Gln substitution at position 
337, present in the rest of the panel of gp120s, appears to compromise antibody binding, 
as 96ZM651 showed only moderate binding and CM, FV3 and FV5 showed none. 
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Interestingly, the amino acid residues at the three critical positions in FV3 and 96ZM651 
are identical, and yet FV3 does not bind to B4e8 with the same avidity as 96ZM651. FV3 
does, however, have a 2 amino acid insertion in that region of the V3 loop. Thus, 
according to our studies, it seems that R337 is the most important of the three mentioned 
by Pantophlet et al241  for B4e8 binding to gp120 to gp120, and that the epitope may be 
affected by the proximity of these three residues. 
 
 
BaL  : MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVELENVTENFNMWKN :  98 
CM  : .....T-.MN.PNL-K...LI..LVI....SNN............RD.D....-..N...HE-....................IH............. :  94 
96ZM651  : ...R.I-LRN.QRW.T..ILGFW.....NVWGN...............K..........S.EK....................IV.G........... :  97 
FV3  : ...MGI-.RNCQQW.I..ILGFW.....N-GGN...............K............EK....................MK.R........... :  96 
FV5        : ...MGI-.RSCQRW.I..LLGFW..L..NG..N............R..K..........S.ER....................MV............. :  97 
HXBC2  : ....................................................................................V.V........... :  98 
                                                                                                                      
                                                                                                                      
             00         *       120         *       140         *       160         *       180         *             
BaL  : NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNC-T-----DLR-NATNGNDTNTTSSS-REM-MGG-GEMKNCSFKITTNIRGKVQKEYALFYELDIV : 186 
CM  : ......Q..V.....................H.TN-----AKL-TTA.NHNNI.SV.N--TIGNIT-D.VR....NM..EL.D.K..VH....K.... : 183 
96ZM651  : D..D.............................TE-----VNVTRNV.N-SV--VNNTTNVNNSMNG-D......N...ELKD.KKNV.....K.... : 186 
HXBC2  : D..D..N........E.................SDVTYNATNAT.N.TTTTH...ETTPYAKISNITDD......NV..GL.D.RKQ.S....R...I : 194 
FV5        : D..D.............................TD--------------------FDPL-DNGTDAM..I......A..ELKD.KR..Q....R.... : 174 
HXBC2  : D............................S...-.-----..K-.D..-----.N...-GR.I.EK-..I.....N.S.S..........F..K...I : 182 
                                                                                                                      
                                                                                                                      
              200         *       220         *       240         *       260         *       280         *           
BaL  : PIDNNS-----NNR--YRLISCNTSVITQACPKISFEPIPIHYCAPAGFAILKCKDKKFNGKGPCSNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVI : 277 
CM  : ..ED.K-----TSSE-....N......K........D.......T...Y.....N.-N...T...K...S.......K.................II. : 274 
96ZM651  : SLNETDDSETG.SSKY....N....AL......V..D...........Y.....NN.T...T...H...........K................GII. : 284 
FV3  : .LNG.KE----.SSE-....N....T.R.....V..D.................N..T...T...HD..........K.................I.. : 287 
FV5        : S..KV.NSSNR.FSM-....N....A.......V..D...........Y.....N..T...T...N...........K....A..........G.II. : 271 
HXBC2  : ....-D-----TTS--.T.T.......S.....V....................NN.T...T...T................................ : 272 
                                                                                                                      
                                                                                                                      
                300         *       320         *       340         *       360         *       380         *         
BaL  : RSENFADNAKTIIVQLNESVEINCTRPNNNTRKSIH--IGPGRALYTTGEIIGDIRQAHCNLSRAKWNDTLNKIVIKLREQFGN-KTIVFKHSSGGDP : 372 
CM  : ....LTN.......H..K.........S....T..P--....Q.F.R..D......K.Y.EINGT...EV.TQVTE..K.H.-.N...I.QPP....L : 369 
96ZM651  : ....LTN.V.....H..R.I..V.V.......Q.--IR....QTF.A..D...........I..TN.TK..REVRN....H.-PN.N.T..P.....L : 379 
FV3  : ....LTN...I...H.......K.S..G......VRIG..R.QTF.A..KV..........V..EA..K..E.VKR..G.H.-PNS..T.N......L : 384 
FV5        : .P..L.N.V......F......V...........--VR....QTF.A......N.......I.ES...K..QNVAKR.K.H.-PN.N.T.APA...GL : 366 
HXBC2  : ..V..M...........T.........S...I.R.RIQR.....FV.M.K-...M......I......N..KQ.AS........N...I..Q...... : 369 
                                                                                                                      
                                                                                                                      
                  400         *       420         *       440         *       460         *       480         *       
BaL  : EIVTHSFNCGGEFFYCNSTQLFNSTW-N-----VTEESNNTVENNTITLPCRIKQIINMWQKVGRAMYAPPIRGQIRCSSNITGLLLTRDGG--P-ED : 461 
CM  : ..TM.H...-.......T.R...N.--CIE----N-GTMGGC-.G..I...K........-GA.Q.......S.R.N.V.....I....-..--AINT : 454 
96ZM651  : ..T......R.......TSG..-----------SINYTE.NTDGTP.......R.......E..........E.N.A.K.D......V....STNDST : 466 
FV3  : ..T......R.......TSD..----------KDNITIT.STN.TV...Q...........RA.Q.I.......N.T.N.............-KDNKT : 471 
FV5        : ..T......R.......TSK.....YNSNDTERDYNGTG.NSTDSI..IQ.....F.....R..Q.......E.NVT.K.I...........---SNT : 461 
HXBC2  : ..........................F.ST--WS..G....EGSD...................K.......S...................--K-GN : 462 
                                                                                                                      
                                                                                       
                    500         *       520         *       540         *              
BaL  : NK---TEVFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR--------------- : 510 
CM  : T-----.T......NIK..-..-.......Q.....I...R......E....--------------- : 499 
96ZM651  : .N--N..I...A..................E.K...I...E......E....--------------- : 516 
FV3  : .NENK..I......................E.K...I...T......E....--------------- : 523 
FV5        : -----..T...V..................EVR...I...R.Q....E....--------------- : 508 
HXBC2  : .E---S.I............................................--------------- : 511 
 
Figure 4.3: Amino Acid Alignment of the gp120s characterised by ELISA, including 
HXBC2 as a reference sequence, with the V3 loop highlighted. The V3 loop is shaded 
red, with amino acids implicated in the F425 B4e8 epitope in blue. 
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4.6.2.3.3. 5F7 and 4G10 
 
The monoclonal antibodies 5F7 and 4G10 were raised against a 25 amino acid sequence 
derived from the V3 loop of the HIV-1 isolate BH10185. This sequence, 
TRKSIRIQRGPGRAFVTIGKIGNMR, is not highly conserved, however, and 
comparison with the V3 loops of the proteins being analysed (red in figure 4.3) reveals 
that the sequences are completely different, with the most conserved region being the 
GPGR motif found at the tip of V3. It is therefore not surprising that none of the proteins 
being studied showed any reactivity with either of these antibodies. 
 
4.6.2.4. Antibodies to the constant regions of gp120 
4.6.2.4.1. ID6 
 
ID6 was raised against a subtype B HIV-1 isolate but showed binding activity with clade 
E and clade A/E isolates176. This is probably due to the fact that the epitope is found in a 
highly conserved region of C1177. This epitope, amino acids 86 to 100 of the HIV-1MN 
gp120 sequence (consensus amino acids 87 to 101 in figure 4.4, shaded green) is well 
conserved between all gp120 variants analysed in these experiments. It is therefore not 
surprising that each of the gp120s showed binding with this antibody, with FV3 and 
96ZM651 showing high binding, FV5 and BaL showing good binding, and CM showing 
low binding. Interestingly, CM gp120 which, together with BaL, contains the epitope for 
ID6 with no substitutions showed the poorest reactivity with ID6. This is intriguing and 
examination of the amino acid sequence around the ID6 epitope provides no clear 
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explanation for the difference in binding to ID6 between the two antibodies. CM does, 
however, have a histidine residue at position 85. It is tempting to speculate that the bulky 
aromatic ring in the histidine side-chain somehow hinders the interaction of CM and ID6 
by its proximity to the epitope for ID6.  
 
 
 
BaL  : MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVELENVTENFNMWKN :  98 
CM  : .....T-.MN.PNL-K...LI..LVI....SNN............RD.D....-..N...HE-....................IH............. :  94 
96ZM651  : ...R.I-LRN.QRW.T..ILGFW.....NVWGN...............K..........S.EK....................IV.G........... :  97 
FV3  : ...MGI-.RNCQQW.I..ILGFW.....N-GGN...............K............EK....................MK.R........... :  96 
FV5        : ...MGI-.RSCQRW.I..LLGFW..L..NG..N............R..K..........S.ER....................MV............. :  97 
HXBC2  : ....................................................................................V.V........... :  98 
                                                                                                                      
                                                                                                                      
             00         *       120         *       140         *       160         *       180         *             
BaL  : NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNC-T-----DLR-NATNGNDTNTTSSS-REM-MGG-GEMKNCSFKITTNIRGKVQKEYALFYELDIV : 186 
CM  : ......Q..V.....................H.TN-----AKL-TTA.NHNNI.SV.N--TIGNIT-D.VR....NM..EL.D.K..VH....K.... : 183 
96ZM651  : D..D.............................TE-----VNVTRNV.N-SV--VNNTTNVNNSMNG-D......N...ELKD.KKNV.....K.... : 186 
HXBC2  : D..D..N........E.................SDVTYNATNAT.N.TTTTH...ETTPYAKISNITDD......NV..GL.D.RKQ.S....R...I : 194 
FV5        : D..D.............................TD--------------------FDPL-DNGTDAM..I......A..ELKD.KR..Q....R.... : 174 
HXBC2  : D............................S...-.-----..K-.D..-----.N...-GR.I.EK-..I.....N.S.S..........F..K...I : 182 
                                                                                                                      
                                                                                                                      
              200         *       220         *       240         *       260         *       280         *           
BaL  : PIDNNS-----NNR--YRLISCNTSVITQACPKISFEPIPIHYCAPAGFAILKCKDKKFNGKGPCSNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVI : 277 
CM  : ..ED.K-----TSSE-....N......K........D.......T...Y.....N.-N...T...K...S.......K.................II. : 274 
96ZM651  : SLNETDDSETG.SSKY....N....AL......V..D...........Y.....NN.T...T...H...........K................GII. : 284 
FV3  : .LNG.KE----.SSE-....N....T.R.....V..D.................N..T...T...HD..........K.................I.. : 287 
FV5        : S..KV.NSSNR.FSM-....N....A.......V..D...........Y.....N..T...T...N...........K....A..........G.II. : 271 
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BaL  : RSENFADNAKTIIVQLNESVEINCTRPNNNTRKSIH--IGPGRALYTTGEIIGDIRQAHCNLSRAKWNDTLNKIVIKLREQFGN-KTIVFKHSSGGDP : 372 
CM  : ....LTN.......H..K.........S....T..P--....Q.F.R..D......K.Y.EINGT...EV.TQVTE..K.H.-.N...I.QPP....L : 369 
96ZM651  : ....LTN.V.....H..R.I..V.V.......Q.--IR....QTF.A..D...........I..TN.TK..REVRN....H.-PN.N.T..P.....L : 379 
FV3  : ....LTN...I...H.......K.S..G......VRIG..R.QTF.A..KV..........V..EA..K..E.VKR..G.H.-PNS..T.N......L : 384 
FV5        : .P..L.N.V......F......V...........--VR....QTF.A......N.......I.ES...K..QNVAKR.K.H.-PN.N.T.APA...GL : 366 
HXBC2  : ..V..M...........T.........S...I.R.RIQR.....FV.M.K-...M......I......N..KQ.AS........N...I..Q...... : 369 
                                                                                                                      
                                                                                                                      
                  400         *       420         *       440         *       460         *       480         *       
BaL  : EIVTHSFNCGGEFFYCNSTQLFNSTW-N-----VTEESNNTVENNTITLPCRIKQIINMWQKVGRAMYAPPIRGQIRCSSNITGLLLTRDGG--P-ED : 461 
CM  : ..TM.H...-.......T.R...N.--CIE----N-GTMGGC-.G..I...K........-GA.Q.......S.R.N.V.....I....-..--AINT : 454 
96ZM651  : ..T......R.......TSG..-----------SINYTE.NTDGTP.......R.......E..........E.N.A.K.D......V....STNDST : 466 
FV3  : ..T......R.......TSD..----------KDNITIT.STN.TV...Q...........RA.Q.I.......N.T.N.............-KDNKT : 471 
FV5        : ..T......R.......TSK.....YNSNDTERDYNGTG.NSTDSI..IQ.....F.....R..Q.......E.NVT.K.I...........---SNT : 461 
HXBC2  : ..........................F.ST--WS..G....EGSD...................K.......S...................--K-GN : 462 
                                                                                                                      
                                                                                       
                    500         *       520         *       540         *              
BaL  : NK---TEVFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR--------------- : 510 
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96ZM651  : .N--N..I...A..................E.K...I...E......E....--------------- : 516 
FV3  : .NENK..I......................E.K...I...T......E....--------------- : 523 
FV5        : -----..T...V..................EVR...I...R.Q....E....--------------- : 508 
HXBC2  : .E---S.I............................................--------------- : 511 
                                                                                       
 
Figure 4.4: Amino Acid Alignment of the gp120s characterised by ELISA, including 
HXBC2 as a reference sequence, with the epitopes for antibodies against the 
constant regions of gp120 highlighted. Epitopes are shaded as follows: ID6 in green, 
Chessie 13-39.1 in pink, 9301 in blue and 670-30D in red. 
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4.6.2.4.2. Chessie 13-39.1 
 
The monoclonal antibody, Chessie 13-39.1 recognizes a linear epitope in the C2 region of 
gp120. This epitope, corresponding to the sequence RVVSTQLLLNGSLAEEVVIR175 
(amino acids 274-295, highlighted in pink in figure 4.4) is relatively well conserved 
between the five proteins analysed, of which BaL and FV3 showed moderate binding, 
CM showed good binding and FV5 and 96ZM651 showed low binding affinity for this 
antibody.  Interestingly, although the epitope is less well conserved in CM than in BaL, 
CM shows better reactivity with Chessie 13-39.1. There is no clear reason for this in the 
amino acid sequence, but taken together with other intriguing results obtained for the CM 
gp120, such as its lack of reactivity with ID6 and 654-30d, it seems possible that the 
conformation of the CM protein may be fundamentally different to the conformations of 
the other proteins studied, resulting in altered antibody epitope accessibility. Our CD4 
binding data for CM (figure 4.4) suggests, however, that the fundamental structural 
nature of this protein is retained. 
 
4.6.2.4.3. 670-30d 
 
670-30d binds to an epitope in the C5 region of gp120, PTKAKRR (amino acids 529-
535, shaded red in figure 4.4) and shows good cross-clade reactivity184, 243. In our isolates, 
670-30d showed good reactivity with BaL, where the epitope is completely conserved. 
The only other gp120 that bound to this antibody was CM, which showed low reactivity. 
It is interesting to note that although there is a substitution in the third position of the 
epitope in CM (lysine to arginine), the charge of the region is retained as both lysine and 
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arginine are positively charged amino acids. Substitutions are also present in the epitope 
for the other gp120s, however, these substitutions result in a change in the overall charge 
of the epitope. Taken together with the lack of reactivity of these proteins with 670-30D, 
this suggests that the charge of the region may directly affect antibody affinity for gp120 
or else play a role in gp120 conformation and therefore the accessibility of the antibody 
epitope. 
 
4.6.2.4.4. MAb 9301 
 
All gp120 variants tested reacted well with 9301 (epitope is shaded blue in figure 4.4, 
amino acids 506-519), with BaL, CM and 96ZM651 showing high binding and FV3 and 
FV5 showing good binding. This is not surprising as the C5 epitope is highly conserved 
between isolates, although changes to the epitope appear to be well tolerated as shown by 
the activity of 9301 with CM gp120. Although the binding site for 9301 in CM contains 
two substitutions and two deletions, the ability of the antibody to bind CM is retained. 
CM is the only isolate with an amino acid sequence differing from that recognised by 
9301, and the changes to the epitope do not appear to significantly alter antibody binding. 
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4.6.2.5. Antibodies recognising the glycan structure of gp120 
4.6.2.5.1. 2G12 
 
The exact location of the epitope of the broadly neutralising antibody 2G12 is 
controversial. Research has led to the two slightly different models for 2G12 binding. The 
first suggests that the core epitope for 2G12 is made up entirely of the N-linked glycans 
present at positions 295 (320), 332 (355), and 392 (415) and supported peripherally by 
glycans at positions 386 (409) and 448 (473), with 2G12 having no contact with the 
peptide backbone244 (numbering in this section refers to the HXBc2 consensus sequence, 
with numbers in brackets indicating the corresponding amino acid positions in figure 4.5; 
all significant glycosylation sites are highlighted in yellow in figure 4.5). The second 
model for binding of 2G12 suggests that the core epitope is formed by N-linked glycans 
at positions 295 (320) and 332 (355) and supported by glycans at positions 339 (362), 
386 (409) and 392 (415)216. Resolution of the crystal structure of 2G12, however, led to 
the suggestion that 2G12 and gp120 make critical contacts at positions 332 (355) and 392 
(415), with a potential contact at position 339 (362)245. In this model, the glycan at 
position 295 (320) is postulated to play an indirect role in 2G12 binding by shielding the 
glycan at 332 (355) from further processing into a complex carbohydrate. This is 
significant as 2G12 recognises high mannose and/or hybrid carbohydrates, rather than 
complex ones216, 244. 2G12 has been hailed as the most predictable antibody with regard 
to the presence of the residues important for its binding to gp120 and its ability to 
neutralize HIV234.  
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BaL  : MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVELENVTENFNMWKN :  98 
CM  : .....T-.MN.PNL-K...LI..LVI....SNN............RD.D....-..N...HE-....................IH............. :  94 
96ZM651  : ...R.I-LRN.QRW.T..ILGFW.....NVWGN...............K..........S.EK....................IV.G........... :  97 
FV3  : ...MGI-.RNCQQW.I..ILGFW.....N-GGN...............K............EK....................MK.R........... :  96 
FV5        : ...MGI-.RSCQRW.I..LLGFW..L..NG..N............R..K..........S.ER....................MV............. :  97 
HXBc2  : ....................................................................................V.V........... :  98 
                                                                                                                      
                                                                                                                      
             00         *       120         *       140         *       160         *       180         *             
BaL  : NMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNC-T-----DLR-NATNGNDTNTTSSS-REM-MGG-GEMKNCSFKITTNIRGKVQKEYALFYELDIV : 186 
CM  : ......Q..V.....................H.TN-----AKL-TTA.NHNNI.SV.N--TIGNIT-D.VR....NM..EL.D.K..VH....K.... : 183 
96ZM651  : D..D.............................TE-----VNVTRNV.N-SV--VNNTTNVNNSMNG-D......N...ELKD.KKNV.....K.... : 186 
HXBC2  : D..D..N........E.................SDVTYNATNAT.N.TTTTH...ETTPYAKISNITDD......NV..GL.D.RKQ.S....R...I : 194 
FV5        : D..D.............................TD--------------------FDPL-DNGTDAM..I......A..ELKD.KR..Q....R.... : 174 
HXBc2  : D............................S...-.-----..K-.D..-----.N...-GR.I.EK-..I.....N.S.S..........F..K...I : 182 
                                                                                                                      
                                                                                                                      
              200         *       220         *       240         *       260         *       280         *           
BaL  : PIDNNS-----NNR--YRLISCNTSVITQACPKISFEPIPIHYCAPAGFAILKCKDKKFNGKGPCSNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVI : 277 
CM  : ..ED.K-----TSSE-....N......K........D.......T...Y.....N.-N...T...K...S.......K.................II. : 274 
96ZM651  : SLNETDDSETG.SSKY....N....AL......V..D...........Y.....NN.T...T...H...........K................GII. : 284 
FV3  : .LNG.KE----.SSE-....N....T.R.....V..D.................N..T...T...HD..........K.................I.. : 287 
FV5        : S..KV.NSSNR.FSM-....N....A.......V..D...........Y.....N..T...T...N...........K....A..........G.II. : 271 
HXBC2  : ....-D-----TTS--.T.T.......S.....V....................NN.T...T...T................................ : 272 
                                                                                                                      
                                                                                                                      
                300         *       320         *       340         *       360         *       380         *         
BaL  : RSENFADNAKTIIVQLNESVEINCTRPNNNTRKSIH--IGPGRALYTTGEIIGDIRQAHCNLSRAKWNDTLNKIVIKLREQFGN-KTIVFKHSSGGDP : 372 
CM  : ....LTN.......H..K.........S....T..P--....Q.F.R..D......K.Y.EINGT...EV.TQVTE..K.H.-.N...I.QPP....L : 369 
96ZM651  : ....LTN.V.....H..R.I..V.V.......Q.--IR....QTF.A..D...........I..TN.TK..REVRN....H.-PN.N.T..P.....L : 379 
FV3  : ....LTN...I...H.......K.S..G......VRIG..R.QTF.A..KV..........V..EA..K..E.VKR..G.H.-PNS..T.N......L : 384 
FV5        : .P..L.N.V......F......V...........--VR....QTF.A......N.......I.ES...K..QNVAKR.K.H.-PN.N.T.APA...GL : 366 
HXBC2  : ..V..M...........T.........S...I.R.RIQR.....FV.M.K-...M......I......N..KQ.AS........N...I..Q...... : 369 
                                                                                                                      
                                                                                                                      
                  400         *       420         *       440         *       460         *       480         *       
BaL  : EIVTHSFNCGGEFFYCNSTQLFNSTW-N-----VTEESNNTVENNTITLPCRIKQIINMWQKVGRAMYAPPIRGQIRCSSNITGLLLTRDGG--P-ED : 461 
CM  : ..TM.H...-.......T.R...N.--CIE----N-GTMGGC-.G..I...K........-GA.Q.......S.R.N.V.....I....-..--AINT : 454 
96ZM651  : ..T......R.......TSG..-----------SINYTE.NTDGTP.......R.......E..........E.N.A.K.D......V....STNDST : 466 
FV3  : ..T......R.......TSD..----------KDNITIT.STN.TV...Q...........RA.Q.I.......N.T.N.............-KDNKT : 471 
FV5        : ..T......R.......TSK.....YNSNDTERDYNGTG.NSTDSI..IQ.....F.....R..Q.......E.NVT.K.I...........---SNT : 461 
HXBC2  : ..........................F.ST--WS..G....EGSD...................K.......S...................--K-GN : 462 
                                                                                                                      
                                                                                       
                    500         *       520         *       540         *              
BaL  : NK---TEVFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKR--------------- : 510 
CM  : T-----.T......NIK..-..-.......Q.....I...R......E....--------------- : 499 
96ZM651  : .N--N..I...A..................E.K...I...E......E....--------------- : 516 
FV3  : .NENK..I......................E.K...I...T......E....--------------- : 523 
FV5        : -----..T...V..................EVR...I...R.Q....E....--------------- : 508 
HXBC2  : .E---S.I............................................--------------- : 511 
                                                                                       
 
 
Figure 4.5: Amino Acid Alignment of the gp120s characterised by ELISA, including 
HXBC2 as a reference sequence, with glycans that have been implicated in 2G12 
binding to gp120 highlighted. Glycans implicated in the literature as important are 
shaded yellow, those in slightly different positions to those cited in the literature are blue. 
Novel glycan implicated for 2G12 binding in subtype C viruses246 is shaded green. 
 
 
In our panel, all the glycosylation sites implicated in having direct or supportive roles in 
2G12 binding were exactly conserved only in BaL, the gp120 with the highest reactivity 
with 2G12 (high). No reactivity was seen with 96ZM651, which is missing glycosylation 
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sites at positions 295 (320), 339 (362), 392 (415) and 448 (473), although there is a 
glycosylation sites present two amino acids downstream of position 392 (415) in this 
isolate (shaded blue in figure 4.5). Interestingly, a moderate amount of reactivity was still 
noted for FV3, FV5 and CM, even though CM is missing one glycosylation site (position 
339 (362)) and both FV3 and FV5 are missing two sites each (position 295 (339) in both 
FV3 and FV5, position 392 (415) in FV3 and position 448 (473) in FV5).  
 
It is remarkable that FV3 and FV5 showed binding to 2G12 in the absence of a glycan at 
position 295 (320), as this glycan has been postulated to be crucial for the interaction of 
gp120 and 2G12216, 231, 244, 246, 247. Furthermore, 2G12 has been shown to have consistently 
low binding to HIV-1 Subtype C recombinant gp120s171 and neutralizing activity against 
HIV-1 Subtype C virions234, 235, 246, 247. FV3 gp120 binds to sCD4 as well as to the 
conformation-dependent monoclonal antibody 654-30D suggesting that the recombinant 
protein is conformationally intact. A possible explanation for the binding of our isolates 
to 2G12 is derived from examining the crystal structure of this antibody, where it is 
suggested that the glycan at position 295 (320) plays only an indirect role in formation of 
the 2G12 epitope by shielding the glycan at position 332 (355) from further processing245. 
As these proteins were produced in insect cells, they will not contain complex 
carbohydrates in their structure 229. Thus, it has been suggested, that the glycan at position 
295 would not be absolutely necessary for formation of the 2G12 epitope in insect-cell 
derived proteins231. This may explain the ability of FV3 and FV5 to bind 2G12 despite 
the absence of a glycosylation site at this position. The absence of this glycan, however, 
has still apparently affected the binding of FV3 and FV5 to 2G12, as the binding seen in 
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these assays was only moderate. Consistent with this, a study where the glycosylation 
sites missing at positions 295 and 392 of a subtype C isolate were reconstituted, binding 
of 2G12 to gp120 was significantly increased, particularly in the case of the glycan at 
position 295231. It is likely that binding of 2G12 to FV3 and FV5 gp120 would be 
significantly higher were glycans present at position 295 (320) in these recombinant 
proteins. Another possible explanation for the surprising results is that 2G12 may have 
bound non-specifically to another component of the gp120 preparation, giving a false 
positive result. While this cannot be ruled out, the differing levels of 2G12 binding 
between FV3 and FV5, as well as the complete absence of 2G12 binding to FV5 in the 
CD4-binding studies, suggest that this is not the case. Preliminary experiments in culture 
also suggest that FV3 may be susceptible to 2G12 neutralization to some extent. To 
elaborate on the role played by N295 in 2G12 binding, we aim to evaluate the binding of 
this antibody to FV3 gp120 expressed in mammalian cells further, as well as its ability to 
neutralize HIV-1 FV3 in cell culture. 
 
Our results differ from others where binding of gp120 to 2G12 did not occur in the 
absence of a glycan at position 295171, 231. Thus, while the glycan on gp120 at N295 plays 
a major role in 2G12 binding, our results suggest there are other important determinants 
for this interaction. To gain further insight into these, we aligned the population-based 
sequences of the isolates used in these studies (CN54, Du151, Du179, SW7, CM9) with 
the cloned FV3 and FV5 sequences (appendix 2, figure S7). While all these sequences 
lacked a glycosylation site at position 295 (position 319 in figure S7), other key glycans 
important for 2G12 binding were conserved and located either in constant regions (332 
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and 339 in C4 (357 and 364 in figure S7), and 448 in C5 (474 in figure S7) or at the base 
of the variable loops (386 in V4 (410 in figure S7). However, the glycan at position 392 
(~416 in figure S7), which has been shown to be critical for 2G12 binding244, 245 occurs 
within the V4 loop, the length of which varies between these isolates. The position of this 
glycan within the loop is thus different for each isolate. This may affect accessibility of 
this glycan to 2G12 and possibly explains the binding of our recombinant subtype C 
gp120 to this antibody.  
 
Another interesting observation with regards to these sequences is the presence of a 
conserved potential glycosylation site at position 442 (467).  This has recently been 
implicated in the formation of the 2G12 epitope in subtype C HIV-1 isolates246. This 
glycosylation site is present in both FV3 and FV5 (shaded green in figure 4.5), but not in 
96ZM651. A glycan present at this position may thus also play a role in the binding of 
FV3 and FV5 to 2G12. 
 
Taken together, these results reinforce the important role played by glycans in formation 
of the epitope for 2G12, and highlight the complexity of the determinants of its binding to 
gp120. 
 
4.6.3. CD4 Binding Studies 
 
The CD4-gp120 binding data were difficult to interpret as they were influenced not only 
by the ability of the gp120 to bind to CD4, but also by the avidity of the monoclonal 
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antibodies used for detection of bound gp120. The orientation of the antibody epitopes 
with respect to the CD4 binding site was also an important factor, as gp120 was detected 
in the CD4-bound state. 2G12 was chosen as a principal detector of the interaction based 
on its ability to bind to all proteins used, except 96ZM651, in gp120-antibody binding 
studies (figures 3.11, S4). Experiments using 2G12 indicated the presence of a functional 
CD4 binding site in BaL, CM and FV3 (figures 3.12, 3.13). Further experiments using 
17b, 48d, and A1g8, antibodies specific to the CD4-induced conformation of gp120, 
confirmed the presence of an intact CD4 binding site in these proteins, and further, in 
96ZM651 (figures 3.12, 3.13). FV5 was consistently unable to bind to CD4 in these 
experiments. 
 
In order to quantify the relative binding affinity of FV3 for CD4 as compared to BaL, the 
CD4 binding data were normalised against the data obtained from antibody recognition 
experiments. Results from the antibody 2G12 were used for normalisation as the binding 
of this antibody to gp120 is not affected by the presence of CD4. After normalisation, 
results indicated that, as compared to BaL, CD4 bound to FV3 with 22% efficiency and 
to CM with 28% efficiency. While CM and FV3 may have a lower affinity for CD4 than 
BaL, it is also possible that these values are an under-representation of actual binding. 
2G12 binds extremely well to BaL, but has lower affinity for the other proteins studied. 
Thus, in both antibody recognition and CD4-binding studies, when the A450 readings for 
the other proteins were within the readable range, BaL absorbance readings were outside 
it and thus set to 3.5. It is likely that the absorbance readings for the BaL-2G12 
interaction in the antibody recognition studies were higher than those in the CD4-binding 
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studies, but as both values were out of range and set to 3.5, this could not be determined 
and thus the binding efficiency of both FV3 and CM may be higher than the calculated 
values. We hope to more accurately determine the affinity of FV3 gp120 for CD4 by 
using Surface Plasmon Resonance. The apparent lesser affinity of FV3 and CM for CD4 
as compared to BaL may be due to structural or glycosylation differences, as inspection 
of residues in contact with CD4 (figure 4.1) does not present an alternative explanation. 
 
The lack of reactivity between CD4 and FV5 may be explained upon examination of the 
crystal structure of gp120 in complex with CD473. Two residues of CD4, Arg59 and 
Phe43, form crucial interactions between gp120 and CD4. Arg59 interacts with Asp368 
and Val430 of gp120, while Phe43 interacts with Asp368, Glu370, Ile371, Asn425, 
Met426, Trp427 and Gly47373. Inspection of the sequence of FV5 reveals an Asp to Gly 
substitution at Asp368. This mutation is not present in any of the other isolates. 
Mutations in Asp368 have serious consequences for CD4 binding73. Asp368 forms 
hydrogen bonds with Arg59 and Leu44 of CD4, as well as with the Phe43 aromatic ring. 
Absence of this residue, therefore, would seriously hinder binding of CD4 to gp120. 
Modeling of this substitution using Swiss-Pdb Viewer 3.7 (SP5)86 indicates that a glycine 
residue at position 368 in FV5 does, indeed, prevent a number of hydrogen bonds 
forming at this position (figure 4.6). Interestingly, this mutation is not found in the 
population based sequence of FV5. It seems unlikely that the substitutions originated 
during PCR. It appears, therefore, that the FV5 gp120 encoded by pTriEx-FV5 represents 
a clone of a minor quasispecies present in the heterogenous pool of viral sequences 
sampled. 
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Figure 4.6: Substitution of Asp for Gly at gp120 position 368. Crystal structure 
downloaded from the Protein Data Bank85, PDB ID: 1gc1, and altered using Swiss-Pdb 
Viewer 3.7 (SP5)86 (http://www.expasy.org/spdbv/). Blue ribbon is gp120, yellow ribbon 
is CD4. (A) Overview of gp120-CD4 binding. Red block surrounds area zoomed in on 
in B and C. (B) When Asp is present at position 368. Dashed green lines indicate 
hydrogen bonds. (B) When Asp is mutated to Gly at position 368. Three hydrogen 
bonds at this position can no longer occur. 
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4.7. Perspective 
 
CD4 and antibody binding studies provide valuable information about the nature of the 
newly synthesized subtype C recombinant glycoproteins FV3 and FV5. Antibodies were 
used that bind to varying linear regions along the length of gp120, as well as several that 
are dependent on intact conformation. The antibodies with linear epitopes confirmed the 
presence of a generally intact amino acid sequence, while the conformation dependent 
antibodies suggest canonical gp120 folding, at least in the case of FV3. Both FV3 and 
FV5 appear to have a unique antigenic structure, different to that of gp120s from other 
clades and from within subtype C.  
 
It is important to note that analysis of the antibody binding studies was done on the 
presumption that the recombinant proteins, in particular FV3, were conformationally 
intact. This may not, however, be the case. The lack of binding of the recombinant 
proteins to many of the antibodies studied, some of which have been able to bind to 
Subtype C isolates in many other studies, may simply be a reflection of degraded or 
conformationally compromised proteins. Indeed, this is a plausible explanation and, 
based on this data, cannot be excluded. A number of factors contest this, however. Firstly, 
FV3 does show some binding activity with the conformationally dependent antibodies 
2G12 and 654-30D. Secondly, FV5, which carries a mutation in a residue known to be 
critical for CD4 binding (D368G), does not react with CD4 or any antibodies requiring an 
intact CD4-binding site.  The fact that this mutation has the expected effect on the ability 
of FV5 to bind CD4 indirectly supports the assumption that the proteins are 
conformationally intact. 
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The lack of binding to many of the antibodies studied may also be attributed to the fact 
that they were produced against clade B viruses, highlighting the fundamental challenge 
of broad HIV neutralisation. Minor changes in amino acid sequence can have profound 
effects on antibody recognition188. Major sequence differences between clades may also 
affect antibody recognition. Variation in amino acid sequence and resulting differences in 
glycosylation patterns between the different clades may result in conformational 
differences between proteins that extend outside the epitopes for each antibody. This may 
hinder the accessibility of these epitopes. Thus, even where epitopes are conserved 
between proteins from different clades, larger conformational differences may result in 
compromised antibody activity, or in antibodies binding to gp120 from other clades with 
much lesser affinity than to clade B proteins.  
 
The glycosylation of these proteins is an issue that is also not completely resolved within 
the context of this project. This is important, as glycans may affect the binding of 
monoclonal antibodies by steric hindrance, or by affecting protein folding. In previous 
studies, Env proteins have been digested using trypsin and the resulting mixtures either 
directly analysed or deglycosylated and then analysed using mass spectrometry and/or 
matrix-assisted laser desorption ionization analysis techniques68, 248.This has made it 
possible to determine both the extent and the nature of gp120 glycosylation. While such 
analysis would have been useful in order to further understand the antibody binding 
characteristics of FV3 and FV5, it was not feasible in this study. Nevertheless, different 
Env proteins vary in their glycosylation patterns and evidence suggests that glycosylation 
patterns even vary when  expressing  a single env248. These proteins are presumably no 
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different. Thus, while knowing the exact glycosylation status of these proteins may aid in 
understanding the antibody binding profiles, it is perhaps not directly important in this 
study. The presence of a uniform band of gp120 that is close to 120kDa when analysed 
by SDS-PAGE, and the ability of the gp120 to bind to lectin confirms that the gp120 is 
glycosylated to a reasonable and relatively uniform extent. The smaller bands, indicating 
incompletely glycosylated or partially degraded gp120, are a natural result of baculoviral 
infection, as cell membranes are damaged and the cytoplasm and incompletely processed 
proteins are released into the supernatant. The MOI and length of infection can be 
manipulated, however, in order to decrease the presence of such products. These products 
are also less evident when transfecting mammalian cells, as this procedure is less 
damaging to the cells than baculoviral infection, and in the long term it may also be 
useful to focus on expression of this protein in mammalian systems. Expression of 
mammalian proteins would also be a useful tool in order to investigate the effects of the 
different glycan processing machinery present in each system, and to determine whether 
this may be a cause of the different binding patterns seen. 
 
FV3 and FV5 show variant antibody binding patterns to the other subtype C protein, 
96ZM651. While 96ZM651 binds very well to B4e8 and 654-30D in the absence of CD4 
as well as to 17b and A1g8 in the presence of CD4, FV3 and FV5 show little or no 
reactivity with these antibodies. In contrast, FV3 and FV5 show enhanced reactivity with 
2G12 when compared 96ZM651. FV3 and FV5 therefore appear to be unique, even 
amongst subtype C isolates. These results, however, are based simply on two 
recombinant proteins, and it would be interesting to study subtype C proteins further, 
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both from within the same cohort as FV3 and FV5 and from others in order to determine 
the extent of variability between subtype C proteins and to elaborate on the determinants 
of monoclonal antibody binding. To this end, plans are in place to produce the 
mammalian counterpart of FV3 as well as to produce and characterise recombinant gp120 
from other subtype C isolates. It would also be valuable to characterise these proteins 
further by characterizing their binding to other antibodies and to further determine, using 
more sophisticated techniques, the ability of these proteins to bind to CD4 and confirm 
their conformational integrity. 
 
In the context of HIV therapeutics, it is of concern that FV3 did not show a large amount 
of reactivity with either of the two broadly neutralising antibodies, 2G12 and IgG1 b12, 
included in the panel. IgG1 b12 has previously shown some reactivity with subtype C 
isolates, as well as neutralising activity against them187, 234, 235. It does not, however, show 
reactivity with FV3 (or 96ZM651) and it has previously been shown that where 
antibodies have no reactivity with a virus, they have correspondingly low neutralizing 
activity187. 
 
Subtype C isolates either require huge concentrations of 2G12 for neutralization249, or are 
altogether resistant to neutralization by this antibody234, 235. It is tempting to speculate that 
because FV3 shows some reactivity with 2G12 it would be susceptible to neutralisation 
by this antibody, although this may not be the case. Firstly, the ability of an antibody to 
bind to a virus does not necessarily correlate with its ability to neutralize it187, 249, 250. 
Secondly, it has also been noted, specifically in the case of 2G12, that weak binding of 
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the antibody to the protein, as in the case of FV3, results in weak neutralization ability of 
2G12249. To this end, experiments are underway in our laboratory to evaluate the 
neutralizing potential of 2G12 in culture against these subtype C isolates. Interestingly, 
preliminary results show some degree of FV3 neutralization by 2G12, and this is being 
investigated further. 
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5. Conclusion 
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Advances in understanding the pathogenesis and molecular characteristics of HIV-1 
assist in the development of strategies to combat the epidemic. Research has traditionally 
focused on subtype B HIV-1, leaving the other subtypes, including subtype C HIV-1 
understudied. The prevalence and alarming spread of subtype C, however, highlights the 
importance of augmenting knowledge on the molecular biology and pathogenesis of this 
HIV-1 clade. This project was aimed at establishing protocols in our laboratory for the 
production of subtype C gp120 to be used for such research. 
 
Once an effective protocol for production and purification of gp120 was in place, the 
antibody recognition profiles of the proteins were established and compared to other 
well-characterised recombinant gp120 proteins.  Very few of the monoclonal anti-gp120 
antibodies available showed any reactivity with the subtype C proteins. It was also 
interesting to note the highly variable profile of epitope presentation, even between 
closely related strains of HIV-1 (i.e. between the different subtype C proteins). While this 
could indicate that the recombinant proteins are conformationally compromised, there is 
evidence to suggest otherwise. Although these finding require further investigation, 
should they hold, they highlight both the importance of studying subtype C and 
comparing it to other subtypes, and the challenge of developing broadly-neutralising 
vaccine strategies. In this context, the importance of antibody-binding studies is 
paramount as these contribute towards elucidating the determinants of antibody 
recognition, essential information for the design of novel immunogens. 
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The FV3 gp120 produced in this study, along with a mammalian-expressed counterpart 
will be used for the development of entry inhibitors. The efficacy of existing gp120 
antagonists to this protein will be evaluated and it will be used, together with phage 
display techniques in order to generate novel compounds. The sequence and antibody 
recognition information will contribute to the wider understanding of HIV-1, specifically 
in a subtype C context. While FV5 cannot be used for further drug development or other 
studies, the lack of binding of this protein to CD4 highlights the importance of a single 
key residue in gp120 for CD4 binding, confirming the potential of this region of gp120 as 
a profoundly important drug target. 
 
Thus, a novel, and valuable subtype C recombinant gp120 has been produced and 
protocols are in place for continuous production of this protein, as well as other subtype 
C proteins of interest. Such proteins will used in the development of therapeutic strategies 
specific to South African HIV-1 strains, and will contribute, in the long term, to 
efficacious and cost-effective anti-HIV-1 approaches. 
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Appendix 1: Standard Protocols and Recipes 
A1. Bacterial Culture 
A1.1. Solutions for Bacterial Culture 
 
Luria Broth (LB) (1 litre) 
10 g tryptone, 5 g yeast extract and 5 g Nacl were combined and the volume brought to 
one litre. The solution was then autoclaved and stored at room temperature until use. 
 
Agar 
3 g Agar was added per 200 ml of LB prior to autoclaving. Agar was then autoclaved and 
cooled slightly before it was used to pour plates. 
 
Ampicillin or Chloramphenicol Stock (1000 x/ 100 mg/ml) 
1 g ampicillin or chloramphenicol was dissolved in 10 ml 50% Ethanol 
 
 
Transformation Buffer (100 mM CaCl2, 10 mM PIPES-HCl, 15% Glycerol, pH 7) 
 
1.4702 g CaCl2.2H2O, 0.3024 g PIPES and 15 ml glycerol were mixed and brought to a 
volume of 75 ml with dH2O. This solution was brought to pH 7.0 with 10 M NaOH and 
made up to a final volume up to 100 ml with dH2O. The transformation buffer was then 
autoclaved and stored at -20ºC. 
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A1.2. Preparation of competent E. coli 
 
100 ml of Luria Broth (LB) was inoculated with either E. coli DH5α or E. coli BL21. For 
E. coli BL21 , chloramphenicol was included at a concentration of 0.1 mg/ml. Cultures 
were grown at 37°C overnight with vigourous shaking. The culture was then diluted 10 
times in LB or LB with chloramphenicol and grown at 37°C with vigourous shaking for a 
further 2-3 hours until the bacteria were in the log phase of growth with an A600 ~ 0.4. 
Cells were pelleted at 2000 x g for 15 minutes at 4°C and the supernatant discarded. The 
pellet was carefully resuspended in 10 ml ice-cold transformation buffer per 50 ml culture 
and incubated for 20 minutes on ice. Cells were pelleted at 1500 x g for 15 minutes at 
4°C and the supernatant discarded. The pellet was then carefully resuspended in 1ml ice-
cold transformation buffer per 50 ml original culture volume and, working on ice, 75 µl 
aliquots of competent E. coli were made and stored at -70°C 
 
A1.3. Transformation of competent E. coli 
 
 
5 µl (approximately 50 ng) of each ligation reaction or 2 µl (approximately 50 ng) 
plasmid DNA was added to a 100 µl aliquot of competent E.coli and incubated on ice for 
20-25 minutes. A mock transformation reaction containing no DNA was also set up. The 
cells were then heat shocked for 30 seconds at 42˚C and placed immediately on ice for 2 
minutes. 250 µl SOC medium (Invitrogen; Carlsbad, CA) was added to each of the tubes, 
which were then placed in a shaking incubator at 37˚C for 1 hour. Each transformation 
reaction was then plated on 2 agar plates (100 µl and 250 µl) and incubated at 37˚C 
overnight. 
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E.coli DH5α were plated on plates containing 0.1 mg/ml ampicillin (Roche; Mannheim, 
Germany), while E.coli BL21 were plated on plates containing 0.1 mg/ml ampicillin and 
0.1 mg/ml chloramphenicol (Sigma; St Louis, MO). 
 
A2. Agarose Electrophoresis 
A2.1 Solutions for Agarose Electrophoresis 
 
 
0.5 M EDTA (pH 8.0) 
93.05 g EDTA was dissolved in 400 ml dH2O and brought to pH 8.0 with 10 M NaOH. It 
was then made up to 500 ml with dH2O, autoclaved and stored at room temperature. 
 
50 x TAE Buffer 
242 g Tris base, 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA pH 8.0 were 
combined and the solution made up to 1 litre in dH2O. The solution was made up to 1 x 
TAE by mixing 20 ml 50 x TAE with 980 ml dH2O before use. 
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A3. SDS-PAGE  
A3.1. Solutions for SDS-PAGE 
 
 
4 x Running Gel Buffer (1.5 M Tris-HCl, pH 8.8) 
36.3 g Tris was dissolved in 50 ml dH2O, and the pH brought to 8.8 with HCl. The 
solution was then made up to a final volume of 200 ml with dH2O and stored at 4°C in 
the dark. 
 
4 x Stacking gel buffer (0.5 M Tris-HCl, pH 6.8) 
3.0 g Tris was dissolved in 40 ml dH2O, and the pH brought to 6.8 with HCl. The 
solution was then made up to a final volume of 50 ml with dH2O and stored at 4°C in the 
dark 
 
10% Sodium Dodecyl Sulphate (SDS) 
10 g SDS  was dissolved in 100 ml dH2O 
 
10% Ammonium Persulphate (APS) 
0.1 g APS was dissolved in 1 ml dH2O. This solution was made up fresh for each gel. 
 
Running gel (For 4 gels): 
12 ml Monomer solution (Sigma; St Louis, MO), 11.25 ml 4x running gel buffer, 21.15 
ml dH2O and 450 µl 10% SDS were combined. Just prior to pouring the gel, 225 µl 10% 
APS and 15 µl TEMED were added to the solution. 
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Stacking gel 
2 ml Monomer solution (Sigma; St Louis, MO), 3.75 ml 4 x stacking gel buffer, 9 ml 
dH2O and 150 µl 10% SDS were combined. Just prior to pouring the stacking gel, 75 µl 
10% APS and 7.5 µl TEMED were added to the solution 
 
2 x Treatment Buffer 
 
2.5 ml 4 x stacking gel buffer, 4.0 ml glycerol, 2.0 mg bromophenol blue and 0.31 g 
Dithiothreitol were combined and the volume brought to 10 ml with dH2O. 
 
 
5 x Tank Buffer 
 
15.14 g Tris, 72.726 g Glycine and 5 g SDS were combined and the volume brought to 
one liter with dH2O. This solution was made up to 1 x tank buffer just before use. 
 
Coomassie Staining Soultion 
 
0.5 g Coomassie® Brilliant Blue R250 was combined with 800 ml methanol, and stirred 
until dissolved. 140 ml acetic acid was then added and the volume brought to 2 litres with 
dH2O. 
 
Destaining Solution 1 (40% Methanol, 7% Acetic Acid) 
 
 
400 ml methanol and 70 ml acetic acid were combined and the volume brought to one 
liter with dH2O. 
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Destaining Solution 2 (5% Methanol, 7% Acetic Acid) 
50 ml methanol was combined with 70 ml acetic acid and the volume brought to 1 litre 
with dH2O. 
 
A3.2. Resolving SDS-PAGE gels 
 
 
8% polyacrylamide gels were poured, and 35 µl of each sample loaded into the wells, 
together with 10 µl of Prestained Protein Marker, Broad Range (New England Biolabs; 
Ipswich, MA) and a positive control. Gels were run in duplicate for approximately 1.5 
hours, at constant current of 12.5 mA, until the samples were stacked, followed by a 
constant current of 25-30 mA, until the dye front was approximately 0.5 cm from the 
bottom of the gel. One gel was then stained with Coomassie® Brilliant Blue R-250 
overnight and destained the next day for two hours in Destain I, followed by Destain II 
until the background of the gel was clear.  
 
A4. Western Blotting 
A4.1. Solutions for Western Blotting 
 
Transfer Buffer 
 
100 ml methanol was combined with 100 ml 5 x tank buffer and the volume brought to 
500 ml with dH2O 
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10 x TBS 
 
80 g NaCl, 2 g KCl and 30 g Tris were combined and the volume was brought to 800 ml 
with dH2O. The pH was brought to 7.4 with HCl and the solution brought to a final 
volume of 1 litre. The solution was then autoclaved and diluted to 1 x TBS just before 
use. 1 ml Tween-20 was added to 1x TBS just before use to make T-TBS. 
 
A4.2. Performing a Western Blot 
 
After running SDS-PAGE, the duplicate SDS-PAGE gel was equilibrated in transfer 
buffer for 10 minutes, and then transferred to Hybond-C nitrocellulose membrane 
(Amersham Biosciences; Freiburg, Germany) on a Trans-Blot SD Semi-Dry Transfer 
Cell (Bio-Rad; Hercules, CA) for 1 hour and 15 minutes at constant current of 50 mA. 
Following protein transfer, samples were blocked for one hour shaking at room 
temperature or overnight at 4°C in 5% fat free milk powder in T-TBS . Three 5-minute 
washes in T-TBS followed before addition of the primary antibody.  
 
After incubation with the primary antibody (as described in section 2.8.4), the membrane 
was washed three times for five minutes in T-TBS. The secondary antibody was then 
added at a concentration of 1:1000 diluted in 2 ml and laid flat on the membrane for 45 
minutes. Depending on the primary antibody, the secondary antibody used was either 
anti-mouse in the case of the mouse monoclonal antibodies, or anti-Human in the case of 
plasma. After this incubation, the membrane was again washed three times for 5 minutes 
in T-TBS before protein detection.  
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Bound secondary antibody was detected on Western Blot membranes using enhanced 
chemiluminescence (ECL). A commercial substrate, SuperSignal West Pico 
Chemiluminescent Substrate (Pierce; Rockford, IL), was used according to the 
manufacturer’s instructions. After the enzymatic reaction, membranes were exposed to 
Fuji Super Rx Medical X-Ray film (Africa Xray Industrial & Medical; La Rochelle, 
South Africa) for varying amounts of time, depending on the signal strength, before 
developing and fixing. 
 
A5. Protein Concentration Determination 
 
Protein was quantitated using a BCA Protein Assay Kit (Pierce; Rockford, IL ). Briefly, a 
standard curve was set up in a 96-well plate (Nunc; Roskilde, Denmark) using the BSA 
standard provided in the kit. BSA was diluted in the same buffer as the protein to be 
quantitated to concentrations of 0 µg/ml, 2 µg/ml, 5 µg/ml, 10 µg/ml, 15 µg/ml, 20 
µg/ml, 25 µg/ml and 50 µg/ml. 25 µl of standard (added in duplicate) or 10 x diluted 
protein (added in triplicate) pipetted into the plate, followed by 200 µl of working reagent 
made up according to the manufacturer’s instructions. Plates were incubated at 56°C for 
up to an hour and the absorbance was read at 570 nm on a ELX808 microplate reader 
(Bio-Tek; Winooski, VT). The protein concentration was then calculated according to the 
generated standard curve. 
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Appendix 2: Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1: Schematic representation of pTriEx-gp120. The gp120-coding region was 
inserted into the multiple cloning site between the NcoI and XhoI digestion sites. The 
pTriEx-gp120 clones were approximately 6.5 kb in length.  pTriEx contains promoters 
for bacterial, insect cell and mammalian protein expression. The promoter and cloning 
regions of pTriEx are flanked by segments of baculovirus genomic DNA (lef-2/ORF603 
and ORF1629) This allows for homologous recombination with the baculoviral backbone 
at the polh locus to create TriEx recombinant viruses. 
 
*  Baculoviral DNA 
sequences for 
homologous 
recombination at the 
polh locus  
pTriEx-gp120 
~6.5 kb 
CMV promotor for 
mammalian systems 
p10  promoter for 
insect systems 
Gp120 insert 
~ 1.5 kb 
T7 promoter for 
bacterial systems 
* 
* 
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Figure S2: Standard Curve generation for FV3 by amplification of a 180 bp segment 
of gp120-encoding DNA. (A) Std curve generated by LightCycler® Software version 
3.5.3. (B) Amplification curves for standards. Number to right of FV3 indicates the log 
number of copies per ml of the sample added to the reaction. i.e. For FV3 10, the 
concentration of the sample added to the PCR reaction was 1 x 1010 gp120 copies/ml  
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Figure S3: Standard Curve generation for FV5 by amplification of a 180 bp segment 
of gp120-encoding DNA. (A) Std curve generated by LightCycler® Software version 
3.5.3. (B) Amplification curves of standards of known concentration. Number to right 
of FV5 in the key indicates the log number of copies per ml of the sample added to the 
reaction. i.e. For FV5 10, the concentration of the sample added to the PCR reaction was 
1 x 1010 gp120 copies/ml  
A 
B 
Crossing points 
Linear Regression 
 
FV5 10 
Repl of FV5 10 
FV5 9 
Repl of FV5 9 
FV5 8 
Repl of FV5 8 
FV5 7 
Repl of FV5 7 
FV5 6 
Repl of FV5 6 
FV5 5 
Repl of FV5 5 
FV5 4 
Repl of FV5 4 
FV5 3 
Repl of FV5 3 
Blank 1 
Blank 2 
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Figure S4: Graphs showing recognition of monoclonal antibodies by a panel of 
gp120s. Antibody recognition of gp120s was analysed by direct ELISA. Graphs show the 
mean A450 value of a triplicate experiment. Error bars indicate standard deviation. (A) 
Human monoclonal antibody recognition (B) Mouse monoclonal antibody 
recognition. 
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Figure S5: Diagrams showing percentage cell viability in insect cell suspension 
culture infections. (A) Cell Viability in individual infections, M: MOI in gp120-
encoding copies/cell (B) All infection viabilities averaged for FV3 and FV5 each. 
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Figure S6: Comparison between insect cell-produced FV3 and mammalian cell-
produced His-tagged FV3. Western Blot analysis. 1: BaL. 2,3,4: Insect cell- produced 
FV3. 5,6: Mammalin cell-produced His-tagged FV3. 
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                 *        20         *        40         *        60         *        80         *            
FV3   : MRVMGIQRNCQQWWIWGILGFWMLMICNG-GNL--WVTVYYGVPVWKEAKTTLFCASDAKAYEKEVHNVWATHACVPTDPNPQEMKLRNVTENFN :  92 
FV5   : ........S..R.................TE..--.........................S........................V.E....... :  93 
CM9   : ...RE.L..Y......S......--...VV...--..................................................H.E....... :  91 
Du151 : ...R..P..WP......T.........RVV...NL...........................D......................V.E....... :  95 
Du179 : ...R.....WP................S.V...--..................................................V.G....... :  93 
SW7   : ......L..Y................GSVV...--..................................................V.D....... :  93 
CN54  : ...T..R..YRHL.R..T.LLG....SSAV...--............G.T............DT.............A.......V.E....... :  93 
                                                                                                              
                                                                                                              
          100         *       120         *       140         *       160         *       180         *       
FV3   : MWKNDMVDQMNEDIISLWDESLKPCVKLTPLCVTLNCSDVT--YNATNATNNTTTTTHNTTETTPYAKISNITDDMKNCSFNVTTGLRDKRKQES : 185 
FV5   : ..........H............................FDPLD.G...M-----------------------GE......KA..E......K.Q : 165 
CM9   : ..........H........................E...A.--..S.THN.A.YND.--------------.AGE..........E......K.Y : 170 
Du151 : ..........H............................AP-------.Y...MH------------------GE.......T..E.....QKAY : 165 
Du179 : ..........H........................K...A--------TY.G.D.------------------.........T..E.....QTVY : 162 
SW7   : ..........H........................H.A..E---.S..SM...M.------------------RE......KT..E....QQNTY : 167 
CN54  : ....E.....Q........................E.R...--S.SN.TYHE.YHE.--------------.-KE.......A..V.....QTVY : 171 
                                                                                                              
                                                                                                              
               200         *       220         *       240         *       260         *       280            
FV3   : ALFYRLDIIPLNGNKE--NSS-EY-RLINCNTSTIRQACPKVSFDPIPIHYCAPAGFAILKCNDKTFNGTGPCHDVSTVQCTHGIKPVVSTQLLL : 276 
FV5   : .........S..KVSNSS.RNFSMY........A.T.....................................N................A.... : 260 
CM9   : ...........G..SSKG.A.-K.-..........T.....................................N..................... : 263 
Du151 : .....P......RRE.NNG.G-..I-.........T.....................................N..................... : 258 
Du179 : .....P......---.S-----..I-..H......T.....................................Q..................... : 248 
SW7   : .....P.....K---SSS...-..I-..H......T........E.................................................. : 257 
CN54  : ...........TKKNYSE...-..Y........A.T................T............I............................. : 265 
                                                                                                              
                                                                                                              
            *       300         *       320         *       340         *       360         *       380       
FV3   : NGSLAEEEIVIRSENLTNNAKIIIVHLNESVEIKCSRPGNNTRKSVRIGIGRGQTFYATGKVIGDIRQAHCNVSREAWNKTLEKVKRKLGEHFPN : 371 
FV5   : ......G.....P...A..V.T...QF......V....N.....--S.R..P........E.............ESK......N.A...K..... : 353 
CM9   : ...................V.T.........P.V.A......I.--..R..PRYA...KET.............E.K......Q.G...K..... : 356 
Du151 : ...................I.T......K....V....N.....--S.R..P........A..............SN.TS...Q.....K...-. : 350 
Du179 : ......G..............T.........D.V..........--S.R..P..A..-.NH...............E..G...E.....Q..... : 340 
SW7   : ......G............V.T.........A.V.....S.KQ.IRN.R..P.RA.H-.NG......K.Y....NNH......Q.........L. : 351 
CN54  : ......G............V.T...........V..........--S.R..P........D.............EDK..E.....S...A...Q. : 358 
                                                                                                              
                                                                                                              
                 *       400         *       420         *       440         *       460         *            
FV3   : STITFNHSSGGDLEITTHSFNCRGEFFYCNTSDLFKDNITITN----------STNNTVITLQCRIKQIINMWQRAGQAIYAPPIRGNITCNSNI : 456 
FV5   : KN...APA...G....................K..NSTYNSN.TERDYNGTGNN.T............F......V.........E.....K.I. : 448 
CM9   : K....APH.......I................K..NRPNGTESNS---NQTTE.NS.RT...............EV...............T... : 448 
Du151 : K..E.KPP........................K..SN----NS---------D.N-.ET...P............V.R.......E.....K... : 431 
Du179 : K..K..S.........................Q..IN----.SN--------D.DI..T...P...........GV.R.......A.....K... : 423 
SW7   : K..E.KSP........................K..NR----..P--------FN.T..N...P...........GV.........E.......S. : 434 
CN54  : K..K.AS.........................G..NGAY.PNGT--------K.NSS.....P...........EV.R.............K... : 445 
                                                                                                              
                                                                                  
          480         *       500         *       520         *       540         
FV3   : TGLLLTRDGGKDNKTNNENKTEIFRPGGGDMRDNWRSELYKYKVVEIKPLGIAPTTAKRRVVEREKR : 523 
FV5   : ..........----..TT---.T...V............................R.Q......... : 508 
CM9   : ..........---EK.TT.EK..................................G........... : 512 
Du151 : ..........---.NTTN---..........................E.......KS.......... : 492 
Du179 : ..........---TD.TT---.....V............................E........... : 484 
SW7   : ..........ISK.N.T..NI..................................E........... : 501 
CN54  : .....V....-TEPN.T----.T.................................T.......... : 507 
                                                                                   
 
Figure S7: Alignment of FV3 and FV5 with population-based amino acids of 
subtype C isolates used in other studies
171, 231
. Glycosylation sites important for 
formation of the 2G12 epitope are highlighted. Where the site is absent, the position it 
should be in is highlighted in green. Where sites are present, they are highlighted in pink. 
 
 
